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Abstract 
 Glioblastoma Multiforme (GBM) continues to be a leading form of malignant brain 
cancer. This is due to its ability to support itself through extensive vasculature and common brain 
tissue located throughout the brain. With these two major factors, GBM presents a high 
variability patient to patient. This provides a need for a theranostic system capable of both 
delivering therapeutic and in close to real-time visually observe delivery results. Current 
methods involve weeks to month between treatment application and available results with very 
few methods available to interpret results. Based on Nemucore Medical Innovation’s drug 
delivery vehicles, nanoemulsions containing chemotherapeutics are being utilized to target 
cancer cells and reduce systemic toxicity. Through the automation of required statistical analysis 
and creation of a wire-frame rat brain model with 174 anatomically defined brain regions a 
software package capable of providing ‘real-time’ pharmacodynamics analysis of Gd3+ 
annotated, receptor-targeted nanoemulsions is one step closer. 
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1.0.0 Introduction 
Glioblastoma Multiforme (GBM) is the most aggressive form of malignant brain tumor 
cancer in adult patients (Agnihotri et. al, 2013). GBM arises from a mutation in astrocytes which 
are comprised of star shaped glial cells of the central nervous system (CNS). Annually, there are 
12,000-14,000 newly diagnosed cases of GBM in the United States; of these new cases, less than 
10% of the patients survive longer than five years (Bryan, 2011). Similarly 8.8% of children 
CNS tumors are comprised of GBM’s (Adamson et. al, 2009). The glial cells these tumors arise 
from compose a significant amount of total brain tissue and are supported through a large 
network of vasculature (Behzadian et. al, 1998). This increases the ability of cancerous variants 
to proliferate quickly compared to other neuronal cell type based cancers. 
Due to anomalies between glioblastomas in different patients, the future of treating these 
aggressive tumors lays in personalized theranostic targeted treatment plans in order to optimize 
survival outcomes. Theranostics is an area of research that combines therapeutics and diagnostics 
into a single modality (Kelkar, 2008). Due to the high mortality rate of GBM-diagnosed patients, 
there exists a strong clinical need for a theranostic approach to rapidly provide feedback in 
treating the disease. Therefore the objectives of this project are: to create a 3D heatmap of Gd 
induced T1 MRI signal overlaid on a rat brain atlas in order to allow visualization of targeted 
nanomedicines within the 174 defined regions of the atlas, and further develop targeting 
specificity of nanomedicines. Together this will create a better system to evaluate therapeutic 
efficacy for treating GBM. 
1.1.0 Current Gold Standard 
The current gold standard for treating Glioblastoma Multiforme is resection surgery 
followed by a combination of ionizing radiation therapy and temozolomide. Temozolomide is an 
12 
 
oral chemotherapy drug that acts as a methylation agent, adding methyl groups to DNA. This 
methylation destroys the functionality of DNA and leads to cell death (Newlands et. al, 1997). 
Experiments continue to prove Temozolomide’s efficacy, although significant improvements 
have only occurred in patients under the age of 45. Even so, the median survival of patients 
undergoing this treatment, is only increased from 14 months to 18 months (Yaneva et. al, 2010).  
The primary challenges in treating GBM consist of delivering therapeutic agents across 
the Blood Brain Barrier (BBB) and minimizing damage to functional healthy brain tissue. The 
BBB is composed of epithelial cells that form tight junctions and cause selective permeability to 
the brain. As a result, in order to further develop treatment of GBM as well as improve patient 
outcomes, it is necessary to create therapies that can easily cross the BBB without damage and 
have high targeting specificity of the cancerous tissue, while limiting healthy brain tissue and 
systemic system exposure. 
The gold standard for imaging Glioblastoma Multiforme in a clinical setting is through 
gadolinium-enhanced Magnetic Resonance Imaging, or MRI (Hou et. al, 2006). MRI produces a 
high resolution image that has the capability to show contrasts within imaging material and 
gadolinium enhances this property. MRI has been used since 1985 to show how tumor tissue 
could be differentiated from healthy brain tissue with the use of gadolinium injections to increase 
the potential of MR imaging (Grossman et. al, 2000). While this is the current gold standard for 
patient visualization of treatment, there are very few options available for post MRI analysis of 
treatment.  
1.2.0 Goals 
This project consist of two main goals. Firstly, to design and test in vitro targeting 
specificity of nanoemulsions (NEs), and secondly, to develop a functional 3D heatmap using the 
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rat brain atlas’s 174 regions of interest. We will perform specificity experiments to prove the 
NEs are binding to specific receptors that are expressed in GBM cells. By quantitatively showing 
selective uptake of our drug, combined with improved MRI analysis of brain by individual 
region, we can prove our drug selectively will bind to the selected receptor in vivo. 
A MatLab program will be created which will make use of previously recorded T1 
weighted MRI data of drug dispersion across the brain. In the future, the 3D MRI heatmap that 
we create can be used for further statistical and visualization analysis of the drug distribution 
data within the brain of rats from in vivo experiments. In order to ensure that certain metrics are 
met we have certain objectives that must be met which include for the program to visualize the 
data in a heatmap fashion, be scalable, be user friendly and robust in function in the hopes that it 
will become a common method for drug delivery analysis in the brain.   
1.3.0 Approach: Nanoemulsions 
To address this problem, our approach will continue to build on Nemucore Medical 
Innovations’ current nanoemulsion (NE) drug delivery design. The overall therapeutic goal of 
this project is to find methods to enhance nanoemulsions in order to create greater GBM 
targeting specificity. These methods will include identifying significant markers presently being 
overexpressed in Glioblastoma Multiforme cells. Identification will involve both reviewing 
current literature as well as testing various known cell receptor ligands on the GBM cell lines. 
Through identification of targeting moieties, targeting ligands for those receptors can be 
chemically synthesized and attached to the surface of Nemucore’s NMI-800 nanoemulsions. 
These NE’s can then be tested in vitro using GBM and brain endothelial cell lines in order to 
prove targeting specificity of the NEs. 
14 
 
GBM is known notoriously for its general resistance to standard chemotherapeutic 
treatments. In order to investigate a targeted NE therapeutic efficacy, the current gold standard 
GBM drug temozolomide will be utilized. Continued research will be conducted for other 
therapeutic drugs may work effectively against GBM. After identifying appropriate targeting 
ligands as well as chemotherapeutic, manufacturing and in vitro testing of the new drug NE will 
be conducted in conjunction with Nemucore. These proof of concept for in vitro tests will then 
be utilized by Nemucore in the near future to perform in vivo testing of the targeted NE’s in 
respect to GBM.  
1.4.0 Approach: 3D Statistical Heatmap 
Though there have been accelerating advancements in the fields of nanotechnology and 
facilitation in drug delivery systems, there are currently no software programs available that 
enable visualization of a 3D model of the drug distribution across a rat brain with 174 defined 
regions of interest for post in vivo analysis. Specifically with the rat brain, current images 
produced by 3D MRI mapping focus on the larger regions of the brain, such as the eloquent 
cortex, gray matter nuclei, white matter tracts, and the intersecting blood vessels of the brain 
(Kikinis, 1996). Thus a 3D heatmap which goes into minute detail, is necessary in order to better 
differentiate distribution of therapeutic drug in the brain. By further developing these diagnostic 
programs, researchers and in the future clinicians will be able to identify specifically where brain 
tumors are located, as well as ensure the chemotherapeutics are accumulating in the correct 
regions of interests, no matter the region size. 
We will be to work off the established Rat Brain Atlas program, and create a more in-
depth MatLab 3D visualization. MatLab will be utilized due to its ability to analyze the current 
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data that is available from Nemucore Medical Innovation’s in vivo testing of the NMI-800 series 
(an example of this series can be seen below in Figure 1).  
This program will be focused on outputting statistical analysis from the atlas program as 
well as displaying the 174 regions of the rat brain gathered from T1 MRI. In addition, the 
visualization of the program will be designed to be interactive and easy to use. 
 The following chapters presented in this report will provided a detail background on the 
topics covered throughout this project include but not limited to Glioblastoma Multiforme, 
theranostics, Nanoemulsions, and data visualization. An overview of our approach to the 
development and testing of this Nanoemulsions series and visualization program are also 
displayed. Further description of alternative conceptual and preliminary designs for both project 
aspects are provided. This is followed by a detailed description of final tested and validated 
designs. Finally, conclusions and avenues for further research are provided for future 
continuation of these designs.  
 
 
 
  
Figure 1: Example schematic of NMI-800 series Nanoemulsion. 
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2.0.0 Literature Review 
 Prior to the design of either aspect of this project, extensive research was needed to fully 
understand the problem presented. In the following sections, we outline what Glioblastoma 
Multiform is and current chemotherapeutic treatments available to patients. Following this, 
relevant biological background is described to compute the idea of theranostic and its relation to 
the combination of our new visual statistical analysis program and Nanoemulsions. In order to 
understand the need for this new analysis method the biological properties of Glioblastoma 
Multiform must first be understood. 
2.1.0 Glioblastoma Multiforme 
Glioblastoma Multiforme (GBM) is an aggressive form of malignant brain tumor in adult 
patients that arises from a mutation in glial cells. Every year there are 12,000-14,000 newly 
diagnosed cases of Glioblastoma Multiforme in the United States. Of these new cases, less than 
10% of the patients survive 5 years (Tutt, 2011). Glioblastomas have two types, primary and 
secondary. Primary types are more aggressive in formation and will expand quickly. These 
primary tumor types are the most common form of glioblastoma. Secondary tumor types have a 
slower growth progress, and evolve over time to form aggressive tumors. These tumors can 
originate from lower-grade tumors and become higher grade (Kleihues & Ohgaki, 1999). There 
are distinct factors that affect primary and secondary glioblastomas including age, genetic 
disruptions, and protein expressions. By studying these differences, therapeutic applications can 
be developed that can have increased effects destroying the cancerous cells (Ohgaki & Kleihues, 
2007).  
Glioblastoma’s morphology can be characterized in terms of the cells that make up the 
tumor. The gliomas can originate in different parts of the brain, arising from many different cells 
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types. The three main cell derived gliomas types are astrocytomas, oligodendrogliomas and 
oliogoastrocytomas (Behin et. al, 2003). Symptoms that arise in the presence of GBM originate 
from various physiological warning signs. GBM has a variety of symptoms including headache, 
nausea, vomiting, and drowsiness. These symptoms are attributed to an increase in pressure in 
the brain due to the rapid growth of the tumor. Glioblastomas have the potential of forming in 
different regions of the brain. Many of these affected regions control motor functions, and 
patients can develop weakness on one side of the body, visual changes, complications in speech 
and difficulties with long and short term memory. Some of the overall symptoms include 
headaches, seizures, focal neurologic deficits, and changes in the status of mental capacity. 
(Grossman et. al, 2004) 
Angiogenesis is the physiological process in which new blood vessels are formed. 
Glioblastomas express angiogenesis and can be characterized by their high vascularization as 
compared to healthy regions of the brain which are not as highly vascularized. This phenomenon 
allows the tumor cells to receive oxygen and nutrition. In a study it was found that stem cell-like 
glioma cells (SCLGC) secreted vascular endothelial growth factor (VEGF) at higher 
concentration as compared with non-SCLGC cell populations. This secretion was induced by 
hypoxia. This in turn supports glioblastomas being highly vascularized, as the cells work hard to 
secrete factors that further allow vascularization to occur. (Bao et. al, 2006) 
Enhanced permeability and retention (EPR) is the process by which molecules of certain 
sized tend to accumulate in tumor tissues more as compared to healthy tissues. This phenomenon 
occurs when the cells that align the tumor tend to have larger gaps in between them to aid in 
oxygen and nutrition intake for the tumor. Therefore angiogenesis and the EPR effects are 
particularly important in tumors and can be taken advantage of for targeted drug delivery to the 
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tumor. In a study, in order to target the αvβ3/αvβ5 integrin’s which are overexpressed in 
angiogenic sites and tumors – including Glioblastoma – it was found that Arg-Gly-Asp peptides 
(RGD) are promising ligand molecules. (Miura et. al, 2013)  
Tumors tend to over express many different receptors due to the unregulated nature of the 
cells. In a study, 25 out of 40 tumors (62.5%) that were examined exhibited overexpression of 
epidermal growth factor receptor (EGFR). EGFR is a cell surface receptor for extracellular 
protein ligands. It was also found that 10 out of the 25 tumors (40%) displayed EGFR gene 
amplification (Haas-Kogan et. al, 2005). Additionally, gliomas have tumor-specific alterations of 
EGFR which can play an important role in helping the tumor progress by influencing the 
interactions of the tumor cells with its environment (Nishikawa et. al, 1994). Overexpression of 
certain genes and factors typically occur in glioblastomas. In addition it has been shown that 
there is an overexpression of human Fn14 receptor gene in migrating glioma cells when 
compared to the minimal expression of Fn14 mRNA in normal brain (Tran et. al, 2003). 
The gold standard for treating glioblastomas is to remove the tumor mass that is present 
at the periphery of the brain by surgery (Agnihotri et. al, 2013). In addition to surgery, 
chemotherapy and radiation are the next most common method of treating gliomas. 
Temozolomide (TMZ) is an oral chemotherapy drug that is used in treating GBM.  TMZ has 
been used in combination with radiation leads to a 16.1% increase in survival rates (Stupp et. al, 
2005). TMZ acts as a methylating agent, adding methyl groups to DNA which destroy its 
functionality and lead to cell death (Newlands et. al, 1997).  
Additionally, GLIADEL which is a biopolymer wafer composed of (poly 
[carboxyphenoxy-propane/sebacic acid] anhydride and contains 3.85% carmustine [BCNU]) is 
used as an adjunct to surgery and radiation. Once the tumor is resected, GLIADEL wafers which 
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are designed to release carmustine–a chemotherapeutic– slowly over a 2- to 3-week period are 
placed in the site of resection. The controlled release rate of the chemotherapeutic is proportional 
to the degradation rate of the polymer. (Domb et. al, 1999) 
Although there are treatments available to help patients that are suffering from 
Glioblastoma Multiforme, these treatments have done little to impact the mortality rate which 
has barely improved since the “war on cancer” was declared in 1972 by the Nixon 
Administration . Current treatments are not able to drastically improve the outcomes for these 
patients and they are predominantly used in improving the quality of the life the patients have for 
this terminal disease. Therefore one of the reasons maintaining the status quo is that the Blood 
Brain Barrier (BBB) prevents hydrophobic chemotherapeutic drugs from reaching the gliomas. 
The BBB is a highly selective barrier to the brain as tight junctions are formed by capillary 
endothelial cells (Hawkins et. al, 2005). Lastly, although epidermal growth factor receptor 
(EGFR) is overexpressed in glioblastomas, only 10-20% of patients show a response to EGFR 
kinase inhibitors (Mellinghoff et. al, 2005). Therefore it is a necessity to come up with 
alternative methods for potent hydrophobic chemotherapeutic drugs to cross the BBB and reach 
the cancerous cells. More research and advances into other overexpressed receptors on the 
glioma cells to target through advanced drug delivery mechanisms is a current topic of study. 
New developments taking place to target brain tumors are quite varied in scope but the 
major themes are circumventing the BBB followed by specifically targeting GBM.  Nanocarriers 
are being developed to deliver drugs that can recognize brain capillary endothelial cells and 
cerebral tumoral cells (Béduneau et. al, 2007). Passive targeting as well as the enhanced 
permeability and retention (EPR) effects have led to developments in the area of drug delivery to 
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tumors (Maeda et. al, 2000). Nanocarriers are designed to protect the encapsulated drugs from 
degradation and are typically in the 30-180 nanometer range in size.  
A platinum anticancer drug-incorporating polymeric micelle (PM) combined with a 
cyclic RGD (cRGD) has been used in recent studies to show the ability to target newly growing 
vasculature of GBMs.  The results of the integrin binding were compared with micelles that 
contained cyclic RAD (cRAD) which is a nonsensical targeting ligand containing the same 
amino acids just in a different order and shows no specificity for integrin’s.  cRGD was 
conjugated to the micelle with a density ranging from 5% to 40% on the outer shell. The 20% 
cRGD-linked micelles showed the most promising best potential for in vitro activity. These 
effects were compared with 20% cRAD-linked micelles which showed little specific binding. 
Additionally the 20% cRGD/micelle was rapidly taken up into U87MG cells whereas the 20% 
cRAD/m was taken in very gradually. cRGD acts as a targeting molecule that is able to cross the 
blood brain tumor barrier (BBTB) and can be actively transported across the vascular barrier of 
the glioblastoma. (Miura et. al, 2013) Overall in order to understand the effective nanodelivery 
of chemotherapeutic drugs and reasoning behind their design / composition, the overall biology 
of the brain must better understood.  
2.2.0 Biology of Brain  
Looking at the brain from the perspective of drug delivery, the most unique challenge 
that needs to be overcome is passage from the circulatory system to isolated brain tissue through 
the blood-brain barrier (BBB). The BBB is primarily comprised of the endothelial cells that line 
the vasculature of the brain, with astrocytes and extracellular interacting with this barrier on the 
luminal surface of the epithelial cells. This barrier helps to maintain the homeostasis of the brain 
environment (which differs greatly from that of normal tissue), which involves tight regulation of 
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the transports of solutes and cells into and out of the central nervous system tissue. (Bhaskar et 
al., 2010) 
 The primary components of the endothelial cells that restrict the permeability of the BBB 
are the tight junctions between adjacent endothelial cells. These tight junctions reduce the space 
between cells so that only small, individual molecules can passively diffuse through them. The 
junctions comprised of many molecules and proteins including the junctional adhesion molecule 
1 (JAM-1), occluding, and claudins. 
Biologically, there are several routes for materials to transverse the BBB as seen in 
Figure 2. Tight junctions only allow incredibly small, aqueous molecules to transverse them 
(e.g., oxygen and carbon dioxide). In brain cancers including GBM, loss of certain tight junction 
proteins has been correlated to increase in BBB permeability. (Hawkins & Davis, 2005)  
 
Figure 2: Various mechanisms by which elements can transport from the blood into the brain through the Blood 
Brain Barrier.1 
Some lipid soluble materials the brain desires can be absorbed by the cells directly and 
cross the BBB. Specific carrier proteins can transport select molecules across including glucose, 
amino acids, nucleosides, and other vital materials. Receptor mediated transcytosis can also be 
1 Ramos-Cabrer, Pedro, & Campos, Francisco. (2012). Liposomes and nanotechnology in drug development: focus on 
neurological targets. International journal of nanomedicine, 8, 951-960. 
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used to transport larger molecules into brain tissue, but is entirely dependent on the types of 
transcytosis receptors that are expressed on the epithelial cells and not astrocytes or other brain 
cells. (Ramos & Campos, 2012) 
With respect to drug delivery, crossing the BBB using biological mechanisms utilized by 
nature, i.e. biomimicry, is highly desired. This desire is because alternative ways to deliver drugs 
to brain tissue can be invasive or complex, and include intraparenchymal injections, temporary 
disruption of the BBB through technologies like high-intensity focused ultrasound, or 
implantation of long term delivery devices like osmotic pumps (Bhaskar et al., 2010). 
  
The blood cerebrospinal fluid (CSF) barrier is a thin layer of blood capillary and choroid 
plexus epithelial cells. The primary barriers exist in choroid plexus tissue, which is found in all 
ventricles in brain. The blood-CSF barrier is structurally similar to the BBB, but distinctly differs 
in the exchange of certain compounds as seen in Figure 3. For instance, calcium influx into the 
CSF from the blood is 10x higher than influx into from blood through the BBB. (Laterra et al., 
1999). This is thought to be related to the fact that the choroid plexus tissue is responsible for 
generating cerebrospinal fluid that is then circulated through the ventricles of the brain, as well 
as the surrounding subarachnoid layer covering the whole brain (Johansson et al., 1997). The 
difference in distribution of CSF from blood may be what drives the difference in transport 
between the BBB and the blood-CSF barrier.  
 
23 
 
 
Figure 3: Structural representation of the blood-CSF barrier and transportation methods. 2 
Looking at drug delivery to the brain through penetration of the blood-CSF barrier, 
studies have demonstrated that facilitated diffusion and active transport from blood into CSF and 
active transport from CSF into blood are all mechanisms that occur at the barrier (Bhaskar et al., 
2010). It has also been quantitatively shown that the blood-CSF barrier is leakier than the BBB 
(Laterra et al., 1999). While our current research efforts are focused on entry through the BBB, 
we believe further research and efforts into drug delivery through the blood-CSF barrier is 
warranted and should be pursued in subsequent research efforts. 
2.3.0 Theranostics 
 Theranostics is a relative innovative field that is currently blooming due to the idea of 
personalized medicine. Personalized medicine is the mindset of how medicine can be tailored to 
each patient based on disease characteristics and bodily responses being different patient to 
patient. Theranostics however, relates to the novel idea of combining diagnostics and therapy. A 
single theranostic approach is defined as a methodology in which both modalities of therapy and 
2 Laterra J, Keep R, Betz LA, et al. Blood—Cerebrospinal Fluid Barrier. In: Siegel GJ, Agranoff BW, Albers RW, et al., editors. 
Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th edition. Philadelphia: Lippincott-Raven; 1999. Available 
from: http://www.ncbi.nlm.nih.gov/books/NBK27998/ 
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diagnostic imaging are incorporated (Kelkar, Sneha, Reineke, 2011).  Theranostics offer the 
ability to utilize a wide variety of imaging techniques in order to detect drug deliver while 
administration is occurring. Overall theranostics can be administered in the form of 
nanoemulsions utilizing the surface for imaging capabilities and the interior for drug reservoirs. 
Further detail will be provided for each of the major components pertaining to theranostics 
below. 
2.3.1 Diagnostics 
One component of theranostics is the diagnostic element, which allows for the viewing of 
where theranostic particles are accumulating once administered to the patient. Diagnostics is the 
methods taken to identify and locate a problem or disease. There are various imaging modalities 
that can be utilized for extracting diagnostic information from tissues. Magnetic resonance 
imaging (MRI) is used commonly to assess the location of gliomas. It was investigated in one 
study if the accuracy of MRI could be enhanced by using PET with an amino acid O-(2-
[F]fluoroethyl)-L-tyrosine (FET). After testing this imaging modality on 31 patients with 
suspected cerebral gliomas, it was concluded that MRI alone yielded 96% sensitivity and 53% 
specificity while the MRI and FET PET yielded 93% sensitivity and 94% specificity. (Pauleit et. 
al, 2005) 
There is also various fluorescence imaging techniques being used (Andersson-Engels et. 
al, 1997). An example is the quantum dots which are used due to their unique optical properties 
including high brightness (Zhang et. al, 2012). Computer-aided diagnosis (CAD) is currently 
being researched for medical imaging and diagnostic radiology. CAD is used by radiologists as a 
“second opinion” to make their final decision. This system can take lateral images which could 
lead to early diagnosis of a disease. (Doi, 2007) 
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2.3.2 Therapeutics  
Diagnostics plays a key role in understanding the extent of a patient’s disease but the 
addition of therapeutics attached to the diagnostic tool enables duality. Generally drug delivery 
has in the past developed several problems relating to: even biodistribution throughout the body, 
a lack of drug specificity toward an intended target cell, larger than needed doses due to systemic 
circulation, systemic toxicity, and overall adverse side-effects due to the needed increase in 
dosage size (Torchilin, 2000). With the advent of theranostics in combination with target specific 
drug delivery, all of these associated problems can be mitigated. These forms of targeting 
theranostics generally use a ligand attached to the surface that selectivity interacts with an 
overexpressed receptor which is attributed to a cancer and not that of noncancerous cells 
(Popescu, 2011). Overall, targeting specificity allows for a lesser dosage required due to a higher 
accumulation at target site and minimalization of systemic toxicity. This new paradigm has the 
ability to change the overall therapeutic index patients’ experience.   
While general drug delivery presents its own challenges, use of theranostics 
methodologies to the brain encounters its own challenges. The brain is encompassed by what is 
referred to as the Blood Brain Barrier (BBB). This barrier is comprised of endothelial cells which 
are tightly packed, leaving tight junctions that restrict solute flux from the blood into the brain. 
Due to these challenges, drug delivery to the brain has two main modes of arrival, either invasive 
or non-invasive (Pehlivan, 2013). Invasive delivery generally includes surgery in which a section 
of skull is removed and the therapeutic is delivered. The therapeutics can be either directly 
administered through injection or via a delivery device system. These procedures take time and 
result with a long healing period post-surgery. Non-invasive treatments are currently being 
26 
 
developed through the field of nanomedicines and are proving to be \advantageous to both 
patient and doctor.   
2.4.0 Nanoemulsions 
Nanoemulsions (NE’s) are nano-scale emulsions based primarily around the biophysical 
properties associated with surfactants, which are materials that decrease the surface tension 
between two liquids. Surfactants are usually amphiphillic molecules, which allow them to 
organize at the surface between two liquids. In the pharmaceutical and biomedical fields, NE’s 
have been defined as oil-in-water emulsions. Generally, their size tends to range from 100 to 500 
nm, though NE’s above and below this size exist (Shah et al., 2010). To achieve specific size 
NE’s, the oil phase and aqueous phase (containing surfactants) can be mixed and put through a 
high stress, high pressure, and mechanical extrusion process. Modifying the process (max 
pressure, length, and repetitions) will alter the size of the Nanoemulsions.  
The current process Nemucore uses to create their Nanoemulsions is high shear 
microfluidization of combined components, performed at 25,000 PSI for 10 cycles. This creates 
Nanoemulsions between 100-150 nm in diameter, which has been determined to be the optimal 
size for treatment of cancers. (Ganta et., al, 2014). 
2.4.1 The Oil Phase 
The internal components are safflower oil and flaxseed oil, purchased from commercial 
suppliers. Safflower oil contains a mix of fatty acids, but the most prevalent is linoleic acid, an 
omega-6 poly-unsaturated fatty acid (PUFA) (Babayan, 1987). While linoleic acid is not found  
in large amounts in the brain, it is a precursor used for the production of Arachidonic Acid, 
which is found in significant amounts in brain cells; when high levels of linoleic acid is fed to 
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rats, high levels of incorporation into brain tissue arachidonic acid was observed (Dopeshwarkar 
et al., 1971). 
Flaxseed Oil, also known as linseed oil, is derived from flax plants. Importantly, the main 
triglyceride component of flaxseed oil is α-linolenic acid, an Omega-3 PUFA (Vereshchagin & 
Novitskaya, 1965). While α-linolenic acid is not used extensively in the body, it can be used as a 
precursor for production of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both 
of which are found in significant amounts in the brain (Burdge & Calder, 2005). 
Drugs added to this oil phase must be lipophilic, and some drugs may need modification 
for efficient loading into the Nanoemulsions, like fatty acid derivative of temozolomide 
(Caccacio & Wrabel, 2014). Use of both flaxseed and safflower oil has been shown to increase 
uptake of the Nanoemulsions to the brain, likely due to the use of the oil components in the 
production of PUFA’s found in brain cells. By enhancing the oil itself to aid in preferential 
distribution throughout the body, Nemucore has further increased the functional capabilities of 
their Nanoemulsions. 
2.4.2 The Aqueous Phase 
Nemucore’s base Nanoemulsions are made from egg lecithin and PEG2000DSPE, which 
self-assemble around hydrophobic materials in water to form Nanoemulsions (Ganta et. al, 
2014). The surfaces of Nemucore’s Nanoemulsions are comprised mostly of the surfactant, 
which is made from egg lecithin. Egg lecithin primarily contains phosphatidyl-choline, and 
phosphatidylethanolamine (PE), which are amphiphilic surfactant molecules. The next largest 
component of the NE’s is the polyethlyne glycol (PEG) layer. Specifically, PEG is conjugated to 
1, 2-distearoyl-sn-glycero-3-phosphoethanolamine in a conjugate labeled PEG2000DSPE. The PE 
portion of the molecule behaves like the PE in egg lecithin, integrating itself into the surfactant 
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layer, and ensuring the PEG tail faces outwards on the NE surface. The PEG2000DSPE, self-
assembles around hydrophobic materials in water to form Nanoemulsions. PEG creates negative 
charge on surface of Nanoemulsions, is known to prevent immune system adhesion to NEs and 
increase systemic circulation times. The DSPE incorporates itself onto the lecithin surface of the 
Nanoemulsions. 
2.4.3 Nemucore Glioblastoma Research and Efforts  
Nemucore has built a solid foundational knowledge on the Nanoemulsions that provide 
targeted delivery of chemotherapy drugs for the treatment of breast and ovarian cancer (Ganta et 
al., 2014a; Ganta et al., 2014b). When they began looking at Glioblastoma Multiforme (GBM), 
early research showed that BBB penetration can be enhanced by loading their Nanoemulsions 
with safflower oil. Safflower oil’s high omega-6 polyunsaturated fatty acid content makes it an 
ideal core oil for the Nanoemulsions due to the high content of its derivatives in the brain. A 
group from the Biochemistry department at Worcester Polytechnic Institute, working on their 
major qualifying project (MQP) over the ‘13/’14 academic year, were able to create a stable 
Nanoemulsions that, when loaded with chemotherapeutic agents, displayed higher cytotoxicity to 
cells than the free drugs. Joseph Cacaccio and Eileen Wrabel were also able establish that the 
Nanoemulsions uptake through in vitro studies. Importantly, they were able to modify 
temozolomide to load it into the Nanoemulsions while still achieving an increased cytotoxicity as 
compared to free temozolomide. Additionally the team began research into potential targeting 
ligands, identifying alpha-7 nicotinic acetylcholine and mu-opioid receptors as potential targets 
(Cacaccio & Wrabel, 2014, unpublished; McCall et al., 2014). 
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2.4.4 Targeting/Imaging  
In order to give these Nanoemulsions diagnostic properties, gadolinium was chelated to 
diethylenetriamine penta-acetic acid (DTPA). Gadolinium chelated DTPA is commonly used as 
an image contrast enhancing agent known as Magnevist (Oudkerk et al., 1995). It works by 
shortening T1 relaxation times of adjacent protons and is useful in targeting GBM, as it will 
accumulate in areas with new vasculature and free protons (both of which are found in and 
around GBM’s). In Nemucore’s nanoemulsion, Gd-DTPA is conjugated to 
phosphatidylethanolamine (PE). PE inserts itself into membrane of the nanoemulsion, leaving 
the Gd-DTPA chelate on the surface (Ganta et. al, 2014). 
2.4.4.1 Targeting: Bradykinin, Alpha-7, and mu-opioid receptors 
 After researching a variety of potential targeting receptors, 3 receptors were chosen for 
this study; the B2 bradykinin receptor, the Alpha-7 homopentamer nicotinic acetylcholine 
receptor, and the mu opioid receptor. Once chosen, appropriate targeting moieties were found, 
and attached to a DSPE-PEG molecule allow the receptors to incorporate into the manufactured 
Nanoemulsions. 
For targeting of the B2 Bradykinin Receptor (B2BR), Cereport has been shown 
increasing BBB permeability through activation of B2BR and subsequent transient opening of 
the Blood Brain Barrier (Bartus et. al, 2000). Identification of an obtainable receptor inhibitor is 
also needed. Icatibant is a peptidomimetic drug made up of 10 amino acids, and has been shown 
to be a potent inhibitor of B2 bradykinin receptor (Cockcroft et. al, 1994). Bradyzide is a 
bradykinin B2 inhibitor that has as 1-(2-nitrophenyl)-4-benzyl thiosemicarbazide core (Burgess 
et. al, 2000). 
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Alpha-7 nicotinic Acetylcholine Receptor (Alpha-7 nAchR) is found primarily in the 
brain, making it a viable target for our Nanoemulsions (Pohanka, 2012). For targeting, a peptide 
sequence obtained from loop 2 of Toxin B in King Cobra Venom has been shown highly 
efficient targeting of alpha-7 nAchR (Zhan et. al, 2010). The individual sequence is conjugated 
to PE and added to the nanoemulsion manufacturing process to create expression on the NE 
surface. A potent competitive targeted inhibitor of this receptor is Nicotine, a 
parasympathomimetic alkaloid which acts as an AchR agonist (Albuquerque et. al, 2009). 
Mu-Opioid Receptor is primarily found in the brains and gastrointestinal tracts of 
mammals. Demorphin, a natural peptide opioid, targets the mu-opioid receptor and has agonistic 
effects. (Amiche et. al, 1988; Mizoguchi et. al, 2011; Broccardo et. al, 2003) A competitive 
targeted inhibitor is Naloxone that is unique in that it is the only known pure antagonist of opioid 
receptors, meaning that is does not also induce some agonist effects (Evans et. al, 1974). Like the 
other targeting moieties, naloxone is chemically bound to PE and used as part of the surfactant 
layer of the nanoemulsion, expressing the naloxone only on the nanoemulsion surface. These 
receptors are important for the Gd-NEs to target and deliver chemotherapeutics. The Gd-NEs can 
then be imaged to prove targeted specificity of the particles to the tumor site.  
2.5.0 Clinical Imaging for the Brain 
Clinical Imaging has been an integral part of diagnosing and treating Glioblastoma 
Multiforme. Within this field there exist multiple forms of imaging modalities for both the 
surgical and clinical environment. While a multitude of imaging methods are available for 
imaging the body, certain imaging modalities display better visualizations of the brain. These 
modalities include Positron Emission Tomography (PET) and Magnetic Resonance Imaging 
(MRI).  
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PET and MRI have presented an opportunity for researchers to examine the correlation 
between human behavior and neurobiological signals (Raichle et. al, 2006). This was first 
presented with the use of PET and was later expanded upon by utilization of functional MRI 
(fMRI). PET imaging works through the detection of gamma rays which are emitted indirectly 
via a positron-emitting radionuclide (also known as a tracer) which is ingested by the patient 
(Bailey, 2005). Due to the fact that the visualization is based on the concentration of gamma rays 
given off by the tracer, it is generally used for imaging functional processes within the body. 
MRI however is designed to investigate the anatomy and physiology of the body. It is able to do 
so through the use of magnetic fields and radio pulses to analyze the reaction of hydrogen atoms 
in order to produce an image. As a result of its capabilities, MRI has become the gold standard 
for clinical imaging of the brain.  
2.5.1 Magnetic Resonance Imaging 
The mechanism by which magnetic resonance imaging works to visualize data is through 
the spin orientations of unpaired protons (hydrogen molecules in water) contained in the body. 
The spin of protons is due to the body’s placement inside an external magnetic field created by 
the MRI machine. The field causes the protons to align according to the orientation of the 
magnetic field and radiofrequency impulses. Radiofrequency waves at specific frequency 
indexes are sent into the patient, and this causes an alteration in the spin of the protons and 
ultimately changes their alignment as a result of new magnetic field. The returned 
radiofrequency pulses and the removal of these pulses is the cause of the protons returning to 
their original alignment. This return in alignment leads to a change in wavelength and is 
measured as the relaxation value. (Hashemi et. al, 2012).  
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There are two weighted MRI relaxation times that refer to the alignment of hydrogen 
molecules in tissues. Both of these relaxation times deal with protons returning to their original 
alignment after a period of excitement of radiofrequency pulses that alters their spin or direction 
and thereby produces an image based on the resonance of the molecules. T1 (longitudinal) deals 
with recovery of magnetism and T2 (transverse) deals with decay of magnetism of the protons in 
different orientations. T1 and T2 are inherent properties of tissues, and they relate to the 
relaxation times of protons within the water molecules contained in tissues. Relaxation times for 
MRI refer to the directional spin of the protons when the energy states for the protons are low. 
This low energy environment will then cause the protons to align in the same direction as the 
magnetic field once the radiofrequency is inhibited. T1 relaxation time specifically deals with the 
time it takes for the proton to align longitudinally or in an upright axial position and go back 
down to a rested state. T2 is the transverse relaxation time that results from echo frequency 
bursts and zonal areas, and the time it takes for the protons to go from an excited spin state to a 
relaxed state in these small burst. A visual explanation of this process can be seen below in 
Figure 4. T1 has better expression of water which can be found in glioblastoma tumor sites and 
imaging the cerebral cortex. The resonance of these protons from excitement of radiofrequency 
pulses creates image by emitting energy. (Hashemi et. al, 2012)  
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 Figure 4: T1 and T2 relaxation times in terms of echo frequency. 
 
T1 and T2 are able to image with less proton density, and they can produce bright images 
with paramagnetic substances like gadolinium and manganese. These substances are developed 
utilizing their large surface concentration of metal ions with high magnetic moments as new 
types of T1 MRI contrast agents that allow for imaging of body tissues during simultaneous 
targeted drug delivery. T1 is used instead of T2 because T2 focuses on more fibrous tissues than 
neural tissues. Additionally, T2 weighted MR images portray a dark domain that has a lower 
signal intensity than T1. (Na et. al, 2009). Current T1-weighted 3D Gradient Echo MRI utilizes 
the T1 signal of pulse sequences in the electromagnetic field to show tissue relaxation times 
within the brain. T1-weighted MRI’s have short echo and repetition times to facilitate quick 
imaging in order to capture complete drug delivery in specific areas of the brain. (Watanabe et. 
al, 2001). The consistency of T1 weighted MRI scans in living rats before and after drug 
injection allows for high resolution visualization of the neural pathways in in vivo 
experimentation (Watanabe 2001). Therefore by developing these 3D imaging techniques we 
will be able to showcase specific regions of the brain from T1 weighted MRI scans. 
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2.6.0 Data Analysis 
While currently the gold standard of imaging for cancer’s such as Glioblastoma 
Multiforme is conducted with Magnetic Resonance Imaging (MRI), there is currently very little 
available in the way of analyzing this data for quantitating therapeutic delivery in a research or 
clinical setting. In a clinical setting, visual representation is given by most MRI machines which 
reveals anomalies in the soft tissue via small image analysis. However if statistical analysis is 
required for research there is almost no previously created program that enables and 
demonstrates specifically chosen operators, functions, and visual representation. The majority of 
brain MRI studies use spatial normalization of voxel images to show contrast for ROI based 
imaging (Scherfler, 2006).  
The primary step in this analysis process is to create a template in Microsoft Excel that 
incorporates all mathematical operators required for relevant statistical analysis. These templates 
are specific to the present study, do not offer much in the way of customizability, and take a 
great deal of time to create. Once the template is created it must be manually populated each 
round of experiments and as such can become very time consuming. Due to this, a need is 
present for an automated program that enables relevant statistical analysis to be completed 
without manual direct input for isolated anatomical regions of the brain.  
2.7.0 Rat Brain Atlas 
The Atlas program, developed at Northeastern University by Dr. Craig Ferris and Dr. 
Praveen Kulkarni, allows for visualization of a vole brain in order to show the different regions 
graphically by sectional analysis. Initially adobe illustrator was used for the project, however due 
to vector graphics capability as well as the small file sizing, it presented some underlying issues 
for 3D formation. These issues centered around regions either being over defined or under 
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defined with too much or little data visually presented. Upon completion of the 2D model, a 3D 
model was created through the use of an algorithm. Two techniques, linearization smoothing and 
decimation, were used in order to improve the visual surface quality of the model. In order to 
view both the 2D and 3D models, any image processing program can be used but primarily 
MIVA should be used. (Ferris et. al, 2013) 
 This program will be utilized in order to section T1 weighted MRI scans into both the 
174 underlying regions of the brain and then into 22 greater regions. Once regionality has been 
conducted, data will be imported into MatLab to further conduct statistical analysis and 
visualization. 
2.8.0 MatLab 
 MatLab will be utilized for the creation of the 3D Gd3+ accumulative Heatmap of the rat 
brain from post Atlas program regionality. MatLab is a high-level computational language that 
specializes in numerical computation, visualization, and programming capabilities. Given these 
capabilities, numerical statistical analysis (such as t-test and specificity indexing) have the ability 
to be programmed and functionalized in MatLab. Similarly, upon conducting the statistical 
analysis, MatLab provides an environment in house in which the data can then be presented in a 
visualization of a brain model with a corresponding gradient. These capabilities demonstrate that 
MatLab is an able programming language environment to conduct the 3D Heatmap portion of the 
project.   
2.9.0 Statistical Analysis 
For the scope of this project a great deal of statistical analysis is required to determine the 
significance and specificity of targeted Nanoemulsions to interact with their cognate receptor 
located within brain. Imunohistochemical studies have indicated the relevant areas where the 
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receptors (mu. Alpha R, and B2) can be found in pathology studies (Albuquerque et al. 2009; 
Amiche et al. 1990; Chen et al. 2000; Goodman & Pasternak 1985; Pomper et al. 2005; 
Quirionet al. 1983; Raidoo et al. 1996; Recht et al. 1985; Seguela et al. 1993; Tribollet et al. 
2004).  Here the targeted Nanoemulsions are interacting with receptors in an intact healthy rat 
brain.  Therefore there needs to be a high degree of certainty that a signal from the resulting MRI 
is truly “above the noise”. Statistical tests, specifically t-tests will be required for comparing data 
for pre scanned brains and data of post scanned drug release. Testing for the null hypothesis, or 
general question on relationship between different MRI data sets, a t-test is used to imply 
statistically significance of data within the set. This test is done to determine whether the 
relationship between the data sets is significant as well. The data sets are considered to be 
populations, and the means are taken for the t test. The equation below will be utilized for single 
sample t-testing.  
𝑡𝑡 = ?̅?𝑥 − 𝜇𝜇0𝑠𝑠
√𝑛𝑛
 
In the above equation μ0 is the population or data set mean,  is the sample mean, s is the 
sample standard deviation and n is the sample size. Single sample t-tests have a degree of 
freedom n-1. For a sampling of data set or population that is random the means will be 
normalized based off of the central limit theorem. (Box et. al, 1978) These test will be conducted 
in order to show if the uptake of targeted Nanoemulsions show significant responses in particular 
regions of the brain when compared to non-targeted Nanoemulsions in rats.  Through this 
analysis testing for the individual data points can be done in order to show over responses to the 
drug.  
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Traditionally specificity of T1 weighted MR data are forms of normalization to show 
how changes in MR measurement correspond to spatial and volumetric changes used in clinical 
diagnosis. This is done by finding the contrast and differences in MR data and dividing it by 
overall MR data and volume of desired area (Laakso, 1998). Specificity can deal with false 
positives along with overall expression in the brain.  
To better show the overall changes in the data a false discovery rate analysis can be 
conducted to compensate for any negative response for the statistically significant data. This 
false discovery method is used for testing multiple null hypotheses or relationships between data 
sets that have more than 5% rejected. In order to avoid large numbers of errors from falsely 
rejected null hypotheses the following variable equation can be utilized in a better normalization 
of the data: 
𝑄𝑄𝑄𝑄 =  𝐸𝐸(𝑄𝑄)  =  𝐸𝐸{𝑉𝑉/(𝑉𝑉 +  𝑆𝑆)}  =  𝐸𝐸(𝑉𝑉/𝑅𝑅) 
In the above equation Qe is a random variable representing the expectation of Q. Where 
Q= V/(V + S) which is the number rejected. Vis the declaration of significance for the true 
statement of the null hypothesis and S is a non-true response declaration of significance for the 
null hypothesis. This false discovery rate method helps indicate which values of the large 
number of rejected data points in the targeted drug data are actually significant in the overall 
results of the data. (Benjamini et. al, 1995) 
Another initial form of data analysis that has to be completed before any statistical 
analysis can occur is the calculation of voxel weighted means for T1 weighted MR data. The 
nature of MRI contrast data is that each point is a voxel, or a compilation of 3D pixel data points, 
in relation to specific areas of the brain. The T1 relaxation scans export contrast MR data points 
with an associated number of voxels for each mean and standard deviation based off of region of 
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the brain. In order to have an accurate statistical analysis each mean value first has to be 
normalized by its corresponding voxel weight to have spatially normalized parametric images 
and data values (Scherfler, 2006). The following equation is representative of the data analysis 
used for each ROI to obtain its corresponding voxel weighted average.  
𝑆𝑆1� = 𝑆𝑆1𝐷𝐷  
Where S1 is the voxel value for an individual ROI 𝐷𝐷 = ∑ {𝐃𝐃1, . . . ,𝐃𝐃𝑛𝑛𝑛𝑛1 }, which is the sum 
of voxels for the larger region the individual ROI is located in (Jones, 2002). The voxel 
weighting done by the equation above is accommodative of the individual anatomic variability 
that occurs for each region of interest for each scan. Each normalized weight value between the 
regions of interest can have their spatial similarities between neighborhoods in overlapped 
regions accounted for by averaging the mean values by the weight per larger region (Gu, 2006). 
These voxel weighted regions of the brain are representative of the categorical comparisons 
between the targeted and non-targeted for all scans. 
With T1-weighted MR data there can be random variation in signals due to the gradient 
nature of echo images and any movement from the animal or person during a scan. Therefore a 
normalization between pre-injection and injected time points is calculated to decrease the 
variability. By decreasing variability in results, the ability to detect changes in images remains. 
Fortunately these discrepancies between scans are distinguishable from the desired observable 
pathological changes and can be accounted for by anatomical location (Lemieux, 1998). The 
spatial normalization of voxel weighted means accounts for predicted variability, whereas the 
normalization between a prescan and the subsequent experimental scans accounts for overall 
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changes in T1 relaxation times. The equation below shows the normalized values between 
prescan and subsequent scans: 
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑄𝑄𝑁𝑁 𝑀𝑀𝑄𝑄𝑁𝑁𝑛𝑛 𝑉𝑉𝑁𝑁𝑁𝑁𝑉𝑉𝑄𝑄𝑠𝑠 = |𝑀𝑀𝑄𝑄𝑁𝑁𝑛𝑛 𝑁𝑁𝑜𝑜 𝑇𝑇𝑁𝑁𝑁𝑁𝑇𝑇𝑄𝑄𝑡𝑡𝑄𝑄𝑁𝑁 𝑆𝑆𝑆𝑆𝑁𝑁𝑛𝑛 −𝑀𝑀𝑄𝑄𝑁𝑁𝑛𝑛 𝑁𝑁𝑜𝑜 𝑃𝑃𝑁𝑁𝑄𝑄𝑆𝑆𝑆𝑆𝑁𝑁𝑛𝑛|  
By finding the absolute value of the normalized mean values the desired changes in 
activity and relaxation times can be observed and quantified. Scans after injection can be 
compared to a normalized control scan which will then have further statistical tests to show 
significance that is done on a voxel-by-voxel basis (Lemieux, 1998). 
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3.0.0 Project Strategy 
 This project was conducted in conjunction with Nemucore Medical Innovations Inc. 
Nemucore Medical Innovations Inc, was founded with the purpose of improving patient care 
through the development of nanomedicines. One line of research is into nanomedicines for the 
cure of Glioblastoma Multiforme and it is the goal of this project to help improve the efficacy of 
this research and provide improved analysis techniques. In the following chapter, we will outline 
the path our team took in order so solidify the capabilities of this project and ensure that our 
sponsor received validated results. 
3.1.0 Client Statement  
Nemucore Medical Innovations has been developing targeted Nanoemulsions (NE) for 
cancer therapies since its foundation in 2008. Through the development of a stable nanoemulsion 
with controllable size, Nemucore has launched preclinical animal trials for the targeted 
Nanoemulsions for breast and ovarian cancer, with plans to move onto Phase 1 trials in the near 
future.  
Nemucore has built a solid foundational knowledge on the Nanoemulsions that provide 
targeted delivery of chemotherapy drugs through Nanoemulsions for breast and ovarian cancer 
(Ganta et al., 2014a; Ganta et al., 2014b). When they began looking at Glioblastoma Multiforme 
(GBM), early research showed that BBB penetration can be enhanced by loading their 
Nanoemulsions with safflower oil. Safflower oil’s high omega-6 polyunsaturated fatty acid 
content makes it an ideal core oil for the Nanoemulsions due to the high content of its derivatives 
in the brain. A group from the Biochemistry department at Worcester Polytechnic Institute, 
working on their major qualifying project (MQP) over the ‘13/’14 academic year, were able to 
create a stable Nanoemulsions that, when loaded with chemotherapeutic agents, displayed higher 
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cytotoxicity to cells than the free drugs. Joseph Cacaccio and Eileen Wrabel were also able 
establish that the Nanoemulsions uptake through in vitro studies. Importantly, they were able to 
modify temozolomide to load it into the Nanoemulsions while still achieving an increased 
cytotoxicity as compared to free temozolomide. Additionally the team researched potential 
targeting ligands, alpha-7 nicotinic acetylcholine and mu-opioid receptors (Cacaccio & Wrabel, 
2014, unpublished; McCall et al., 2014). 
Furthermore research by Nemucore has led to the identification of the B2 bradykinin 
receptor as a potential target (unpublished data), due to the transient opening of the BBB upon 
receptor activation (Chen et al., 2000). Using the above mentioned receptors (MOR-targeted, 
alpha-7 targeted, and B2 bradykinin) Nanoemulsions containing targeting ligands were 
manufactured, and animal trials on rats were conducted during the summer of 2014. These 
results from the study are the basis for the MatLab Statistical Heatmap program to be created in 
this project. As such our initial client statement was defined as the following: 
 
Nemucore as part of its NCI U54-funded Center for Cancer Nanotechnology Excellence 
(CCNE) research has developed a series of nanomedicines which enter the brain. 
Magnetic Resonance Imaging (MRI) can be used to track these nanomedicines in vivo. 
The focus for this project is as follows: 
•   Creating a MATLAB program capable of displaying MRI drug delivery data in order 
to visualize distribution intensity of drug in vivo. 
•   Designing and synthesizing experimental nanomedicines as well as testing novel 
nanomedicines in vitro for uptake and cytotoxicity potential.   
 
Since the initial client statement, Nemucore has had a clear and focused idea of the in 
vitro experimental portion of our project. The MRI T1 visualization by brain region has a 
primary success/fail objective, and further improvements beyond that have been left to the 
discretion of the group with input from Nemucore. It follows that the revised client statement is 
therefore very similar to the original, although it contains clarifications on connecting the image 
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analysis and targeting experiments into a coherent attempt to prove targeting specificity in vivo 
for future research. The finalized client statement can be seen below.  
Revised Client Statement: 
Nemucore as part of its NCI U54-funded Center for Cancer Nanotechnology Excellence 
(CCNE) research has developed a series of nanomedicines that have the capability of 
entering the brain. Using the Nanoemulsion technology developed my Nemucore Medical 
Innovations, we will create a comprehensive imaging and analysis program to determine 
the targeting specificity of Glioblastoma treatment, and improve therapeutic diagnosis. 
We will create a MATLAB program capable of displaying MRI drug delivery data in 
order to visualize distribution intensity of drug. By designing and synthesizing 
experimental Nanomedicines, we can perform in vitro for uptake studies to confirm 
comprehensively that diagnostic evaluation of this Nanoemulsion therapy is directly 
linked to targeted specificity of the therapeutic system. 
 
3.2.0 Approach  
There are several different considerations when planning how to approach a project of 
this magnitude. The primary consideration involves looking all components of the project and 
how to address them in a manner that allows for proper time and consideration to be applied to 
everything. Overall it was decided by the project team to divide into two large topics, the 
biological side and the program side. Within each sub-group, group members were assigned 
different focuses so that multiple parts of the project could work in parallel. The breakdown of 
major components of the project became as follows: Group member 1: Nanoemulsion 
manufacturing, Group member 2: cell culture, Group member 3: statistical analysis, and Group 
member 4: visualization. In this manner, each group member was able to work on separate 
portions of the project while having another member available to collaborate. In order to 
maintain a working time line for set goals throughout the course of the project, a Gantt chart was 
created through the use of Microsoft Project Planner. This was a live document that was 
iteratively updated as tasks varied from original completion time. An abbreviated version of this 
Gantt chart can be seen in Appendix 6. 
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In order to maintain communication between the project sponsor, Tim Coleman, the 
project advisor Patrick Flaherty, and all group members various sets of meeting times were 
implemented. Weekly meetings with Mr. Coleman were established at the start of every term to 
ensure updates occurred in real time. Bi-monthly meeting were created with the on-campus 
advisor to keep him informed of all progression and challenges encountered. Between group 
members bi-weekly meetings were established to meet as a whole group throughout A, B, and C 
term. This was later changes to more frequent meeting times as the project started coming to a 
close. Within sub-groups of the project, meeting times were subjected to preference, need, and 
time constraints but overall were more frequent that group meetings. Open communication 
between all parties involved was maintained through email, phone, and in person contact. 
               
Due to collaboration with Nemucore Medical Innovations Inc., which is funded through 
the Ivy Foundation 3 million dollar brain cancer research fund, this project was entirely funded 
through this avenue. Therefore WPI funding was not utilized through the course of this research. 
 
3.3.0 Objectives and Constraints 
Through this thorough client statement, a set of objectives and constraints were amassed 
for each side of the project. Through these objectives, primary, secondary, and tertiary objectives 
were determined. The following section outlines these objectives and constraints and how they 
pertain to the project and client, Nemucore. 
3.3.1 Objectives 
Overall the objectives of this project represent both imaging and drug delivery aspects of 
theranostics. These include targeting and inhibition testing of Nanoemulsion systems with the 
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focus of targeting Glioblastoma Multiforme, as well as the analysis of these experiments within a 
MatLab based Heatmap program in order to display targeting dispersion across the brain.  
3.3.1.1 Nanoemulsions Primary Objectives 
Our primary objective for the Nanoemulsions (NE) being tested in vitro is proving 
targeting specificity through the addition of targeting moieties. Once we can achieve this, our 
next objective is to prove that targeted, drug-loaded Nanoemulsions are more toxic to 
glioblastoma cells than non-targeted Nanoemulsions. If Nanoemulsions can be achieved, our 
final objective is prove that the targeted Nanoemulsions preferentially target glioblastoma cells 
over healthy brain cells. Overall, these objectives are important to meet in order to ensure the 
Nanoemulsions can be both created with targeting ligands and more importantly be tested in 
vitro to confirm the results, prior to in vivo experimentation of the NEs.  
3.3.1.2 Nanoemulsions Secondary Objectives 
 The secondary objectives for the proof of concept in vitro cell experiments will be 
presented based on how they will aid in accomplishing the primary objectives. In order to 
achieve the first primary objective of proving targeting specificity, the secondary objectives will 
be to perform flow cytometry which is ranked 1, as well as performing fluorescence imaging 
which is ranked 2, of targeted versus inhibited NEs. The next primary objective was to prove that 
targeted NEs are more toxic than the non-targeted NEs. In order to achieve this primary 
objective, the secondary objective is to perform cytotoxicity assays including MTT assay which 
is a colorimetric assay for assessing cell viability. The last primary objective is to prove that 
targeted NEs preferentially target glioblastoma cells. Therefore the secondary objective is to 
compare different cell lines to use for the in vitro testing, for example U87mg cells (GBM cell 
line) and the neurons.  
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3.3.2 3D Statistical Heatmap Objectives 
The MatLab Heatmap program has a tiered objectives based on the need of Nemucore 
and the overall research value to the research community. Overall objectives were presented and 
ranked by the client Nemucore (via a pairwise comparison chart seen in Table 1. In order of 
priority, visualization, scalability, file format, and user friendly were the stated objectives. These 
objectives are explained in further detail below in their respective ranked order and can be teen 
in Table 1. 
 
 Visualization User Friendly File Format Scalability Total 
Visualization  1 1 .5 2. 
User Friendly 0  .5 0 .5 
File Format 0 1  .5 1. 
Scalability .5 .5 1  2 
Table 1: Pairwise comparison chart for heat lab objectives. 
3.3.2.1 3D Statistical Heatmap Primary Objectives 
Primary objective of the 3D Heatmap are the visualization of the brain with three 
intensity gradients in different colors for pre-scan, non-targeted, and targeted of T1 weighted 
MRI data. Visualization is the over encompassing objective for this project with a need for 
scalability between defined 174 regions of the rat brain. This scalability will be achieved through 
statistical value displays depending on region layer. This is the ultimate goal for the software 
program in the future will be to visually represent the location of targeted Nanoemulsions with 
respect to the presence of Glioblastoma Multiforme for in vivo research. The Heatmap 
visualization must be a clear representation of the given MRI data while demonstrating the 
defined 174 regions supplied via the Rat Brain Atlas program. 
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3.3.2.2 3D Statistical Heatmap Secondary Objectives 
In order to accomplish the overarching goal of visualization several subsidiary objectives 
must be met. These objectives include statistical analysis for determining the specificity index. 
Through the differences in preoperative data with the targeted and non-targeted Nanoemulsions, 
an average ratio can be calculated. This ratio will be calculated for each of the 174 regions and 
an average will be taken for the overarching 23 regions. From this specificity index a quartile 
analysis can be done to show the top 25% of the data. It is this top 25% that will represent the 
markers for the heatmap to show drug distribution in the 174 and 23 regions of the brain. These 
values will have corresponding color indexes for each respective gradient across the 
visualization. 
3.3.2.3 3D Statistical Heatmap Tertiary Objectives 
 In order for overall visualization and statistical analysis to be conducted the data from all 
three scans must first be collected and then converted into a usable format for this software 
program. The collection of the data, is primarily due to the projects collaborators location in at 
Northeastern University in Boston. This data will be accessed via a remote cloud once the scans 
have been completed. As for the data itself conversion is not in reference to a manipulation of the 
data but rather a further definition. The collected data from each MRI scan must be run through 
the Rat Brain Atlas. This program defines the data by the 174 regions of the rat brain. Once this 
has been conducted, statistical analysis on each region can be conducted. 
3.3.3 Constraints 
Through the course of this project, many aspects will act as constraints and the most 
important one is time. This project incorporates two sub-sections of work, the MatLab Heatmap 
as well as the targeted Nanoemulsions. Overall, the main constraints that we will encounter in 
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this project will include time, small sample sizes, cost, significance from statistical analysis (t-
tests), and acceptable false discovery rates.  
3.3.3.1 Nanoemulsions Constraints 
For the in vitro cell work, the U87MG cell line to be used for experiments are relatively 
slow growing, which has a major effect on the planning and implementation of experiments. 
There may also be limited receptor availability on the cell surfaces which would reduce the 
targeting ligands to be used on the NE’s. Contamination of the cells could also set back 
experiments by several weeks which poses a constraint for our timeline to see positive results by 
January. 
An overlapping constraint for the sample size is the cost. Animal experimentation is 
expensive and by expanding the sample size the cost of experiments increases dramatically. 
Adding the need to use MRI technology in order to image the data is also costly. The feasibility 
for increasing the sample size is not entirely possible for the scope of this project, but will be 
expanded in future years. Although programing the Heatmap will not have much cost associated 
with it, the manufacturing the Nanoemulsions is costly as it is long process. The production of 
the Nanoemulsions is a half-day process. Additionally, even though the NEs can be frozen after 
being manufactured, they still have a limited shelf-life before breaking down. If we are unable to 
successfully create our designed Nanoemulsions in sufficient quantities, we will be unable to 
carry out our in vitro experiments, as well as provide NE’s for animal trials conducted by 
researchers at NEU. 
The last constraint for the NE’s include that they must be about 150 nm in diameter. This 
is because if the particles are too big, they will not be able to pass through the Blood Brain 
Barrier in vivo. At this size, the NE’s would also be able to take advantage of the enhanced 
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permeability and retention effect of GBM. In contrast if these NE’s are too small (less than 100 
nm), the particles would accumulate anywhere in the body and not just specific cancer sites.   
3.3.3.2 3D Statistical Heatmap Constraints 
As with any project, time is an important consideration and planning ahead is always 
necessary in order to allocate enough time to accomplish the goals outlined in the project 
approach. The MatLab coding for creating the Heatmap is time consuming and sufficient time 
needs to be set aside for debugging the code. Ideally, the Heatmap should be finished (or the 
most basic functional version implemented) by the end of December, as Nemucore has continues 
to generate data that could benefit from this analysis. Grant and patent application plans also fall 
in the time period from December to January for Nemucore, which puts a sense of urgency on 
developing this program as soon as possible to strengthen Nemucore’s claims. Another time 
constraint has to do with the functionality of the code. It takes a certain amount of time to load 
the data and process the data through the functions and visualizations that will be set up with the 
code. The code should not take more than a few minutes to fully compute the visualized 3D 
heatmap, and the more robust the code the more time it will take for data processing.  
Two major constraints for the heatmap is the generating visualization of a rat brain and 
distinctly showing the drug distribution in all 174 regions of the brain. These two constraints are 
the most important and related because without the brain visualization there will be no 
distinction of the 174 regions and vice versa. The need to have an overall encompassing brain 
visualization to show drug distribution in these regions is not only the main goal and objective 
but also a major constraint. Any failure or deviation from this goal will set the entire project back 
and therefore these two aspects must be met.  
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One of the other major constraints facing the team is the small sample size. Currently 
only a sample size n=3 (animal trial data) is being used to determine brain reactivity and receptor 
response for the targeted Nanoemulsion. A larger sample size will be needed in order to ascertain 
significant data for all 174 regions of the brain. The cost of running these experiments is the 
primary limiting factor, and only with convincing preliminary data can we make the case for 
further animal trials. 
In performing statistical analysis of the individual voxels or 3D pixel dta points (scanned 
for drug delivery) that comprise the 174 regions of the rat brain, t tests are required for each 
individual voxel. The t-test will be a constraint in amongst themselves because of the potential 
for greater than 10% error margins. The T1 relaxation data will result in anywhere from 20,000 
to 50,000 voxels of data and in order to see the responsiveness of each small data point, a t test is 
needed to show each voxel’s statistical significance. One problem from this type of statistical 
analysis is having over the 5-10% rejection rate. The relatively small size of certain regions of 
the brain correlated with a small voxel sets a limit to this t-test analysis. As such, voxels that are 
adjacent to one another can produce failed hypothesis tests for the targeted receptors. If two 
smaller regions of the brain are adjacent and one has no receptor recognition and has a p value 
greater than 0.1, subsequently this causes an adjacent voxel to also have an increased p value and 
inadvertently fail the t test (potentially falsely failed). If this is the case then there would be less 
than 90% confidence, and the constraining problem would occur in determining which areas are 
actually expressed, in comparison to those that are not.  
The false discovery rate will help to compensate for the issues of non-statistically 
significant p values from the t test. Though this rate equation can overcompensate for the 
multiple hypothesis testing that occurs from the t tests for each individual voxel. If the null 
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hypothesis is rejected incorrectly consistently throughout the t tests, then the false discovery rate 
is an excellent method for adapting to permissive and constrictive data. The challenge of the 
false discovery rate is in determining which voxels have been wrongly rejected by the t test. 
Therefore it is essential to ensure the false discovery rate will not wrongfully interpret the given 
data. (Benjamini, 1995).   
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4.0.0 Alternative Designs 
 Following the establishment of a project strategy, analysis was conducted in order to 
create preliminary designs for both the targeting efficacy of the Nanoemulsions, the statistical 
analysis, and visualization for in vivo studies, were devised. These designs helped to understand 
specifications, needs, and wants of recipients and prospective users.  
4.1.0 Needs Analysis 
 As listed previously in Section 3, there are a variety of objectives for the different 
components of this project. In order to understand and maintain each set of objectives a weighted 
objectives table was created for various sections of the project. Only main objectives were scored 
utilizing a 1-5 scale, with one being the least important and five being most important. This five-
point scale allowed us to see in a linear fashion the importance of each objective and thus create 
proximate conceptual designs. These tables can be seen below with attributed scores.  
4.1.1 Nanoemulsions 
The nanoemulsions are composed of an aqueous and oil phase containing the various 
components needed. The main objectives for the nanoemulsions are listed in Table 2 below and 
ranked using the aforementioned scale. 
 
Objective Score 
Easy to manufacture 3 
Stable over time 5 
Increased uptake by cells 4 
Non-toxic 4 
Low cost 2 
Table 2: Nanoemulsion high level objectives with weighted accompanying score. 
 The most important objectives for the nanoemulsions is that they must be stable over 
time, then show an increased uptake by the cells, and be non-toxic for in vitro analysis and rats 
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for in vivo analysis. Following that, they must be easy to manufacture and have a low cost to 
produce.  By utilizing these objectives, the nanoemulsions can be created with optimal properties 
for research and pre-clinical purposes. 
 
4.1.2 3D Statistical Heatmap  
 There are two main sections to the 3D Statistical Heatmap, in order to maintain 
independent objectives for both sections a breakdown of specific weighted objectives table were 
conducted. Observing the aforementioned scale both analyses can be seen below in Table 3.  
Objective Score 
Little user input 2 
Clear output 5 
Reproducible/Robust  4 
Cross-system compatibility 3 
Understandable for possible Debugging  4 
Table 3: Needs Analysis of non-technical components to the 3D Statistical Heatmap Program. 
 Upon running this program for either portion of this project there are objectives that must 
be maintained in order to ensure that the program is usable by the general population of users. As 
such a weighted objects table was created to ensure that these types of objectives were 
maintained throughout construction of this program. As seen above in Table 3, Clear Output was 
rated as highest and most important. Clear and easy to read outputs are very important given that 
this program is directed for a variety of users and thus if the output is complicated and hard to 
read, fewer users will utilize this program. At the opposite side of the scale, ‘Little User Input’ is 
ranked as the least important. Given that the user opens the User Guide (as instructed upon 
opening the program) regardless of how many files are needed, the instructions are easily 
understood and thus the input might be cumbersome but easily completed. While non-technical 
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objectives ensure the program is useable by a wide variety of people and systems, there are many 
technical objectives required for the success of both statistical and visual representation. 
Objective Score 
Utilizing Spatial Weighting of Voxels 5 
Normalization of Data to PreScan 4 
Averaging of Scans across test subjects n 3 
Specificity between Targeted and 
Nontargeted 
4 
T Test to show Significance  5 
Table 4: Technical statistical objectives for 3D Statistical Heatmap Program. 
As stated in Table 4, it can be seen that the spatial weighting of the regions of interest 
based of voxel numbers and spatial recognition of the areas of the brain is one the most 
important objectives. The other most important objective of the statistical analysis of the in vivo 
study data is the t test that are used to determine if the uptake is significant when compared to 
control animals. Normalization of the data with the prescan and the Specificity Index created to 
show percent uptake between the targeted and nontargeted averages were ranked second highest 
due to the need to have normalized data when comparing an experiment to a control. In addition 
the specificity index was ranked second due to the novelty in this approach of analysis 
Nanoemulsions uptake in regions of the brain. The averaging of the scans across the number of 
test subjects n is important to be done but for specificity the individual scans per rat is sufficient. 
Also for t test the test need to be done for the whole sample size, but can be conducted without 
finding averages.  
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Objective Score 
Utilizing connection algorithm 4 
Point Cloud generation 3 
Ease of Use 2 
Application of Heatmap 5 
Clear output 5 
Table 5: Objective scoring for visualization objectives of 3D Statistical Heatmap Program. 
The Statistical Visualization has many sub-objectives needed in order to recreate the rat 
brain atlas as a 3D model. As such only the main high-level objectives were chosen for the 
weighted objectives table seen above in Table 5. Application of Heatmap and Clear output were 
rated of highest importance in order to comply with our client statement. In order for these 
objectives to be met however other sub-functionality, such as those rated 4 and 3 (utilizing 
connection algorithm and point cloud generation respectively) must be addressed and utilized. 
Each of those is necessary to create the ability for the application of the heatmap. However, at all 
stages of the process the output can be clear and easy to see/read thus this functionality object 
was always maintained.  
4.2.0 Functions  
 To ensure all sections of this project are measurable, functions and specifications were 
discussed with our sponsor and created by the group. Described and listed below are relevant 
high level functions needed for each section. For a complete list of functional specifications as 
needed for the 3D Statistical Heatmap can be found in Appendix 1.  
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4.2.1 Nanoemulsions 
Functions Specifications 
Consistent Size 150nm and PDI <0.3 
Negatively Charged NE Surface -20 to -40 mV with SD <10 
Long Term Stability < 10 nm change in size over 3-4 weeks 
Fluroescence for uptake studies Loading of Rhodamine into NEs 
Table 6: Functionality of cell specifications with numerical parameters. 
A critical aspect of the Nanoemulsions is that they fall within a specified size range seen 
above in Table 6, which will create preferential passage through the loose junctions of cancer 
vascular epithelial cells over passage between epithelial cells in healthy vasculature tissue. We 
have determined an optimal size to be 150 nm, with a dynamic light scattering polydispersity 
index, which indicates the relative uniformity of particle size, to be less than 0.3. Another 
important feature of our Nanoemulsions is their evasion of the mononuclear phagocyte system, 
which can be evaded by creating a negatively charged surface to reduce protein-particle 
interactions. Our target goal for surface charge is for our Nanoemulsions to have a surface charge 
between -20 to -40 mV, with fairly small standard deviation of <10 mV. From a manufacturing 
perspective, the Nanoemulsions need to still be functional for greater than a month to justify their 
use as a theranostic tool, as creating them on demand would delay the original purpose of 
reducing the time to diagnose the effectiveness of a new therapy. 
4.2.2 3D Statistical Heatmap 
 In order for this program to work functions must happen in a specific order. First and 
foremost, the data must be correctly loaded, stored, and then saved for future use. Research 
demonstrated that a hash map or in MatLab a Containers.Map function allows for this type of 
data to be stored and later recalled. Secondly all numerical statistical analysis must be conducted. 
This is initiated by finding the voxel weight of each region of interest in regards to its 
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surrounding regions. Past research has shown that the optimal way of distinguishing one region 
from another is through the voxel spatial ratios and weighting of the associated MRI data. A key 
function in analyzing the data is to normalize it with the initial pre scan data to find the change in 
T1 relaxation over the different time points. This normalization serves the function of 
minimizing the noise of a resting brain. Specificity shows the contrast of drug accumulation and 
receptor response in the brain per region. The T tests are conducted to show confidence in the 
previous analysis, and without them there would be no statistical analysis to show that the results 
are valid. A compiled these functionalities and their specifications can be seen in Table 7. 
Functions Specifications 
MatLab Script will Load ‘n’ amount of 
data 
Read and store desired data through hash map 
ability. 
Store and sort all data with correct sub-section 
headings  
Voxel Weighting   Take Associated voxel weight of T1 data and 
find special ratio based on surrounding ROI 
Normalize Data  Normalize scan data with initial pre scan to 
find true value of drug uptake for T1 
relaxation times 
Specificity Index Have gradient heatmap show the top quartile 
(75%) for specificity per ROI 
T Tests  Have heatmap showing where 90% 
confidence per ROI is. 
Display 63 PNG’s in 3D Environment Alter PNG regions to demonstrate ‘see 
through’ in Photoshop. 
Utilize 3dplot function. 
Bound Sub-Regions in all 63 PNG’s Utilize Ramer-Douglas-Peucker algorithm 
Maintain all sub-regions per slice. 
Apply Heatmap to Bounded Regions Detect bound region edges 
Correspond regions between slices 
Table 7: Desired functionality and specifications describing these functionalities for the 3D Statistical Heatmap.. 
Without this analysis the heatmap cannot be applied. In order to demonstrate 
visualization 3dplot is used due to its ability to plot points in a 3D environment. Once the point 
are plotted for all 63 PNG slices, the Ramer-Douglas Peucker algorithm is utilized due to its 
ability to connect these points while not altering the overall visual consistency. This algorithm 
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also has been show to work efficiently while displaying minimal outliers for various sized data 
sets. Finally application of the heatmap must correspond through sections of various slices, 
which can be done through assigning these bound regions under a common variable. Overall 
these functions enable the complete statistical analysis and visual demonstration of the MRI T1 
weighted data for in vivo Nanoemulsion studies. 
4.3.0 Conceptual Designs 
 Through iteration and trial and error, successful methodology and results were conducted. 
To do this, decisions involving biology, statistical analysis, and programming were made by the 
team. This was in order to reach the final goal and in this sections the designs from these 
decision are discussed. 
4.3.1 Nanoemulsions 
As outlined in the client statement, this section of the project revolved around observing 
the characteristics and stability of nanoemulsions, and testing these nanoemulsions against cell 
lines to determine the efficiency and specificity of cellular uptake. To accomplish both of these 
goals, different experiments and instruments were identified. 
A zetasizer machine can be used to measure the size and zeta potential of the 
nanoemulsions, providing key data (initial size and surface charge) to observe that the 
nanoemulsions achieved the desired design characteristics. Periodic observations of the 
nanoemulsions using the zetasizer would inform us on the stability of the nanoemulsions over 
time, along with any changes in size or charge. 
In measuring the uptake of nanoemulsions in cells lines, several in vitro experiments 
were identified. The fastest experiment identified was fluorescent microscopy, in which 
nanoemulsions loaded with fluorescent molecules would be dosed onto cells, with observation of 
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uptake confirmed through microscopy of the samples using wavelengths that induce fluorescence 
of the marker molecules. While this could provide visually informative data, it is only qualitative 
data that is by itself is subject to scrutiny. Quantitative experimental data would also be needed 
to confirm any results, which can be deduced from the flow cytometry tests. 
Flow cytometry is a laser-based technology in which cells are passed single-file through a 
light beam that is set to excite fluorescent markers, while a detector analyzes fluorescent signals 
emitted from the cells (Dittrich & Gohde, 1973). This system allows high throughput 
quantitative analysis of cells through the use of fluorescent markers. After discussing with 
researchers at Nemucore, it was decided that this would be the best experiment to attempt to 
obtain quantitative data. 
4.3.2 3D Statistical Heatmap 
 Throughout the course of this project there have been constant iterations of code design. 
In order to have a comparable design however by which the final code could be checked against, 
a template was created in Microsoft Excel first. The template was designed based off of 
manually done statistical analysis performed on the in vivo studies in excel. This template 
automates the manual derivations and allows for the user to have results instantaneously. This 
template demonstrates all statistical analysis needed for the loading of the in vivo data files, first 
by sorting the data based off of ROI designation. The ROI designation of the 174 regions is 
organized based off of larger areas of the brain. These areas of the brain have associated voxel 
values, and therefore the excel template then uses the voxel values to weight the mean value per 
ROI. Then based off of preliminary MRI scan data the normalization of subsequent scan data is 
conducted for the control and targeted rats. The larger areas of the brain then have averaging for 
each scan per individual rat and then over all samples. The sample size of rats utilizes a 
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Nemucore developed specificity index, which is based off of averages of the targeted regions 
over averages of the control. Ideally the ROI’s having the most uptake can be seen from the top 
75% and thus a quartile analysis is performed with the ROI’s falling within that quartile being 
highlighted in excel. Finally based off of the sample size a t tests at a 90% confidence level 
between targeted and control is conducted for each ROI and for the larger areas of the brain. The 
final output of the excel template is have all ROI names and ID’s followed by specificity with 
top 75% values highlighted for first the larger regions of the brain and then the individual ROIs. 
Then following the specificity index the t test’s p values are arrange by larger regions then ROI 
and highlighted to show p values that fall within the 90% confidence range. All analysis 
descriptions can be found in Section 5.6.2.  
The condensed overall goal for this excel template can be seen in the following flow 
diagram. 
𝐿𝐿𝑁𝑁𝑁𝑁𝑁𝑁 𝐷𝐷𝑁𝑁𝑡𝑡𝑁𝑁 → 𝑆𝑆𝑁𝑁𝑁𝑁𝑡𝑡 𝐷𝐷𝑁𝑁𝑡𝑡𝑁𝑁 𝐵𝐵𝑁𝑁𝑠𝑠𝑄𝑄𝑁𝑁 𝑁𝑁𝑛𝑛 𝑅𝑅𝑅𝑅𝑅𝑅 → 𝑉𝑉𝑁𝑁𝑥𝑥𝑄𝑄𝑁𝑁 𝑊𝑊𝑄𝑄𝑁𝑁𝑇𝑇ℎ𝑡𝑡 𝑁𝑁𝑜𝑜 𝐷𝐷𝑁𝑁𝑡𝑡𝑁𝑁 →
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑡𝑡𝑁𝑁𝑁𝑁𝑛𝑛 𝑤𝑤𝑁𝑁𝑡𝑡ℎ 𝑃𝑃𝑁𝑁𝑄𝑄𝑆𝑆𝑆𝑆𝑁𝑁𝑛𝑛 → 𝐴𝐴𝐴𝐴𝑄𝑄𝑁𝑁𝑁𝑁𝑇𝑇𝑄𝑄 𝑆𝑆𝑆𝑆𝑁𝑁𝑛𝑛𝑠𝑠 → 𝑆𝑆𝑆𝑆𝑄𝑄𝑆𝑆𝑁𝑁𝑜𝑜𝑁𝑁𝑆𝑆𝑁𝑁𝑡𝑡𝑆𝑆 𝐶𝐶𝑁𝑁𝑛𝑛𝑡𝑡𝑁𝑁𝑁𝑁𝑁𝑁 𝐴𝐴.𝐸𝐸𝑥𝑥𝑆𝑆𝑄𝑄𝑁𝑁𝑁𝑁𝑁𝑁𝑄𝑄𝑛𝑛𝑡𝑡 →
𝑇𝑇 𝑇𝑇𝑄𝑄𝑠𝑠𝑡𝑡𝑠𝑠 𝐶𝐶𝑁𝑁𝑛𝑛𝑡𝑡𝑁𝑁𝑁𝑁𝑁𝑁 𝐴𝐴.𝐸𝐸𝑥𝑥𝑆𝑆𝑄𝑄𝑁𝑁𝑁𝑁𝑁𝑁𝑄𝑄𝑛𝑛𝑡𝑡  
This design for a template is a compilation of all the individual analysis conducted at 
Nemucore for the in vivo studies. For each set of data for the different receptor response similar 
statistical analysis was conducted. Significance was determined at 95% and 90% confidence to 
show how many regions of interest had significant uptake. The specificity was originally done as 
a percentage, but because of the increasing difference between control average and targeted 
average it was decided to make it a quotient of targeted over control. This quotient is a better 
representation of the uptake at specific ROI’s. The decision to make the template at a confidence 
of 90% was done based off of the idea that since the Nanoemulsions were crossing the Blood 
Brain Barrier and accumulating in regions of the brain, that a 90% confidence was enough to 
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show that a significant uptake had occurred. Thus the change from the original percentage idea 
and 95% confidence was seen early on in the project.  
There has been much trial and error associated with the visualization of the 3D rat brain 
model and applied statistical output. Given the nature of code, iterating and debugging have been 
key components to the preliminary design process. However as with anything there is a starting 
point, in terms of this visualization process the Northeastern rat atlas similarly structured to vole 
atlas seen below in Figure 5, is the basis of our visualization program.  
 
Figure 5: Demonstration of the Vole atlas model created by researchers at Northeastern University.3 
This 3D model seen below is comprised and built from a total of 63 portable network 
graphic’s (PNG). Each PNG slice denotes sections of the 174 individual regions of a rat brain 
cycled through from top to bottom. An example of these slices can be seen in Figure 5, denoted 
are all sub regions of the brain on that slice via abbreviated names, color coordination 
3 Ferris, Craig F., Ph.D, and Praveen P. Kulkarni, Ph.D. MRI Vole Brain Atlas. Boston: \ 
Ekam Solutions LLC, 2013. 
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(demonstrating regions that span across multiple slices), and explanations of all present 
abbreviations on each slice.  
After the alteration of all 63 PNG files the stack function was utilized in MatLab. While 
this was successful it demonstrated the need for ridding the slices of present text and that this 
function would not be usable with the slices in their current state. This was due to the slices still 
maintaining their grey background which would obscure any stacking with the other 63 slices 
making the program null and void. 
Upon this understanding, it was determined that the slices would undergo image 
processing in order to ensure opacity throughout all 63 PNG slices while maintaining sectional 
confinement. In order to achieve this, the PNG slices would need to be reconstructed in MatLab. 
In order to create whole regions out of the now created point cloud several methods were 
discussed. These methods ranged from normalized cuts and image segmentation to reduction of 
points need for digitizing a line. Two methods will be discussed below with the rational for 
which method was chosen following.  
A grouping algorithm which utilizes normalized cuts and image segmentation in order to 
unbiasedly measure disassociation between subgroups and association within subgroups was 
researched. This first method utilized an approach of measuring total dissimilarity between 
portions of an image as well as groups in the image that have total similarity within. This utilized 
generalized eigenvalue system to compute the minimum normalized cut needed for image 
partitioning. Through measuring the association value of connections between one node and all 
others on the image cut values are determined with the goal of “minimizing the disassociation 
between the groups and maximizing the association within the groups” (Shi, Malik, 1997). This 
method focuses not so much on the idea that there is a specific partition subset (which utilize 
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low, mid-, and high-level knowledge of the images) but instead use level knowledge to create 
further repartitioning and subgroup division based on association (Shi, Malik, 2000). This 
method demonstrates very clear dissection and partitioning of image portions (as seen in Figure 
6).  
 
Figure 6: Weather radar image depicting component with partition Ncut value less than 0.08.4 
As seen above, the static image was segmented based on the greatest level of association 
within a nodal grouping but the maximum disassociation from other groups creating partitions. 
The original image can be seen in (a) and the partitions can be seen following in (b) to (g). Each 
denotes very clear differences between partitions and demostrates the value of this algorithm.  
 Another method of association that was studied was the Ramer-Douglas-Peucker line 
reduction algorithm. This algorithm approaches the idea of grouping from a different direction. 
Instead of looking at dissaciation between subgroup clusters, this algorithm instead looks at 
individual points and line segments. Line segments are dictated through chain encoding and 
4 J. Shi and J. Malik, "Normalized Cuts and Image Segmentation," Technical Report CSD-97-940, UC Berkley, 1997. 
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skeleton encoding. For the purposes of this application chain encoding was primarily utilized. 
Chain encoding is comprised of “a sequence of end to end vectors, where the length and 
direction of vectors are selected from a fixed, usually four or eight, number of possibilities” 
(Douglas & Peucker, 1973). In order to create the line, each cell of the image or document being 
digitized is recorded as “yes-no” depending on whether or not that cell encloses a line. 
Depending on the value chosen dictating the fineness of the ‘mesh’ created by these points the 
time and processing ability creates a great variability in the time taken to create an output.  
 
Figure 7: Line transformed in 140 points and refined to the same line shown with 25 points. 5 
 An example of the Ramer-Douglas-Peucker line-reduction algorithm is shown above in 
Figure 7. It can be seen that this algorithm utilises a starting curve between critical points and 
recursilvy dividing the created line between the fist and last point. Similarly when dealing with a 
curved line points are chosen along the curve and chians created between these points as seen in 
Figure 8 below. In other words via a reduction in the “richness of texture along lines” through 
the elimination of points a “straighter line segment is created (Wessel & Smith, 1996). Overall 
this allows the digitation and reconstruction of an image which is primarily constructed of lines. 
5 Douglas, David H., and Thomas K. Peucker. "Algorithms for the reduction of the number of points required to 
represent a digitized line or its caricature."Cartographica: The International Journal for Geographic Information and 
Geovisualization 10.2 (1973): 112-122. 
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Figure 8: Visual demonstration of the Ramer-Douglas-Peucker algorithm simplifying a curve.6 
4.4.0 Feasibility Study/Experiments 
 In order to ensure that all experiments were possible, assessments and research was 
conducted. Assessments concerning constraints, objectives, and want were accounted for as well.  
4.4.1 Nanoemulsions 
Having decided on the range of experiments we wanted to conduct, we held several 
meetings with the CEO and the primary researcher of Nemucore Medical Innovations, Tim 
Coleman and Niravkumar Patel, to discuss the feasibility of our experiments. It was decided 
early on that fluorescence-activated cell sorting (FACS) would be our primary means of 
procuring quantitative data on the uptake of our nanoemulsions, would could be accomplished 
through the use of research facilities at UMass Memorial Medical Center. In talks about the 
availability of cell lines for in vitro testing, it was determined that it was within our budget to 
purchase an additional cell line from the ATCC to conduct additional experiments, if it was 
needed. 
In our characterization of the NEs, it was determined that we could rely on the mass-
spectrometry and nano-scale visualization of the NEs performed by the previous research group 
(Caccacio & Wrabel, 2014). As long as our zeta-sizing results lined up with their findings, we 
6Ramer, Urs. "An iterative procedure for the polygonal approximation of plane curves." Computer Graphics and 
Image Processing 1.3 (1972): 244-256. 
65 
 
                                                          
were confident that our new Nanoemulsions would be similar enough to previous NEs that our 
results could be combined with previous research efforts. 
                  In terms of performing the experiments, we spent several weeks at the beginning of 
the project familiarizing ourselves with the lab equipment and the manufacturing of the NEs 
themselves. We determined it was feasible for two group members to manufacture NEs and 
perform in vitro testing, with the assistance of researchers at Nemucore. We were confident that 
given our constraints we could still produce relevant data that would inform and alter the design 
and manufacturing of the NEs for preferential targeting through the blood-brain barrier. 
4.4.2 3D Statistical Heatmap 
There are many difficulties that had to be overcome over the course of this project when 
dealing with software and hardware issues. The goal for the 3D Heatmap portion of the project is 
to have the capabilities of running in one sitting, while only using only the standard MatLab 
package. The first issue of feasibility with this is MatLab’s relatively high cost for a license. The 
student package is $50 without any of the additional add-on packages. The home package is 
~$150 and the education package is $500. And the professional standard package for MatLab 
costs $2,150. The licensing for this software can become expensive depending on the intended 
use. For the scope of this project we have been able to use the education package that is offered 
to all students at WPI. In addition our sponsors at Nemucore bought an education license as well 
for the Nemucore site to allow better facilitation of the project on and off their facility. The 
intended audience for our statistical software is Nemucore and other universities; at these 
locations it will be standard for them to have educational licenses for MatLab.  
 A huge portion of time allotted with coding is in the research and debugging stages. In 
the development of code, especially with data analysis for a large quantity of data sets, it is 
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standard for human errors and coding mistakes to occur. A large portion of time is spent on 
researching the functions, algorithms, data types, and methods used for writing code. Due to the 
shear learning curve of coding this portion of the project was split between two members to 
better optimize time allotted to coding and minimize human errors by having multiple people 
working on the same section of code to minimize error. A very prominent issue with MatLab is 
the constant error messages that come up. MatLab is very particular with data types, calling 
methods, saving and other functions and logistics of coding that cause numerous error messages 
to occur when coding. Time is largest constraint for coding, due to the many iterations and 
debugging processes that have to occur to make sure the code can run in a singular sitting. Time 
must be allotted to remedy errors in the code along with finding any mistakes that could have 
been made while analyzing data for the MRI scans of the 174 regions of the brain or the 63 PNG 
files for the visualization. That being stated the time now needed to complete a particular code 
will vary based off of individual capabilities and overall coding process. The division of work 
and coding portions allows for better use of time to ensure that all portions of the statistical 
analysis and visualization are met. 
The major software limitation for this project is using the basic MatLab package without 
any add-ons. The goal of the project is to use the standard package of MatLab to enable other 
facilities use of our software. With that idea in mind, the visualization portion becomes more 
difficult due to the restrictions of not using the visualization and image processing add-ons that 
are available for purchase through Math Works. Besides the software limitations that MatLab 
has, there are also hardware limitations. These limitations of the computers used must be 
considered. The processing ability of the computer running the code plays a major role in the 
ability to analyze the data and make a visual representation of the computed results. Without 
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proper processing capabilities the code will break part way through the iterations and result in 
either a crash of the computer itself or misleading error messages in the code. The computer 
handling the amount of data being loaded from the in vivo rat study files is as pertinent to the 
coding phase as it is to the running of the code. Another processing issue arises from the size of 
the images and the visual capabilities that MatLab has. The ability for the computer to take large 
image files and find the desired areas of interest in the image while running multiple images for 
optimization is crucial. For image processing the amount of RAM/CPU that is taken up due to 
the size of the image files used in the Atlas program is another issue. A computer has to have 
enough RAM and processing capabilities in order to run the visualization algorithms. The size of 
the PNG files needs adequate CPU in order to run algorithms to make the domains and 
boundaries of the 174 regions of the brain. The time and technological resources for the 
feasibility of this project has been considered in order to optimize coding capabilities and ensure 
that the desired outputs are observed.  
The creation of a functioning statistical analysis with visualization capabilities software 
requires many optimization methods. The feasibility for running an n of 3 sample size of data 
with fours scans for each and 174 T1 values and associated voxel values through statistical 
analysis becomes cumbersome. Optimization is needed in order to confirm the right voxel 
weighting, normalization and subsequent data analysis is consistent for all following studies and 
varying sample sizes. The likelihood of having a code run for the entire sample size and analyze 
all the statistics without any errors takes many iterations. The need for using optimization and 
condensing techniques offered in MatLab are needed in order to have accurate analysis that 
matches the work done by the excel template and manual methods, but with the automations of a 
running software program. To optimize the visualization of a 3D rat brain a buffer must be used 
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for the PNG iteration and subsequent algorithm application. By enacting a buffer it frees up 
processor power to run the algorithm on small sections of the PNGs quickly thus overall 
improving the length of time required for the program to run.  
4.5.0 Modeling 
 To ensure that experiments and programming are able to run correctly and successfully 
various forms of modeling were researched. This included cell lines for viable in vitro studies, as 
well as, correct representative statistical analysis for in vivo studies. 
4.5.1 Nanoemulsions 
The choice of cell lines to test for in vitro experiments is extremely important in 
determining how relevant any of our experimental observations and results are. The major 
constraining criteria were that they were cell lines that were derived from Glioblastoma or blood-
brain barrier tissues, and between them all they expressed the three receptors we had designed 
NEs to target. 
The U-87 MG cell line derived from human malignant gliomas which has had extensive 
use for in vitro experiments (PontÉN et al, 1968). They are known to express the mu opioid 
receptorin relatively low amounts, expression of the receptor can be upregulated through 
treatment with morphine (Mahajan et al. 2003). Additionally, the cell lien expresses the B2 
bradykinin receptor (Wang & Xue 2007). However, the cell line does not express the alpha-7 
nAchR (Khalil et al. 2013). Their importance in this study as a human glioma cannot be 
understated, even though they do not possess all three receptors we are investigating. 
The bEnd.3 cell line is derived from mouse brain endothelial cells, which are what comprise the 
majority of the blood brain barrier (He et al. 2010). These cells are important models for 
examining how our manufactured NEs interact with the cells of the blood brain barrier. While 
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specific literature on expression of the three receptors we are investigating has not been found 
(due to the relatively small amount of research performed with this cell line), these cells would 
be expected to express the alpha-7 nAchR and to not express the B2 bradykinin and mu-opioid 
receptors (McCall et al. 2014) 
The C6 glioma cell line is a rat derived cell line that is morphologically similar to 
Glioblastoma Multiforme when injected into neonatal rats (Benda et al. 1968; Auer et al. 1981; 
Sampson et al. 1999). It has been shown to naturally express the mu-opioid receptor (Bohn et al. 
1998), as well as the alpha-7 nicotinic acetylcholine receptor and the B2 bradykini receptor 
(Niranjan et al. 2012; Wang et al. 2007). While our ideal in vitro model would be a human 
Glioblastoma-derived cell line, the expression of all three receptors of interest on the C6 cell line 
make it an excellent candidate for our experiments, given our time and budget constraints. 
4.5.2 3D Statistical Heatmap 
The programs utilized for all the statistical analysis and visualization of the in vivo rat 
study MRI data are excel and MatLab. These programs have multi-functioning capabilities that 
are able to handle the large amounts of data from this study and future studies in a manual and 
automated way respectively.  
In order to conduct the statistical analysis needed to determine the gadolinium 
concentration for the targeted Nanoemulsions versus the nontargeted Nanoemulsions many 
established statistical models are used. T testing is a generally common tested used when there 
are multiple sample populations of similar sizes. T testing was used to show the significance of 
the data analysis and Gd3+ uptake by the cells in the in vivo study. The two tailed t-test utilized is  
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Where ?̅?𝑥 is the mean for the targeted scan values and 𝑆𝑆� is the nontargeted scan values. 
And s is the standard deviation. This model is used to show the significance of the T1 weighted 
MRI data to show gadolinium uptake.  
A major model for the visualization and defining the areas for the 174 regions of interest 
for a rat brain is the Atlas program developed by Northeastern University. The Atlas program 
utilizes MRI scan images and overlays slices of a rat brain with colored boundaries for the 
different regions of interest. These 63 slices of a rat brain can show where the highest contrast is 
visually in the MRI scans. Given that the basis of the program is to work on statistical analysis 
the equations utilized are described in further detail in Section 5.3.2.  
4.6.0 Decisions 
 Through the design process, many final decisions were made through iterative processes 
due to encountered failures and challenges. Listed below are the reasoning behind what would 
lead to the final results both for the Nanoemulsions and 3D Statistical Heatmap. 
4.6.1 Nanoemulsions 
     Following the failure of our original fluorescent activate cell sorting (FACS) 
experiments, we had to make critical decisions about how we were going to move our 
experiments forward in a way that would create meaningful and significant data. We originally 
tested two cell lines in vitro, the U87MG human glioma cell line, and the bEnd.3 mouse brain 
vascular endothelial cells. With difficulties in cell adhesion affecting the viability of our results, 
the decision was made to switch from a cell adhesion to a cell suspension dosing method. 
Though dosing a cell suspension for FACS analysis is not done often, we believed it would allow 
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us to gain relevant and meaningful data from the U87 and bEnd.3 cell lines. We decided that a 
new cell line expressing all three potential receptors would be required to provide corroboration 
of the results we would obtain in the U87MG and bEnd.3 cell lines. Our research led to the 
purchase of the C6 rat glioma cell line, as we found literature supporting that the cell line 
expresses all 3 receptors we are investigating (Benda et al. 1968; Auer et al. 1981; Sampson et al. 
1999; Bohn et al. 1998; Niranjan et al. 2012; Wang et al. 2007). 
4.6.2 3D Statistical Heatmap 
The primary focus of this portion of the project was to load previously recorded T1 
weighted MRI data of three subjects of various time point, store, perform statistical analysis, and 
finally demonstrate that analysis visually across a 3D rat brain model constructed in MatLab. 
Through the design process of this project however, many variations of both sides of this 
program were encountered. These variations and the reasoning as to why they were not used for 
the final program iteration are explained below. In order for any statistical analysis to be 
conducted the in vivo subject data needed to first be loaded, sorted, and stored appropriately 
within MatLab. The data is stored in comma-separated values (CSV) format, as such ‘csvread’ 
was primarily used as the loading function. This function however proved to not read this data 
correctly and would return an error. As such given the nature of CSV files the loading function 
was changed to ‘xlsread’ which allowed for the appropriate sub-arguments ensuring that the data 
was read and loaded correctly. 
In addition to the statistical and visualization codes, the excel template went through 
many iterations before it was finally completed and fully functional.  
The initial design for statistical analysis for the MatLab code deviated from the original plan 
that was set up via the Excel template analysis. The initial code created for a statistical 3D 
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Statistical Heatmap was for a singular rat at a time in order to show the where drug 
uptake/receptor response was occurring at the scan time points. The order the different 
mathematical functions were used followed a strategic pattern to best convey flow within the 
code. The first strategy used 8 files for a single rat and went through the loading and sorting of 
the data then attributing each mean T1 value with is spatial voxel recognition value. The original 
physical orientation of the data was non-viable for the sorting mechanism chosen. Therefore it 
was decided that the data needed to be transposed from a horizontal orientation to a vertical 
orientation. Once this was done sorting became fairly simple.  
Following that the normalization of the data occurred with specificity following. This 
first iteration of code only utilized one rat and only calculated average specificity values for the 
larger 22 regions of the brain and not individual 174 regions. Upon further discussion and need 
for further development of the software all 174 regions had specificity analysis done for all 174 
regions comparing the nontargeted to the targeted scan results. These first iterations of code were 
based off of a user selecting each of the 8  individual files needed for the analysis that originate 
from raw MRI T1 weighted data files. After more deliberation it was decided to have the code 
run for a changeable sample size to be used in future studies. As a model the code was created to 
run through all three rat study sets of files. The first new development in this code iteration is the 
decision to have each sample in the test have its own folder with the subsequent 8 files inside. 
The user now only needs to select one folder per sample instead of all 8 files. The choice to make 
the folders contain the eight files for each rat was decided upon due to the ability to change a few 
variables to have the code run for larger sample sizes. It is easier for the user to select a folder 
containing all the files than to select the individual files for each sample. Through the use of for 
loops and storing data in containers called maps the access to the data files and the ability to 
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create larger studies sizes is now utilized.  The loops allow for simultaneous analysis of the three 
scan points and the ability to change the sample size if a larger study is conducted. The final 
iteration of the code will have the user select the desired number of folders depending on the size 
of the study, and then the code will export csv files one for each rat for specificity that has 
columns for each time point, and another csv file that has a column for each scan over the whole 
study of rats.  
The choice to make the folders contain the eight files for each rat was decided upon due 
to the ability to change a few variables to have the code run for larger sample sizes. It is easier 
for the user to select a folder containing all the files than to select the individual files for each 
sample. Through the use of for loops and storing data in containers called maps the access to the 
data files and the ability to create larger studies sizes is now utilized. 
Once the data has undergone statistical analysis the decision had to be made for as to how 
the 64 PNG slices of the rat brain model would be converted into a 3D model. The major factor 
would be how to reconstruct these images. For the most part there are only a few methods to do 
this, and most require a large amount of processing ability on part of the user’s computer. This 
decision centered around which algorithm to use once the PNG slices had been transformed into 
a point cloud. In order to maintain the design specification (a full list of all design specifications 
for this program can be seen in Appendix 1) of ensuring that this program is available for the 
general population, it became self-evident which algorithm. The Ramer-Douglas-Peucker line 
reduction algorithm enables the point cloud to be transformed back into the 174 sub-regions 
depicted in the original rat atlas PNG’s provided by our collaborators at Northeastern University. 
This particular algorithm has the ability to be ran with a buffer which lessens the strain on a 
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computer's processor. It also contains the ability to handle high level branching outputs present 
among the PNG slices.  
4.7.0 Preliminary Data 
As is customary with any experimental or programming project, many iterations are 
conducted per experiment or working session with some changes being greater than those of 
others. In this section we’d like to address some of the major preliminary finding that led to 
ultimate changes in our final program iteration and experimentation.  
4.7.1 Nanoemulsions 
The iterative design process was such that the preliminary data obtained helped the team 
improve upon the nanoemulsions design as well as experimental procedures in order to achieve 
the desired outcomes. As such, the size of the nanoemulsions became of interest to try to 
stabilize as well the flow cytometry methodology. The results from the original experiments are 
presented below. 
The size of the nanoemulsions was measured using a Digital Light Scattering (DLS) 
machine every seven days for up to one month starting the day the NEs were manufactured. The 
tables above show size distribution of the nanoemulsions that were created with a low PEG 
density. NEs with polydispersity index (PDI) indices less than 0.1 are referred to as 
“monodisperse” while PDI of > 0.1 indicates that the data may require further analysis to 
determine if it is valid. The zeta potential indicates the electro kinetic potential in colloidal 
suspensions. A negative charge on the NEs is preferred as it reduces the chances of blood clots 
when administered in vivo.  
Table 8 and 9 contain data for the non-targeted, mu-opioid, b2-bradykinin, and alpha-7 
nAChR targeted NEs. The size and PDI of all NEs are increasing rapidly over time. 
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 Table 8: Size distribution and zeta potential for non-targeted and mu-opioid targeted NEs. 
 
Table 9: Size distribution and zeta potential for b2-bradykinin and alpha-7 nAChR targeted NEs. 
Flow cytometry was performed (as seen in Figure 9) and all of the nanoemulsions 
contained a higher density of PEG. The untreated cells (both U87MG and the bEnd.3 cells) show 
a baseline level of 2 geometric mean fluorescence. For the U87MG cells, there is a 0.5 fold 
increase in the uptake of the non-targeted NEs and a 0.25 fold increase in the uptake of the mu-
opioid targeted NEs. For the bEnd.3 cells, there is a 0.75 fold increase in the uptake of non-
targeted NEs and a 0.25 fold increase in the uptake of mu-opioid targeted NEs. Overall however, 
there were not enough cells to efficiently quantify fluorescent uptake of the NEs. We believe the 
low cells counts were caused by cells lifting off the wells during the dosing and washing stages 
of the experiment. As a result, the data may not be representative of the uptake of nanoemulsions 
Non-Targeted NE
Day 0 7 14 21 0 7 14 21
Size Distribution (nm) PDI
170.2 166.5 164.7 160.7 0.015 0.005 0.068 0.079
Zeta Potential (mV) Standard Deviation (mV)
-40.1 -40.4 -50.1 8.44 9.8 10.2
Mu-Opioid Targeted NE 
Size Distribution (nm) PDI
203.5 191.8 201 0.081 0.086 0.117
Zeta Potential (mV) Standard Deviation (mV)
-31.9 -30.2 -39.9 8.63 10.5 8.13
B2-Bradykinin Targeted NE
Day 0 7 14 21 0 7 14 21
Size Distribution (nm) PDI
195.1 215.5 223.8 0.047 0.218 0.177
Zeta Potential (mV) Standard Deviation (mV)
-18.5 -27.1 -36.3 6.9 7.39 9.51
Alpha-7 nAChR Targeted NE 
Size Distribution (nm) PDI
188.7 214.9 233.6 0.059 0.249 0.221
Zeta Potential (mV) Standard Deviation (mV)
-29.3 -35 -37.7 9.16 10 10
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by the cells. These results led us to select the C6 rat glioma cell line as an alternative cell line to 
U87’s that may encounter fewer issues with cell adhesion during these types of experiments.  
 
Figure 9: The untreated cells were set at a geometric mean fluorescence baseline of 2. 
4.7.2 3D Statistical Heatmap 
As we went through the iteration process for the statistical analysis we started by 
manually doing the analysis in excel for the in vivo study. This is a large spreadsheet with over 9 
tabs in order to paste all the data into its relevant areas. In order to get a functioning excel 
spreadsheet at the individual region of interest and subsystem level multiple columns were 
needed for each type of analysis. The spreadsheet originally only found specificity and p values 
from t tests for the 22 subsystems and not all 174 regions. Once the data from the subsystems 
was found to match earlier analysis conducted by Nemucore, the analysis was expanded to cover 
all 174 regions of interest. Shown in Table 10 below, is the original analysis for all three 
receptors for the 22 subsystems can be seen in Table 10. This is before voxel weighting which 
was utilized in the final template and MatLab code. 
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 Table 10: Analysis conducted in Microsoft Excel for three testing receptors (highlighted in grey) which 
corresponding t-test and specificity indexing in 22 subsystems of the rat brain. 
The above table has highlighted areas, the yellow denoting the areas where the p value is 
less than 0.10 and the blue is the top 25% values for the specificity index. Also in this table in the 
grey columns is the receptor density that was discussed in the Section 2.0.0 of this report. 
We were then able to automate this entire process by using MatLab. The analysis utilizes 
nontargeted and Targeted scans and pre scan per rat which are a total of 8 spreadsheets. These 
spreadsheets are used for each of the three scan points and a pre scan for both the targeted and 
nontargeted rat studies. From the study there were a total of 24 spreadsheets used, but for the 
initial onset of code only 8 were utilized to do analysis on a singular rat. The initial iteration of 
the code focused on loading the data from the 8 files and then transposing them into a vertical 
formatted cell array. This initial code also took the T1 weighted mean MRI data points and 
weighted them by their voxel spatial values. Once the voxel weights were verified with that from 
the Excel template the normalization of each scan point with the pre scan was conducted. Again 
this was verified with past calculations using the same data for the alpha 7 receptor. Then the 
specificity was calculated for the first scan. Once this was verified the analysis was done for the 
Scan 1 Scan 2 Scan 3 Scan 1 Scan 2 Scan 3 Scan 1 Scan 2 Scan 3 Scan 1 Scan 2 Scan 3 Scan 1 Scan 2 Scan 3 Scan 1 Scan 2 Scan 3
Olfactory Bulb N/A 0.426 0.033 0.317 1.141 1.459 1.180 L 0.991 0.437 0.625 0.998 1.164 0.925 L 0.251 0.763 0.520 0.798 1.067 0.910
Olfactory Areas H 0.657 0.136 0.792 1.116 1.377 1.041 P 0.657 0.349 0.315 1.126 1.152 0.849 L 0.392 0.715 0.587 0.777 1.076 0.935
Limbic Lobe N/A 0.269 0.314 0.165 1.278 1.181 1.286 H 0.921 0.770 0.831 0.975 1.179 1.048 M 0.472 0.851 0.358 0.828 0.966 1.163
Insular Cortex N/A 0.062 0.087 0.400 1.457 1.478 1.181 H 0.010 0.048 0.267 1.579 1.484 1.094 N/A 0.548 0.267 0.212 0.923 1.222 1.141
Occipital Lobe M-H 0.100 0.022 0.029 1.500 1.486 1.654 P 0.862 0.676 0.307 0.942 1.085 1.208 N/A 0.984 0.737 0.015 0.995 1.053 1.486
Temporal Lobe M 0.011 0.019 0.017 1.757 1.433 1.328 P 0.077 0.034 0.119 1.740 1.663 1.438 L 0.565 0.505 0.095 1.135 1.090 1.202
Parietal Lobe N/A 0.215 0.000 0.031 1.147 1.462 1.274 P 0.049 0.645 0.531 0.768 1.048 0.950 N/A 0.014 0.049 0.001 0.775 1.171 1.283
Frontal Lobe H 0.883 0.010 0.147 1.025 1.467 1.209 P 0.454 0.711 0.186 0.867 1.064 0.846 N/A 0.0247 0.3323 0.7826 0.6364 1.1441 0.9756
Hippocampal 
Formation H 0.170 0.831 0.236 1.236 1.017 1.105
P w/ H 
Molecular 
0.773 0.417 0.752 1.046 0.924 1.036 M-L 0.4313 0.9524 0.0087 1.1330 0.9952 1.2318
Amygdaloid Nuclear 
Complex H 0.934 0.535 0.371 1.018 1.133 0.864 H 0.384 0.263 0.301 1.232 1.293 1.200 M-H 0.1042 0.832 0.297 0.669 0.959 0.838
Basal Ganglia N/A 0.089 0.000 0.046 1.219 1.754 1.182 P Within 0.319 0.004 0.884 0.728 1.486 1.018 M 0.1669 0.0000 0.0111 0.8486 1.5709 1.2162
Basal Forebrain N/A 0.650 0.000 0.263 0.797 2.398 1.238 P 0.150 0.000 0.440 0.690 1.680 1.092 N/A 0.036 0.0020 0.078 0.620 1.528 1.233
Septum N/A 0.028 0.069 0.206 2.065 2.310 1.671 M 0.428 0.100 0.641 1.281 1.884 1.220 H 0.235 0.057 0.283 1.317 1.926 1.558
Hypothalamus M 0.714 0.920 0.408 0.918 1.024 0.862 H 0.028 0.029 0.019 1.788 1.705 1.600 L 0.419 0.707 0.947 0.862 1.066 0.991
Pituitary M 0.522 0.791 0.250 0.798 0.877 0.649 H 0.026 0.142 0.022 0.149 0.336 0.211 L 0.045 0.445 0.156 0.314 0.690 0.579
Thalamus L 0.210 0.202 0.072 1.192 1.127 1.157 M-H 0.906 0.963 0.760 1.023 0.994 1.037 H 0.476 0.523 0.040 1.122 1.069 1.201
Epithalamus L 0.609 0.712 0.739 0.699 0.811 0.823 M 0.970 0.835 0.813 0.980 1.092 1.111 H 0.951 0.681 0.365 0.951 0.681 0.365
Cerebellum M-L 0.001 0.050 0.023 1.505 1.206 1.284 M 0.325 0.753 0.303 1.166 1.038 1.134 N/A 0.473 0.381 0.041 1.108 1.091 1.246
Pons N/A 0.812 0.674 0.766 1.048 0.949 1.041 M 0.480 0.603 0.171 1.159 1.072 1.214 N/A 0.780 0.710 0.008 1.049 1.038 1.330
Tectum H 0.528 0.803 0.978 0.828 0.948 1.008 P 0.126 0.183 0.361 0.590 0.763 0.768 M 0.043 0.068 0.701 0.476 0.658 0.913
Cerebral Peduncle N/A 0.159 0.707 0.538 0.742 1.057 1.106 P 0.005 0.037 0.135 0.435 0.748 0.912 M 0.044 0.146 0.001 0.633 0.658 1.409
Medulla Oblongata N/A 0.339 0.931 0.299 1.377 1.060 1.260 M 0.935 0.585 0.950 1.068 0.918 1.034 N/A 0.607 0.625 0.440 0.872 0.924 1.146
mu-
Opioid R 
ExpressBrain Section
Bradykinin B2 Targeted NE mu-Opioid Receptor Targeted NE 
Gd-annotated Targeted NEs accumulate in distinct regions of the brain that are statistically different than Gd-annotated NT-NE as determined by stratifying the rat brain into 174 ROI following MRI
Specificity Indext-test 90% Confidence
α -7 nAChR Targeted NE 
Metencephaon
t-test 90% Confidence Specificity Index t-test 90% Confidence Specificity Index
Cerebral Cortex
Basal Forebrain
Diencephalon
α-7 
nAChR 
Express
Bradykinin 
R B2 
Express
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subsequent scans as well. The initial code iteration had an export of three separate excel csv files, 
one for each scan time points. 
Upon further analysis it was realized that the analysis needed to be conducted on all three 
rats from the study for both the targeted and nontargeted Nanoemulsions in order to determine if 
the data was statistically significant. It was then that the loading of the files was restructured so 
that the user would select a folder per rat with the 8 files inside the folder. This was done to 
allow a quicker user interface, as defined by our objectives, in order to allow the user to not 
select all 24 files individually. Once the voxel weighting and specificity analysis were 
accommodated for all three rats and saved in their respective Containers.map files t-testing could 
be conducted to show the significance of the specificity data. The final code then uses statistical 
analysis that can go from analyzing a single rat to an n of n for larger clinical relevance. 
During the writing of this program, several times code was needed to be scratched and 
completely rewritten or sections altered. One of the first testing periods for 3D representation of 
the PNG slices can be seen below in Figure 10. It was first thought that showing the slices in a 
3D environment was the immediate need of the project. However upon doing this it was soon 
realized that the images needed to undergo some processing in order to extract the pure outlines 
of each sub-divided region. It was also discovered that the manner in which the slice was being 
displayed was not viable. This was due to the function utilized plotting images rather than the 
needed arrays formatted post-image processing. 
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Figure 10: One PNG slice displayed unaltered in 3D environment. 
In order to process the images, generic color value ranges were assign in order to find all 
of the lines utilized in the outlining portions of the 63 PNG slices. These generic ranges however 
didn’t allow for enough points to be copied into the new arrays so the ranges were altered from 
the generic values to a range that enabled the significant out of points to be collected and 
transferred. The pixels that were found within the desired color ranges the coordinate location 
was transferred into an array. More of this methodology will be discussed in the following 
Design Verification Section 5.0.0. Once all coordinates for all 63 PNG slice were found through 
the scrip the points were plotted in a 3D environment. This enabled verification that a significant 
amount of points had been discovered and transferred. In some cases not enough points in certain 
colors were found so the ranges had to be adjusted. While regions look distinct within the point 
cloud, these are not bounded regions that were present in the original PNG’s. In order to achieve 
this the Ramer-Douglas-Peucker algorithm was applied. The workings of this algorithm are 
described within Section 4.6.0.  
80 
 
 
Figure 11: First iteration of Ramer-Douglas-Peucker Algorithm on single slice. 
Upon the first application of the algorithm to a simple PNG (given the varying functional 
regions some PNG slices displayed no branching while others displayed great amounts). As seen 
in Figure 11 above, the algorithm failed. It was found out through application of separate colors 
for the ‘starting point’, seen in red and the ‘next dot’ seen in blue that the slope by which the 
algorithm was to follow was set incorrectly. Also the algorithm was connecting enough 
coordinates that areas were appearing filled in which was not the objective. This meant that when 
encountering certain angles the slope would transform to infinity and thus be unable to compute 
or would connect the incorrect dots. This was easily remedied by altering the slope parameter. A 
similar problem was encountered on the complicated branching PNG slices as well. As seen 
below in Figure 12, the algorithm is causing the same ‘zig-zag’ pattern seen in a much more 
drastic degree in Figure 11. This is caused however by a completely different parameter. 
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Figure 12: Following iteration of application of Ramer-Douglas-Peucker Algorithm to multi-branching slice. 
 As seen above, the connect lines are unable to continue in a fluid general path and instead 
‘zig-zag’ until finally terminating in the incorrect direction across a region. For the Ramer-
Douglas-Peucker algorithm there is a parameter by which the distance between the connecting 
points must be set manually for each data-set. This variable parameter was set in the ‘default’ 
value and thus needed to be altered through trial and error. Upon completion of the new point 
distance parameter value the algorithm was ready for application to all 63 PNGs.  
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5.0.0 Design Verification 
 Described in this section are the methodologies the project team followed and enacted 
generating resulting data. This section is sub-divided by each major project subject.  
5.1.0 Nanoemulsions 
5.1.1 General Manufacturing of Nanoemulsions 
Nanoemulsions are comprised of an aqueous phase and oil phase. The aqueous phase is 
composed of Polyethylene glycol (PEG), an easily modifiable polymer which acts as a stealthing 
agent, a targeting moiety conjugated to PEG (ex. Mu-Opioid-PEG), Egg lecithin which is an 
emulsifying agent, as well as glycerol and DI water for in vitro testing of the Nanoemulsions. 
The glycerol helps maintain the isotonicity of the final formulations. The oil phase consists of 
Flaxseed oil which contains Omega 3 and Omega 6 fatty acids that aid in the uptake of the drugs 
into the brain. Additionally, a fluorescent hydrophobic red dye, rhodamine, was also added to the 
oil phase for the hydrophobic uptake studies. Active pharmaceutical ingredients (API) for 
example lapidated Temozolomide or Docetaxel can be loaded into the oil phase. 
After preparation of the two phases, the aqueous and oil phases were combined and 
vortexed to create a basic emulsion to be processed through the LV1 Microfluidizer. Once the 
emulsions were finished, the size and surface charge of the Nanoemulsions was measured on the 
Malvern SV90 and the Nanoemulsions were stored at 4°C. 
5.1.2 Normalization of Fluorescence  
The rhodamine contained in the oil core of the Nanoemulsions was not quantified. 
Therefore the amount of fluorescence was measured and then normalized to the sample with the 
minimum fluorescence. Triplicate Nanoemulsion samples were loaded into a 96-well plate and 
diluted serially with water. The bottom row was used as a negative control and contained only 
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water. The plate was loaded into a BioTex Synergy HT plate reader and shook for 20 seconds. 
The plate was excited at 530± 14.5 nm and fluorescence was read at 590 ± 17.5 nm. The 
fluorescence level was plotted, and a linear range was found. The Nanoemulsion with the lowest 
fluorescence level was used to normalize the remaining samples.   
5.2.0 Cell Lines 
The human glioma cell line U87 MG was obtained from the ATCC, and the human brain 
endothelial cell line, bEnd.3, was obtained from Dr. Rachel Sirianni at the Barrow Neurological 
Institute. They were continuously cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal bovine serum and 1% penicillin/streptomycin, in a humidified incubator at 
37°C with 5% CO2. The rat glioma cell line C6 was also obtained from the ATCC. The cells 
were continuously cultured in F12K media. All cell culture media and sterile equipment was 
purchased from Fisher Scientific unless otherwise stated.  
5.3.0 Fluorescent Uptake studies 
Rhodamine was used as a florescent marker that was contained in the Nanoemulsions oil 
core and utilized for the uptake study. 200,000 cells (U87mg and b.End3) were plated in 
coverslip-containing wells of a 6 well plate. 2 mL of Dulbecco Minimum Essential Media 
(DMEM) plus 10% serum was added to each well. The plates were placed inside the incubator at 
37°C and 5% CO2. After 24 hours the media was removed and 2 mL of serum free media 
containing the Nanoemulsions was added to each well (1:100 dilution). The well plates were 
incubated and the cells were fixed for 20 minutes with formalin at time intervals of 30 min, 1 
hour, and 4 hours (cells washed with PBS prior to fixation). The cover slips were then taken out 
of the wells and placed inverted on a glass mount with mounting media slowFade Gold antifade 
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reagent supplemented with DAPI (Life Technologies). The Slides were then left in the dark for 
30 minutes at which point cells were viewed under Leica DMI3000 B florescence microscope. 
5.4.0 Flow Cytometry (in plates) 
The U87mg cells and the b.End3 cells were seeded at a density of 200,000 cells per well 
in 6 well-plates. After 24 hours the media was removed for some of the wells to be pre-treated 
with Naloxone which is a pure opioid antagonist. After 45 minutes of pre-treatment, the cells 
media for all wells except for wells left untreated was removed and media with a 1:100 dilution 
of the Non-targeted and Demorphine-targeted Nanoemulsions was added to the wells. The media 
with the treatment was removed after one hour and the cells were trypsonized and centrifuged. 
The supernatant was removed and the cells were re-suspended in a 1% BSA solution and placed 
on ice to be taken to UMASS Flow Cytometry Core.    
5.5.0 Flow Cytometry (in suspension) 
U87mg cells and b.End3 cells were seeded in T-75 Flasks in order to have 4,500,000 
cells per cell line, prior to experiment. On the day of experiment, DMEM complete, DMEM 
serum free, Serum, and PBS were used and 1% BSA in PBS was prepared. After 24 hours the 
media was removed for each cell line and detach using trypsin (3mL per flask for 2-3 minutes 
depending upon cell line, bEND3 take longer) and neutralized using 12 mL media. The cells 
were then placed in 50 mL tubes and centrifuged at 2000 rmp for 8 minutes. They were then re-
suspend in 10 mL of Serum Free media and counted. After counting, 500,000 cells were placed 
per tube (1.5 mL tubes) with a final volume of 1 ml Serum Free Media total. At this point, add 
the Nanoemulsions (ex.) NT-NE and Dem-NE) were added to the tubes at a dilution of 1:100. 
The tubes were then placed on a tumbler for 1 hour in the incubator so the cells were 
continuously rotating.  After the 1 hour incubation, the cells were centrifuged at 2500 rmp for 5 
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minutes and washed 3 times with 1 ml ice cold PBS per tube. After the final wash, 400 ul of PBS 
with 1% BSA was added to the 1.5mL tubes containing the cell pellets to re-suspend the cells. 
The cells were then placed in small labeled tubes and in an ice bucket to be taken to UMASS 
Flow Cytometry Core. 
5.6.0 3D Statistical Heatmap 
Currently there is no program available by which full statistical analysis and 
corresponding visualization can be achieved for analysis of Nemucore NMI-800 Nanoemulsion 
series of theranostics of glioblastoma. As such a program has been devised through the excel 
iterations and MatLab programing to fill this niche of combining MRI technology with biology 
of Nanoemulsion uptake. This program is responsible for statistical analysis of eight data files 
needed per rat while demonstrating accumulation across a skeletal model of the rat brain Atlas 
(courtesy of our collaborators at Northeastern University) as well as displaying MRI 3D model 
scans at various time points.  
5.6.1 Statistical Analysis of In Vivo Studies 
Nemucore Medical Innovations Inc. has previously conducted Nanoemulsion in vivo 
testing at Northeastern University using 3 rats with four scans per each rat. The studies followed 
a format of an initial scan prior to any injection, with scans being recorded at 20 minutes, 40 
minutes, and 1 hour time points. Studies involved untreated nontargeted and targeted 
Nanoemulsions injected into subjects. The data received from these subjects was then subjected 
to analysis.  
Analysis of the in vivo studies resulted in a series of outputs. The primary output is a 
comma separated values document also known as a CSV file. For each scan per each subject a 
CSV file is created, each subject resulted in a total of 8 CSV files, 4 for the nontargeted and 4 for 
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the targeted Nanoemulsions. The primary means of analysis of these files was created in Excel. 
For this program, all inputs were manually copied into Excel creating a very time consuming and 
prone to user error. This excel template does however display all corresponding statistical 
information in an easily readable format with corresponding significance statistical analysis. This 
template has minimal user input and runs automatically through all the derivations and statistical 
analysis of the data. This template was converted to be run through MatLab in order to 
streamline and lower risks of human input error, and so that all analysis can be done 
simultaneously for all rats in the study. The desired output of this program involves not only a 
single document per subject of all labeled statistical analysis but also a 3D heatmap visualization 
of a rat brain model with corresponding statistical values from the MRI scans.  
While these are the desired outputs, there are however some functional specifications that 
must be met in order to ensure user functionality and program success. These functionalities 
include processes to ensure user ease but also to ensure correct and mathematically sound output. 
Some of these functions include but are not limited to user file selection, completion of all 
statistical analysis, output both numerically and visually, and be able to run on only MatLab with 
no needed plug-ins. A full list of these desired functional specifications can be seen in Appendix 
1.  
This program enables capabilities that are currently not available all in one place. There 
are currently programs that enable 3D visualization of a rat brain model (such as the Atlas 
program provided by Northeastern University). Most MRI analysis software contains this 
capability as well. While these programs can generate detailed 3D representations of data. They 
lack the ability to provide the statistical output and significance required for analysis of this data 
to show specifically which areas of the brain have the most uptake of NEs or other drug delivery 
87 
 
systems. This MatLab program will unite the statistical analysis needed with visual display that 
allows the user to quantifiably see where accumulation of the Nanoemulsions is occurring. 
The original data files are outputted from MRI scans, as such they are not in a readable 
format for this MatLab program. The MRI data must be ran through a conversion program 
available from the collaborators at Northeastern University. This will output the CSV file that 
has rows for the name of the scan and time point, Region of Interest Name, ID number, voxel 
value for the ROI, mean T1 value, and standard deviation. The MatLab code in conjunction with 
the rat brain Atlas gives voxel values to correlate MRI images with bounded regions.  
In order to analyze these files for each time point statistical analysis is applied through 
our newly developed MatLab program. Before the MatLab code was developed an initial 
template was made in Excel to be used as validation and verification for the code, and to also 
automate manual manipulation if only small sample studies will be conducted in the future. The 
excel template is a multi-tab spreadsheet that takes user copied data and automatically looks up 
and runs through the data for statistical analysis. The first 8 sheets of the spreadsheet are for the 
compiled MRI data for each of the three scans for the control and experimental cohorts, and the 
other two tabs being for the pre-scan data. The final tab is the Template tab which hosts all the 
regions of interest organized by name, ID number, and the larger subsystem of the brain they fall 
within. The names and ID numbers are locked in place to utilize scrolling capabilities to allow 
for further inspection of the statistical analysis data, raw data, normalized data, and weighted 
data that is called from the other sheets of the spreadsheet. The template is currently set up for an 
n of three rats, based off of previously conducted experiments. 
The template utilizes an H-lookup based off of file/sheet name and the corresponding 
column with desired ROI. It was a very intensive multi-step process to have all 174 ROI’s and 
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corresponding mean average and voxel data looked up, therefore the dropdown function of excel 
allows for it to be copied for all 174 regions. Once the look up of all the data for all 8 files and 
three scan times points the template goes through analysis of the means. The first step in 
analyzing the mean data from MRI scans is to run it through a spatial voxel weighting based on 
surrounding regions of the brain. By additional properties the sum of the over raining larger 
region for each of the 174 ROI’s was taken and then each individual ROI had its corresponding 
number of voxels divided by the sum of the voxels for the larger region it belongs to. Once the 
voxel weight was determined in the many tables in the Template tab of the spreadsheet the cell 
with which the mean value for the scan number and pre scan is multiplied by the voxel weight. 
The problem with this voxel weight is that it is solely based off of the voxel weight per scan and 
it does not take into account the voxel weight of the pre scan, due to the overlapping ROI data 
and complexity of the analysis in comparison to Microsoft Excel’s capabilities. This weighting 
system allows for spatial recognition of the regions so that they are independent of other regions 
that are not part of the same subsystem they are in. Once the voxel weight for each mean is taken 
the data is transferred to new cells once it has been normalized. This normalization is taking the 
absolute value of the pre scan and subtracting it from the subsequent scans. Once the 
normalization and voxel weighting is done with the data, the cells of the spreadsheet are then 
used in averaging of each of the 22 subsystems, specificity index and t testing for the n of 3 rats 
for all three scan time points. The t-tests are done to show the significance of the specificity data 
and overall targeted Nanoemulsion uptake. An average for each scan for each of the 22 regions 
was conducted using the sum function in excel for both the control and targeted Nanoemulsions. 
A user guide was created to show where and what data to paste into each tab, and to give 
an overview of the statistical analysis that is being done in the template it can be found in 
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Appendix 2. Although this excel template goes through all the statistical analysis the user 
interface is very heavy by having the user find the desired files and copy and paste the data into 
specific places within the overall spreadsheet. This method of qualitative statistical analysis is 
very cumbersome due to the multitude of sheets needed to differentiate between data files. This 
method also utilizes a great amount of RAM which can cause the computers processor to slow 
response, in addition to the potential of human with copying and pasting the data potentially in 
the wrong area which skews the results.  
Due to the ineffective nature of this project when computed through excel, another 
method by which to conduct the desired statistical material was needed. MatLab was chosen as 
the environment in which to build this program due to a number of reasons. MatLab can be 
hosted by all computers (some accommodations might have to be made dependent on the 
operating system), and has the ability to execute without the need of specific plugins or add-on’s. 
The statistical analysis of the 174 regions of interest for all three scans and sample size of 3 rats 
was done to optimize and automate outputs used for visualization. The program incorporates 
normalization, spatial voxel weighting, specificity of drug uptake within an ROI and t testing to 
support the claims of Nemucore that their Nanoemulsions are indeed crossing the Blood Brain 
Barrier and having significant uptake within regions of the brain for targeted Nanoemulsions. 
Regardless of the Nanoemulsion being tested in vivo, eight files of data is generated per subject 
because of the pre scan and three subsequent scans for the control group and experimental group. 
These files are generated from each time point in the MRI scan during the course of the study. 
The MRI data is run through the Atlas program (created by collaborators at Northeastern 
University) in which the following data is organized chronologically by ROI ID Number and not 
by the subsystems.  
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The methodology of how the finalized statistical analysis code manipulates MRI data to 
show the specific areas where significant uptake of targeted Nanoemulsions are accumulating in 
the brain is described below in detail. 
The statistical analysis code starts by first uploading and storing the 8 CSV files that are 
in a folder for each rat.  The outputted files from the MRI scans and MatLab analysis created by 
Northeastern University give the contrast imaging data for all 174 regions of interest of a rat 
brain. Each rat has 8 files associated with it that are stored within a singular folder per rat. All of 
the files within the folder, and the folders themselves, are in the same format to allow for 
searching, transposing and sorting of data. This is done via a transpose function that takes the 
whole array of data and repositioning them into a vertical position. Once transposed the code 
picks out specific ROI data to reorganize them based off of the 22 subsystems that the ROI’s are 
in. Once the data is sorted and stored into a cell array for each subsystem voxel spatial weighting 
is done in order to ensure that the mean T1 values are based off of specific locations from the 
MRI scans. The raw mean values for all 174 regions of interest are saved for all eight files, by 
utilizing a for loop the voxel weighting of each region of interest can be conducted once and then 
automated for the remaining 7 files.  The loop first finds the mean values of all the sub regions, it 
then finds the corresponding number of voxels for each sub region.  Each region of interest is 
part of a larger region of the rat brain, and therefore the total sum of the voxels in these 
subsystems is surmised. After the summation of the total number of voxels for each of the 22 
subsystems, a for loop is utilized for each in order to find the voxel weight for each individual 
ROI. To find the individual voxel weight per ROI the code takes the voxel number for each 
region and divides it by the sum of the voxels for each of the subsystem the ROI is located in. 
This voxel weighting is done by the equation shown below.  
91 
 
𝑉𝑉𝑁𝑁𝑥𝑥𝑄𝑄𝑁𝑁 𝑊𝑊𝑄𝑄𝑁𝑁𝑇𝑇ℎ𝑡𝑡 𝑁𝑁𝑜𝑜 𝑅𝑅𝑅𝑅𝑅𝑅 = 𝑁𝑁𝑉𝑉𝑁𝑁𝑁𝑁𝑄𝑄𝑁𝑁 𝑉𝑉𝑁𝑁𝑥𝑥𝑄𝑄𝑁𝑁𝑠𝑠 𝑅𝑅𝑅𝑅𝑅𝑅
∑𝑁𝑁𝑉𝑉𝑁𝑁𝑁𝑁𝑄𝑄𝑁𝑁 𝑉𝑉𝑁𝑁𝑥𝑥𝑄𝑄𝑁𝑁𝑠𝑠 𝑅𝑅𝑅𝑅𝑅𝑅 𝑜𝑜𝑁𝑁𝑁𝑁 𝐿𝐿𝑁𝑁𝑁𝑁𝑇𝑇𝑄𝑄𝑁𝑁 𝑅𝑅𝑄𝑄𝑇𝑇𝑁𝑁𝑁𝑁𝑛𝑛  
The voxel weighted means are then saved into a Containers.map format that allows the 
voxel weight for each subsystem to be saved with a specific name. By saving each subsystem 
with its own identifier the calling of specific ROI’s is easier than calling from a giant 174 by 1 
cell array. This map container is also utilized for saving and calling data from all three rats since 
the code loops through and does the transposing, sorting and voxel weighting for all three rats 
and saving all data within a singular map. The initial calling from the map is for the 8 files per 
rat. These files are for the pre scan of the targeted and subsequent three scans and the same for 
the nontargeted scans. The call method utilizes variable names for 8 files to differentiate them. 
The calling of each subsystem for each of the eight files to better normalize each scan with the 
pre scan data for all three rats. This is done by optimizing the calling with a for loop that iterates 
8 times for all 22 sets of data for the subsequent 174 regions, that is within a loop that iterates 
three times once for each rat. After all of the voxel weighting for the mean values for the 174 sub 
regions is called for each file, the normalization for each scan by subtracting the prescan value is 
calculate. Again a loop is utilized for all three scan time points and sample size of the study.  
The first scan for both the targeted and nontargeted rats is a prescan. This prescan is the 
resting MRI data for each rat. In order to get accurate MR data for each region of interest 
normalization of the data has to happen. The normalization for each of the three scans for all the 
regions of interest occurs by taking the absolute value of the voxel weighted mean for each 
region of interest for a scan subtracted by the voxel weighted mean value of the same region of 
interest for the pre scan. This is optimized by the use of a for loop that iterates three times in 
order to do the pre scan subtracted by the following three scans. The resting scan taken at the 
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onset of testing is a precursor for brain volume and area occupied by each region of interest. This 
resting value gives a better understanding of the contrast that is done through the addition of 
targeted and nontargeted Nanoemulsions. This normalization is calculated by equation shown 
below.  
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑄𝑄𝑁𝑁 𝑀𝑀𝑄𝑄𝑁𝑁𝑛𝑛 𝑉𝑉𝑁𝑁𝑁𝑁𝑉𝑉𝑄𝑄𝑠𝑠 = |𝑀𝑀𝑄𝑄𝑁𝑁𝑛𝑛 𝑁𝑁𝑜𝑜 𝑇𝑇𝑁𝑁𝑁𝑁𝑇𝑇𝑄𝑄𝑡𝑡𝑄𝑄𝑁𝑁 𝑆𝑆𝑆𝑆𝑁𝑁𝑛𝑛 −𝑀𝑀𝑄𝑄𝑁𝑁𝑛𝑛 𝑁𝑁𝑜𝑜 𝑃𝑃𝑁𝑁𝑄𝑄𝑆𝑆𝑆𝑆𝑁𝑁𝑛𝑛| 
Simultaneously as the normalization for the targeted and nontargeted data is being 
calculated the specificity index is analyzed. The specificity index is a percentage average value 
that takes the normalized value of the targeted scan and divides it by the nontargeted scan point. 
This shows where the highest concentration of targeted NE’s are going based off of the 
specificity of Gd3+ uptake in each region. This percentage change is shown in equation below.  
𝑆𝑆𝑆𝑆𝑄𝑄𝑆𝑆𝑁𝑁𝑜𝑜𝑁𝑁𝑆𝑆𝑡𝑡𝑆𝑆 𝑁𝑁𝑜𝑜 𝑁𝑁𝑛𝑛𝑁𝑁𝑁𝑁𝐴𝐴𝑁𝑁𝑁𝑁𝑉𝑉𝑁𝑁𝑁𝑁 𝑅𝑅𝑅𝑅𝑅𝑅 = (𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑄𝑄𝑁𝑁 𝐷𝐷𝑁𝑁𝑡𝑡𝑁𝑁 𝑜𝑜𝑁𝑁𝑁𝑁 𝑇𝑇𝑁𝑁𝑁𝑁𝑇𝑇𝑄𝑄𝑡𝑡𝑄𝑄𝑁𝑁 𝑆𝑆𝑆𝑆𝑁𝑁𝑛𝑛#)
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑄𝑄𝑁𝑁 𝐷𝐷𝑁𝑁𝑡𝑡𝑁𝑁 𝑜𝑜𝑁𝑁𝑁𝑁 𝑁𝑁𝑁𝑁𝑛𝑛𝑇𝑇𝑁𝑁𝑁𝑁𝑇𝑇𝑄𝑄𝑡𝑡𝑄𝑄𝑁𝑁 𝑆𝑆𝑆𝑆𝑁𝑁𝑛𝑛# 
While the code runs for specificity of the individual ROI’s it also calculates the average 
value for each subsystem. Once the normalization is computed the average for the 22 overlying 
regions is calculated. The normalized voxel weighted mean for each region of interest in the 
larger region is added together and then averaged to find the overall average value for the larger 
region. The average specificity per subsystem is calculated by equation below.  
𝑆𝑆𝑆𝑆𝑄𝑄𝑆𝑆𝑁𝑁𝑜𝑜𝑁𝑁𝑆𝑆𝑡𝑡𝑆𝑆 𝑜𝑜𝑁𝑁𝑁𝑁 𝐿𝐿𝑁𝑁𝑁𝑁𝑇𝑇𝑄𝑄𝑁𝑁 𝑅𝑅𝑄𝑄𝑇𝑇𝑁𝑁𝑁𝑁𝑛𝑛 = 𝐴𝐴𝐴𝐴𝑄𝑄𝑁𝑁𝑁𝑁𝑇𝑇𝑄𝑄 𝑜𝑜𝑁𝑁𝑁𝑁 𝑇𝑇𝑁𝑁𝑁𝑁𝑇𝑇𝑄𝑄𝑡𝑡𝑄𝑄𝑁𝑁 𝑆𝑆𝑆𝑆𝑁𝑁𝑛𝑛#
𝐴𝐴𝐴𝐴𝑄𝑄𝑁𝑁𝑁𝑁𝑇𝑇𝑄𝑄 𝑜𝑜𝑁𝑁𝑁𝑁 𝑁𝑁𝑁𝑁𝑛𝑛 − 𝑇𝑇𝑁𝑁𝑁𝑁𝑇𝑇𝑄𝑄𝑡𝑡𝑄𝑄𝑁𝑁 𝑆𝑆𝑆𝑆𝑁𝑁𝑛𝑛 # 
The specificity index is an averaged based concept that Nemucore and team developed to 
show a percentage difference between the targeted Nanoemulsions and non-targeted 
Nanoemulsions. Thee normalized averages are used to show specific targeted Nanoemulsion 
uptake based on Gd3+ concentrations at the specific ROI or subsystem.  
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After specificity index is calculated for all 174 ROI for each rat the values were 
compared to the manual excel spreadsheet to make sure they were within the same order of 
magnitude. There were slight differences between the Excel template and the MatLab analysis 
due to the template only have voxel weighting for the scan time points and not the prescan, while 
the MatLab program does voxel weighting for all data points.  
The final analysis needed is T-testing to see statistically where areas have significant 
difference between Nontargeted and Targeted Nanoemulsion uptake in healthy rat brain tissue. 
T-testing for a two sample 2-tailed test is an established equation, shown in equation.  
𝑡𝑡 = ?̅?𝑥 − 𝑆𝑆�
�𝑠𝑠𝑥𝑥
2
𝑛𝑛 + 𝑠𝑠𝑦𝑦2𝑁𝑁 
Where x ̅ is the mean for the targeted scan values and y ̅ is the nontargeted scan values. 
And ‘s’ is the standard deviation for each population. This equation gives a p value which gives 
the degree of confidence in the difference of the T1 weighted MRI data to show gadolinium 
uptake between the nontargeted and targeted Nanoemulsions.  
The above equation for t testing takes two separate populations, the targeted and the 
nontargeted Nanoemulsions, and finds if the populations are different. Our focus was at a 90% 
confidence interval and if the t test resulted in a p value less than 0.10 than the difference 
between the uptake of the targeted and nontargeted Nanoemulsions is significant. This 
significant difference relates to the uptake of the Nanoemulsion to that specific region of interest 
to show that the carrier system is staying in that part of the brain after a certain time point after 
injection. The data used in the t test is the normalized voxel weighted T1 mean value for both the 
targeted and nontargeted Nanoemulsion. The t test compares all three rats of the targeted NEs 
94 
 
study to that of the nontargeted rats. This is done to show if there is a difference between the 
samples for each scan point. 
The t-tests are conducted for all 174 regions across the entire sample study, and in order 
to verify the validity of the data the p-values were compared to those manually calculated in the 
excel template under similar conditions. As stated with the specificity index the t-test p-values 
will vary slightly due to the difference in voxel weighting between the Excel template and the 
MatLab program.  
Finally once specificity and t-testing are done, the results are exported in CSV files in 
order to be utilized by the visualization software. The specificity index exports three CSV files, 
one for each rat that has a column for the ROI ID number, ROI name and then three columns for 
the different scan time points. One CSV file is exported for T-testing with a column for ROI Id 
number, a column for ROI name and then three columns one for each scan point.  
5.6.2 3D Visualization of Rat Brain Atlas Slices 
 It was originally thought that by running script through the use of ImageJ all slices could 
be cropped to the same dimensions and then stacked base to top using MatLab’s ‘stack’ function. 
Upon completing this cropping scrip in ImageJ it was found that this could not be completed 
through one virtual stack and an expansion scrip was needed. Once this was done and all PNG’s 
were cropped along the same dimensions, it was found that not all PNG’s were created along the 
same vertical axis. So that while most external text was removed, some rat brain sections were 
altered as well. In order to maintain aspect ratio of each PNG (for easier stacking later and to 
maintain correct biological representation) each was manually altered in CS 5 Photoshop. This 
alteration included the removal of all textual writing and cropping images to reduce gray space 
surrounding outlined rat brain regions. An example of this can be seen below in Figure 13.  
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Figure 13: Both pre-processed, shown with full text and labeled locations, and post-processed, sans-text, rat brain 
atlas slices. 
Upon completion of the pre-processing required, the PNG slices were then imported into 
MatLab. In order to digitize and recreate these PNGs a multi-step process was used. At first 
designated color ranges for detection within each PNG were set. These ranges were originally set 
to generic values and the fine-tuned according to script response. These values designated the 
range in which each pixel would have to be in in order for its coordinate to be copied. The PNG 
themselves were loaded so that a script (reference Appendix 5 for all MatLab code) would search 
through each PNG pixel by pixel. The PNG slices are approximately 3000 by 3000 pixels so 
upon first implement the script required ample time to run. To optimize this process a buffer was 
implemented so that prescribed amount of pixels at a time were checked and copied instead of 
the entirety of each PNG. Once each PNG slice was searched the script resulted in as many 
arrays for each PNG as color types found. From there each coordinate with the corresponding 
color was generated as a point cloud as seen in Figure 14. These arrays were saved in MatLab’s 
equivalent of a hash map, Containers.Map. The use of a hash map system for data storage 
allowed for not only the data points coordinate to be saved but also the associated color value.  
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Figure 14: Point cloud rendering of all copied coordinates from 63 PNG rat brain atlas slices. 
While this was a benchmarking point to ensure that coordinates had in fact been copied 
correctly from the next step became connecting coordinates in a manner that reconstructed the 
174 defined functional regions on each slice. This is due to the points seeming to create a 
translucent representation with defined regions, just as the original PNG slices displayed. 
However, this is a point cloud and the points are only coordinates and not connecting lines.  In 
this current state there is no viable way to apply a heatmap given that there are no bound regions 
available. In order to bind these regions a recursive algorithm was utilized and can be seen in 
Figure 15.  
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Figure 15: First iteration and debugging of the Ramer-Douglas-Peucker Algorithm on simple non-branching slice. 
The Ramer-Douglas Peucker algorithm was utilized for this capability (reference Section 
4.0.0. for more information on this algorithm). Through several iterations across a simple non-
branching PNG slice this algorithm was tuned to the dataset. This process can be seen above in 
Figure 15. This algorithm allows for not only non-branching coordinate systems to be connected 
but also for more complicated multi-branching coordinate systems as well. In order for this 
algorithm to be correctly applied to this data set some parameters have to be changes. This 
concerns the parameter dictating the distance the algorithm goes from one point to the next. To 
see when the incorrect value is used reference Section 4.7.0 and Figure 16 below. With the 
correct value set for this parameter this application has to be optimized as well. This is done 
through another buffer system. 
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Figure 16: First pass application of Ramer-Douglas-Peucker Algorithm on all 63 slices with set distance parameter 
and breath for search. 
 In order to connect large quantities of coordinates, a buffer was instigated. Similar to the 
functionality of the one described previously this one functioned through a breath for search. 
Breath for search is a common algorithm used for searching for nearby points of interest. This 
works through searching a file at an arbitrary or fixed starting point that is then identified as a 
node. This search then explores outward and known areas form more nodes while areas awaiting 
discover are known as the frontier. The search can be set to look at a certain number of elements 
outwards, in this case 6 was chosen due to its successful ability to find points with this data set. 
By setting this search to 6, the breadth for search was also able to search in a single direction 
therefore illuminating overlapping lines and region alteration.  Once all coordinate were connect 
properly the resulting new hash map structure was plotted. The plotting color was changed to 
black for easier viewing capabilities.  
The final model can be seen below in Figure 17 from multiple views. As well as the User 
Guide for this program viewed in Appendix 3.  
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Figure 17: Final application of Ramer-Douglas-Peucker algorithm with optimized parameters. 
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6.0.0 Discussion 
Through the course of experimentation and analysis several points of discussion 
pertaining to results and societal measures of the project scope. These subjects are covered in the 
following sections.  
6.1.0 Results  
 Through design and iteration for both Nanoemulsion manufacturing, targeting specificity, 
statistical analysis, and visualization point of discussion appeared. These points as well as this 
projects application to the global market in a variety of aspects are covered below. 
6.1.1 Nanoemulsions 
Our fluorescent microscopy experiments revealed a stark contrast being non-targeted and 
mu opioid receptor targeted nanoemulsions, with the targeted NEs demonstrating faster uptake 
into the cells almost immediately. This data indicates that the targeted nanoemulsions are most 
likely entering the cells through two mechanisms; a slower mechanism that the non-targeted NEs 
use, as a well as a faster mechanism, most likely mediated the NE-receptor interaction. The 
alpha-7 and B2 bradykinin targeted nanoemulsions did not show a clear difference in uptake, 
although there appears to be slightly higher levels of fluorescence in the B2 bradykinin NEs at 4 
hours. As literature states that the U-87 MG cells that were treated do not express alpha-7 
receptor and do express the B2 bradykinin receptor, these results are also in agreement that some 
level of targeting specificity has been achieved with these nanoemulsions. It should be noted that 
the nanoemulsions used in these experiments were made from formulations with lower amounts 
of PEG. The NEs were all slightly larger than our target size of 150 nm (170-200) and the alpha-
7 and B2 bradykinin targeted NEs displayed Oswald ripening, making them untenable as 
therapeutic options. 
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The initial flow cytometry experiment that was performed did not provide conclusive 
results as to the whether the targeted NEs led to an increased uptake by the U87MG and bEnd.3 
cells. This was because the cell counts were low for both cell populations following the washing 
steps in the experimental protocol. Therefore, the flow cytometer was had difficulty identifying 
enough cells for a representative population of fluorescently targeted cells. For both the U87MG 
and bEnd.3 cells, there was an increased uptake of non-targeted NEs as compared to the mu-
opioid targeted NEs. The bEnd.3 cells show a higher uptake of both the non-targeted and the mu-
opioid targeted NEs which may be due to the various factors such as the cell mediated 
endocytosis specific to each cell line or the number of receptors that are present on each cell line. 
Overall however the method of plate treated cells for flow cytometry analysis was found to be 
inefficient and therefore the following flow cytometry experiments were performed with cell 
suspensions. 
The U87MG cells were utilized for suspension flow cytometry and there was a 0.5 fold 
increase of the alpha-7 nAChR targeted NEs by the cells which were also significant and a 0.48 
fold increase of the non-targeted and mu-opioid targeted NEs. The suspension flow cytometry 
performed on the bEnd.3 cells showed a higher uptake of non-targeted NEs as compared to the 
mu-opioid targeted and alpha-7 nAChR targeted NEs which both showed significant uptake as 
compared to the non-targeted NEs. Lastly, the C6 cells that were utilized for the suspension flow 
cytometry showed a must higher fold increase in the uptake of the non-targeted, mu-opioid 
targeted, and alpha-7 nAChR targeted NEs. Both targeted NEs show significant uptake by the C6 
cells which can be due to various factors. These cells are derived from rat glioma cells and may 
either have increased numbers of receptors on them, or may be due to enhanced cell meditated 
endocytosis by the cells. 
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The data obtained from the suspension flow cytometry on the U87MG, bEnd.3, and C6 
cells indicate that there is increased uptake of the nanoemulsions by the cells. Although the fold 
increase in uptake by the targeted NEs is statistically significant as compared to the non-targeted 
(in most cases), the overall fold increase is not much higher. This may be due to the 
pharmacodynamics uptake of the nanoemulsions by the cells which can be affected by intrinsic 
properties of the cells. The data conveyed in this report is a good starting point for future 
iterations in quantitatively assessing the uptake of the NEs. Further analysis into the number of 
receptors on the cells, whether trypsinization prior to treatment with NEs affects receptor 
presence on surface of cells, as well as the ligand-receptor interactions need to be performed.   
As shown in Section 7.1.0, we did not observe fluorescence within C6 cells at 
concentrations of targeted-ligand-fluorescent marker conjugate ranging from 100 nM to 2 µM. 
Fluorescence was observed in the 1 and 2 µM concentrations, though none of the fluorescence 
appeared to be localized within any of the cells. Our results indicate that the conjugation of 
fluorescent markers to the mu-opioid targeting ligand was successful (as evidenced by the 
observed fluorescence), but it does not appear that any of the cells enveloped the fluorescent 
markers. While the initial conclusion is that targeting specificity was not achieved, which would 
explain our flow cytometry results (targeted uptake levels similar to non-targeted uptake levels), 
further research led us to question whether this is convincing enough proof that targeting and 
uptake through the mu-opioid receptor does not occur with our specific targeting ligand. 
Literature shows that the C6 cell line does express mu-opioid receptor, but it is expressed in 
relatively low concentrations compared to other brain tissue. These final experiments were 
conducted on C6 cells that had been passaged more than 20 times, and excessive amounts of cell 
passaging can lead to loss of protein expression (Vierck et al. 2000). Ideally, genetic analysis of 
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the cell line would have been performed at a passage close to the time of the experiment, to 
quantitatively prove that the cells being experimented on were actively expressing the mu-opioid 
receptor.  
6.1.2 3D Statically Heatmap 
The 3D Statistical Heatmap is geared toward a directed focus group of clinicians, 
researcher, and patients, however this group is comprised of individuals from all around the 
world. Research concerning treatment options for Glioblastoma Multiforme that are non-invasive 
are becoming very important as technology advances. Due to the lack of guided therapies 
available to both researchers and in industry, a great need has to be met in order to create an 
interface between the biology and the aggressive nature of these tumors with clinically relevant 
visualization of where the tumors are located. This need allows for new therapies to be 
continually developed due to the threat of high mortality rate of GBM. These areas of research 
also open doors into treatment applications of similar forms of tumor. Due to collaboration and 
continued research from those across the world, technology that allows the ability to see where 
delivery of therapeutics is occurring is very important. As such a software program that enables 
the combination of not only the visual representation of these therapeutics but also the correlated 
statistical analysis in a visual form.   
 This application for advancement in GBM research through this integrated software 
package has the ability to create a huge industry and clinical impact. It was the goal of this 
project team to create an integrative program that was able to complete full statistical analysis for 
studies of various sizes and visual 3D statistical heatmap through the use of Northeastern 
University PNG Rat Brain Atlas to correlate Nanoemulsion uptake in a healthy rat brain. While 
the overall ground level capabilities have been the primary focus of this project team there are 
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some key capabilities that ensure wide range of availability for whomever requires it. In order to 
accomplish this a few factors have to be considered. Not only will the statistical analysis and 
visualization of the Rat Atlas PNG’s be useful for further research at Nemucore, but it will aid in 
our collaborators at Northeastern University, TGen, UNC, and Mayo Clinic, as well with their 
future studies and expansions of the rat atlas to diseased rat brains and eventually human. The 
diversity of this software that can be applicable not only to Nemucore’s Nanoemulsion studies, 
but also to any other program that utilized T1 weighted MRI data for rat brains. Similarly, the 
software program has been specifically designed in a fairly common programming language so 
that anyone with the base model and an understanding of MatLab will be able to utilize it.   
To have a fully functioning program for statistical analysis and visualization optimization 
is key. In order to achieve the best possible outcomes the use of loops and functions are needed 
in order to minimize code length and to automate many repetitive functions. Through the design 
iteration process the code for statistical analysis has been modified so that with only a few 
alterations it can essentially run an n=1 or n= infinity cohort study. This is tremendous feat due 
to need for larger pre-clinical rat trails in order to eventually produce data sets leading to clinical 
trials and FDA approval of novel therapies for the huge unmet clinical need of GBM. By making 
the program more robust and able to handle large study sizes the applications for this program 
will expand. This statistical analysis can be used with other drug delivery systems beside 
Nanoemulsion, it can be used with micelles, dendrimers and other drug delivery vehicles to see 
uptake of drug, DNA, RNA, and other molecules to the desired sites in the brain. Other vehicles 
can have the same specificity index applied to them as long as they have BBB penetrating 
abilities and accumulation in brain tissue. This program can go on to be used in the study of 
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other diseases such as Alzheimer’s, Parkinson’s’ and other neurodegenerative diseases that have 
subpar standards of care.  
The final output of the statistical analysis portion of the program is 4 CSV files. The first 
three CSV files exported are The Specificity Index per Rat. The format of the CSV file is that the 
first two columns are the ROI ID and ROI Name Respectively. These columns are organized 
based off of the subsystem organization. The final three columns are Scans 1, 2, 3 respectively 
with specificity index values populating these columns. The other CSV file is the T-Testing at 
90% Confidence which could be increased to 95% with a larger rat cohort size. The format is the 
same as the Specificity Index CSV files except the last three columns are populated with p values 
that are from the T-test to show the significant difference from the nontargeted to the targeted 
Nanoemulsion study.  The number of CSV files exported will change in future studies when 
greater numbers of rats are used.  
Table 11 below, is a sample of one of the specificity index outputs from the code.  
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 Table 11: Example exported specificity index per singular rat subject. 
Below is a sample from the T-test p-value data in Table 12.  
ROI ID ROI Name Scan 1 Scan 2 Scan 3
57 Glomerular Layer 1.026 3.242 2.255
53 External Plexiform Layer 0.559 58.945 1.498
59 Granular Cell Layer 0.871 0.822 0.634
152 Tenia Tecta 0.976 29.285 2.450
20 Anterior Olfactory Nucleus 1.485 2.770 1.811
102 Caudal Piriform Ctx 2.476 23.757 0.785
103 Rostral Piriform Ctx 6.363 4.030 4.728
31 Anterior Cingulate Area 2.175 43.090 6.935
125 Retrosplenial Caudal Ctx 0.505 5.085 3.685
126 Retrosplenial  Rostral Ctx 1.736 26.079 3.010
64 Insular Ctx 1.306 3.560 12.975
156 Visual 1 Ctx 2.659 12.593 2.633
157 Visual 2 Ctx 1.774 4.490 5.459
150 Temporal Ctx 10.305 14.869 8.493
52 Entorhinal Ctx 0.653 13.999 6.757
23 Auditory Ctx 0.561 39.090 7.994
50 Ectorhinal Ctx 0.841 1.859 0.853
114 Perirhinal Ctx 0.113 3.629 6.699
116 Parietal Ctx 1.771 3.908 1.258
130 Primary Somatosensory Ctx Barrel Field 0.100 9.697 0.641
131 Primary Somatosensory Ctx Forelimb 1.212 4.524 30.787
132 Primary Somatosensory Ctx Hindlimb 0.491 5.365 0.533
133 Primary Somatosensory Ctx Jaw 59.828 2.474 4.434
134 Primary Somatosensory Ctx Shoulder 0.156 3.168 7.524
135 Primary Somatosensory Ctx Trunk 1.772 3.753 12.913
136 Primary Somatosensory Ctx Upper Lip 0.817 11.459 3.633
137 Secondary Somaotsensory Ctx 0.418 10.184 39.310
166 Ventral Orbital Ctx 0.977 1.831 4.137
88 Medial Orbital Ctx 2.009 3.859 0.871
75 Lateral Orbital Ctx 1.553 39.102 1.990
63 Infralimbic Ctx 0.739 1.751 3.509
115 Prelimbic Ctx 1.292 6.540 2.783
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 Table 12: Example exported t-test per singular rat subject. 
As seen above all p-values are less than 1 to show they are a percentage confidence 
indicator. The p-values below 0.10 show where there is significant difference between the 
targeted and nontargeted NEs. The difference in uptake is indicative where there is a high 
15 Anterior Amygdaloid Nucleus 0.171844 0.158601 0.484151
68 Lateral Amygdaloid Nucleus 0.707964 0.106203 0.47145
61 Intercalated Amygdaloid Nucleus 0.482454 0.34067 0.183167
35 Cortical Amygdaloid Nucleus 0.904532 0.112732 0.088561
83 Medial Amygdaloid Nucleus 0.074249 0.826933 0.328087
49 Extended Amydala 0.372195 0.099929 0.364696
42 Dorsal Lateral Striatum 0.400214 0.140855 0.40999
44 Dorsal Medial Striatum 0.790607 0.201776 0.826938
162 Ventral Lateral Striatum 0.197928 0.42091 0.737179
165 Ventral Medial Striatum 0.168154 0.233421 0.504716
153 Olfactory Tubercles 0.577345 0.335894 0.750221
16 Accumbens Core 0.015999 0.432343 0.867008
17 Accumbens Shell 0.81239 0.69455 0.493062
58 Globus Pallidus 0.481276 0.214994 0.218261
167 Ventral Pallidum 0.65627 0.045779 0.789037
146 Subthalamic Nucleus 0.830234 0.284021 0.840754
174 Zona Incerta 0.700927 0.273579 0.725713
111 Prerubral Field 0.936506 0.056164 0.287869
51 Endopiriform Nucleus 0.563445 0.099451 0.71149
139 Substantia Innominata 0.446852 0.12276 0.381538
33 Claustrum 0.789756 0.211078 0.864362
145 Bed nucleus Stria Terminalis 0.791104 0.016557 0.681647
78 Lateral Septal Nucleus 0.10658 0.44399 0.20487
151 Triangular Septal Nucleus 0.158011 0.383403 0.155321
91 Medial Septum 0.937101 0.006876 0.544414
39 Diagonal Band of Broca 0.643184 0.407652 0.258641
18 Anterior Hypothalamic Area 0.6463 0.104332 0.270428
73 Lateral Hypothalamus 0.433276 0.846791 0.98421
104 Premammillary Nucleus 0.827815 0.102191 0.197706
149 Supramammillary Nucleus 0.773525 0.412334 0.473281
138 Suprachiasmatic Nucleus 0.904264 0.146379 0.602502
94 Paraventricular Nuclus 0.841688 0.138479 0.172884
22 Arcuate Nucleus 0.610004 0.188316 0.103489
43 Dorsal Medial Nucleus 0.96429 0.153854 0.161855
100 Posterior Hypothalamic Area 0.952688 0.147263 0.336443
81 Magnocellular Preoptic Nucleus 0.503764 0.390894 0.253546
86 Medial Mammillary Nucleus 0.427026 0.108867 0.57412
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concentration of receptors at that location. These in vivo rat studies were conducted for μ-opioid 
receptor, alpha7 and bradykinin receptors across targeted and nontargeted NEs.  The statistical 
analysis code can be conducted for these and other receptors as ligands become available and 
show where the most significant uptake is being seen at specific regions of interest.  
As shown in the preliminary section of the data the following table illustrates the initial 
analysis done to show which subsystems of the brain have the most significant uptake of the 
targeted NEs.  
 
Table 13: Example of final Analysis of Specificity Index and T-Testing Microsoft Excel output. 
As seen in Table 13 above the areas with the most significant uptake are those with both 
yellow and blue highlighted areas.  The analysis of the original MRI data from Northeastern in 
vivo rat study was done on targeted NEs and MRI T1 data. The above table shows literature 
review of the receptors locations. This was done for all 174 regions but rolled this up into 22 
subsystems of the brain based off of literature review and location in the brain. This will be 
continually improved, to show receptor density at the subsystem locations. The yellow 
corresponds to the p values less than 0.10. This is to show statistically where areas have 
significant difference between nontargeted and targeted Nanoemulsion uptake in healthy rat 
Scan 1 Scan 2 Scan 3 Scan 1 Scan 2 Scan 3 Scan 1 Scan 2 Scan 3 Scan 1 Scan 2 Scan 3 Scan 1 Scan 2 Scan 3 Scan 1 Scan 2 Scan 3
Olfactory Bulb N/A 0.426 0.033 0.317 1.141 1.459 1.180 L 0.991 0.437 0.625 0.998 1.164 0.925 L 0.251 0.763 0.520 0.798 1.067 0.910
Olfactory Areas H 0.657 0.136 0.792 1.116 1.377 1.041 P 0.657 0.349 0.315 1.126 1.152 0.849 L 0.392 0.715 0.587 0.777 1.076 0.935
Limbic Lobe N/A 0.269 0.314 0.165 1.278 1.181 1.286 H 0.921 0.770 0.831 0.975 1.179 1.048 M 0.472 0.851 0.358 0.828 0.966 1.163
Insular Cortex N/A 0.062 0.087 0.400 1.457 1.478 1.181 H 0.010 0.048 0.267 1.579 1.484 1.094 N/A 0.548 0.267 0.212 0.923 1.222 1.141
Occipital Lobe M-H 0.100 0.022 0.029 1.500 1.486 1.654 P 0.862 0.676 0.307 0.942 1.085 1.208 N/A 0.984 0.737 0.015 0.995 1.053 1.486
Temporal Lobe M 0.011 0.019 0.017 1.757 1.433 1.328 P 0.077 0.034 0.119 1.740 1.663 1.438 L 0.565 0.505 0.095 1.135 1.090 1.202
Parietal Lobe N/A 0.215 0.000 0.031 1.147 1.462 1.274 P 0.049 0.645 0.531 0.768 1.048 0.950 N/A 0.014 0.049 0.001 0.775 1.171 1.283
Frontal Lobe H 0.883 0.010 0.147 1.025 1.467 1.209 P 0.454 0.711 0.186 0.867 1.064 0.846 N/A 0.0247 0.3323 0.7826 0.6364 1.1441 0.9756
Hippocampal 
Formation H 0.170 0.831 0.236 1.236 1.017 1.105
P w/ H 
Molecular 
0.773 0.417 0.752 1.046 0.924 1.036 M-L 0.4313 0.9524 0.0087 1.1330 0.9952 1.2318
Amygdaloid Nuclear 
Complex H 0.934 0.535 0.371 1.018 1.133 0.864 H 0.384 0.263 0.301 1.232 1.293 1.200 M-H 0.1042 0.832 0.297 0.669 0.959 0.838
Basal Ganglia N/A 0.089 0.000 0.046 1.219 1.754 1.182 P Within 0.319 0.004 0.884 0.728 1.486 1.018 M 0.1669 0.0000 0.0111 0.8486 1.5709 1.2162
Basal Forebrain N/A 0.650 0.000 0.263 0.797 2.398 1.238 P 0.150 0.000 0.440 0.690 1.680 1.092 N/A 0.036 0.0020 0.078 0.620 1.528 1.233
Septum N/A 0.028 0.069 0.206 2.065 2.310 1.671 M 0.428 0.100 0.641 1.281 1.884 1.220 H 0.235 0.057 0.283 1.317 1.926 1.558
Hypothalamus M 0.714 0.920 0.408 0.918 1.024 0.862 H 0.028 0.029 0.019 1.788 1.705 1.600 L 0.419 0.707 0.947 0.862 1.066 0.991
Pituitary M 0.522 0.791 0.250 0.798 0.877 0.649 H 0.026 0.142 0.022 0.149 0.336 0.211 L 0.045 0.445 0.156 0.314 0.690 0.579
Thalamus L 0.210 0.202 0.072 1.192 1.127 1.157 M-H 0.906 0.963 0.760 1.023 0.994 1.037 H 0.476 0.523 0.040 1.122 1.069 1.201
Epithalamus L 0.609 0.712 0.739 0.699 0.811 0.823 M 0.970 0.835 0.813 0.980 1.092 1.111 H 0.951 0.681 0.365 0.951 0.681 0.365
Cerebellum M-L 0.001 0.050 0.023 1.505 1.206 1.284 M 0.325 0.753 0.303 1.166 1.038 1.134 N/A 0.473 0.381 0.041 1.108 1.091 1.246
Pons N/A 0.812 0.674 0.766 1.048 0.949 1.041 M 0.480 0.603 0.171 1.159 1.072 1.214 N/A 0.780 0.710 0.008 1.049 1.038 1.330
Tectum H 0.528 0.803 0.978 0.828 0.948 1.008 P 0.126 0.183 0.361 0.590 0.763 0.768 M 0.043 0.068 0.701 0.476 0.658 0.913
Cerebral Peduncle N/A 0.159 0.707 0.538 0.742 1.057 1.106 P 0.005 0.037 0.135 0.435 0.748 0.912 M 0.044 0.146 0.001 0.633 0.658 1.409
Medulla Oblongata N/A 0.339 0.931 0.299 1.377 1.060 1.260 M 0.935 0.585 0.950 1.068 0.918 1.034 N/A 0.607 0.625 0.440 0.872 0.924 1.146
mu-
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brain tissue. The  blue represents the top 25% of the specificity index, which shows where the 
highest concentration of targeted NEs are going based off of the specificity of Gd3+ uptake in 
each region. There is a direct correlation between T1 signal and Gd3+ uptake concentration in the 
brain for enhanced MRI data. Most significant sections with uptake are the Temporal Lobe, 
Parietal Lobe, and Frontal Lobe, which are the most frequent places where Glioblastoma 
Multiforme manifests.  
 Visualization for the 174 functionally defined Rat Brain Atlas was comprised of 63 
PNGs. These PNGs were successfully digitized and recreated in MatLab as seen in Section 5.6.0. 
While the wire-frame model was created, the application of the visual statistical heatmap did not 
occur. This was due to several factors including time, knowledge of algorithms, and complexity 
of branching systems. The heatmap application is vital to the overall software package. Currently 
both required bases for the heatmap application have been created, the visualization wire-frame 
model and the statistical analysis. With these robust bases the heatmap code can be applied to the 
bounded regions within the wire-frame model. Through this combination a full software package 
enabling not only significant statistical analysis but also visualization of the Gd3+ and by 
understanding of the ration of Gd3+/Drug accumulation within the rat brain model will be 
possible. 
6.2.0 Social Implications 
 In order to grasp the full complexity and implication of this project avenues concerning 
the relationship between this project and the world were researched and reported. These findings 
can be found in the section below covering the economic, environmental, societal, political, 
ethical, health and safety, and sustainability impacts. 
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6.2.1 Economic Impact 
 For both components of the project there are fairly low economic impacts. For future 
application of the 3D Statistical Heatmap the program itself is essential open source. This means 
that it is freely available to the general public for their own use. However, if the project team 
sponsor, Nemucore Medical Innovations, decided to move forward with creating a fully external 
executable that could run independent of MatLab then the software package could be patented 
and sold at a cost. Pending this decision however, the only cost incurred to a potential user is the 
licensing fee via MatLab for use of their product. Overall this is minimal and available world-
wide.  
 For the nanoemulsions, the largest economic spending is the cost of manufacturing.  The 
chemical synthesis and conjugation of targeting ligands can greatly add to the final cost of the 
NEs. Additionally, the microfluidizer machine has a maintenance cost to be considered. In the 
future when these nanoemulsions become available to the general public as a targeted drug 
delivery vehicle, the cost of chemotherapeutic treatment of cancers may be lowered as less drug 
can be used to have the same impact locally on the tumor. Therefore, these NEs can potentially 
reduce healthcare costs for patients and hospitals in the future. 
6.2.2 Environmental Impact 
 While the environment can be greatly affected due to shipping, manufacturing, and 
distribution processes there is very little of this seen in this project. Both components are fairly 
self-sufficient in these respects. The 3D Statistical Heatmap is distributed through the use of the 
web so shipping, distribution, and manufacturing cost are mitigated. An associated 
environmental impact can be contributed via the electricity used to power computers utilizing 
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this program. This however, is mitigated due to computer general use on a daily basis outweigh 
to power required to run this software package.  
 The environment must always be considered when working with chemical synthesis of 
drug carriers. Waste control must be closely monitored during the manufacturing process to 
ensure the water supply of the city does not become contaminated.  
6.2.3 Societal Influence 
 This project has a huge societal influence and impact. Overall the aim of this project is to 
create a program that allows visualization of a drug delivery system for treatment of one of the 
deadliest tumor types a patient can encounter. As such, the combination of furthering targeting 
efficacy of these drug delivery systems, which are non-invasive to the patient, and provided a 
software package that can visualize the delivery system opens numerous possibilities for not only 
treatment of Glioblastoma Multiforme but also other deadly diseases. This project gives patients 
a glimpse into a future where they will be able to receive treatment for otherwise extremely 
deadly diseases.  
 By having access to the nanoemulsions as a targeted therapy patients will be able to have 
enhanced benefits from their chemotherapeutic treatments and therefore will be able to recover 
faster. Therefore, the physical as well as the mental health of patients receiving these treatments 
will be great improved which will lead to positive societal influences. 
6.2.4 Political Ramifications 
 In addition to the Societal and Scientific influence our project has, it is also important to 
take legal and political ramifications into consideration. Due to the novelty of this integrative 
guided therapy software there is no real prior art in the United State Patent and Trademark 
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Office. The legality comes from using pre-acquired data and information from Northeastern 
University in the form of their Rat atlas. But being collaborators they are entitled to 
acknowledgement and right to the software itself. IN addition the use of live animals were done 
prior to the start of this project, but the data was collect from rat studies. Organizations like 
PETA, are against animal studies, but for the scope of this project all animal studies were 
conducted in a humane manner. Other political ramifications could be from healthcare providers. 
In the future if this is adapted to human use and to be used as a “Real Time” Pharmacodynamics 
Guided Therapy healthcare practitioners, insurance companies, and big corporations could be 
involved with regulation and application of our technology. Although this program is still in the 
early developments for research use only, the potential for larger companies and federal funding 
and insurance may be applicable in the future. The nanoemulsions will impact healthcare 
practitioners as well as insurance companies in the ways they treat patients. As such, the 
government which also has great influences on health care will be impacted by this new 
technology. 
6.2.5 Ethical Considerations 
 There are currently no ethical considerations within the scope of this project. No human 
patients were utilized in the creation of the 3D Statistical Heatmap. While data was gathered 
through the use of rat subjects, all were treated in conjunction with humane treatment standards.  
If the project were to be used for human trials it would have to be regulated and all cytotoxic 
effects would have to be considered.  
 Tt is important to continue to consider the humane conditions under which the NEs are 
tested during clinical trials. If the drugs carried by the nanoemulsions increase health risks for the 
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patient, an ethical issue ensues on whether the carriers can be used to treat cancers. Therefore the 
safety of these NEs are of prime interest in future investigations 
6.2.6 Health and Safety 
For the scope of this project only human cell lines were used and there were no direct 
interfaces of the NEs with humans. The software is purely statistical and visual in nature and 
therefore has no health concerns for the user. If our guided therapy software program was to be 
applied for a human brain for real time analysis of NEs uptake then many considerations will 
have to be taken. The cytotoxicity of the NEs themselves and their circulation throughout the 
body along with accumulation in the brain have to be considered. Also the effect if the NEs are 
delivering chemotherapeutics to non-cancerous sites. The consideration for the safety of the 
patient must be the top priority when injecting any drug delivery system, therefore strict 
regulatory and FDA standards would have to be applied in order to ensure that the efficacy and 
biocompatibility of the NEs is up to regulation.  
6.2.7 Sustainability 
 The 3D Statistical Heatmap provides an interface and ability to be sustainable and 
improvable for generations to come. Given that it is programmed in a fairly common language it 
can be accepted across many different types of operating systems. Given that is a program as 
well, the logic of the script can be transferred between programming languages. Meaning that as 
new languages are created that provide better capabilities for end product results the code can 
continually be iterated to improve and adapt. As with any material, the recyclability of the 
nanoemulsions must be considered. Therefore the chemicals that are used to synthesize the NEs 
are important to consider and chosen based on how sustainable they are.  
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7.0.0 Final Design and Verification 
After iteration and design alterations, final specifications and models were created for 
both the nanoemulsions manufacturing and the 3D Statistical Heatmap. The results and 
verification are described below. 
7.1.0 Nanoemulsions 
After design iterations the nanoemulsions were measured for stability over time. U87MG 
cells were used for uptake studies with the NEs that provided qualitative data. Additionally, flow 
cytometry was performed with U87MG, bEnd.3, and C6 cells to gather quantitative data. Lastly, 
a binding study was performed to better understand the interaction between the mu-opioid 
targeted ligand and the mu-opioid receptor on the C6 cells. The final results from the 
experiments can be seen below.         
7.1.1 Stable Nanoemulsion Size  
Tables 14, 15, and 16 show size distribution of the nanoemulsions that were created with 
a higher density of PEG. The polydispersity index (PDI) indices of less than 0.1 are referred to as 
“monodisperse” while PDI of > 0.1 indicates that the data may require further analysis to 
determine if the data is valid. The zeta potential indicates the electro kinetic potential in colloidal 
suspensions. A negative charge on the NEs is preferred as it reduces the chances of blood clots 
when administered in vivo. The size of the NEs is stable over time at around 150 nm which is the 
within the expected range.  
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 Table 14: Size distribution and zeta potential for non-targeted and mu-opioid targeted NEs. Initial iteration with 
increased PEG density on NEs. Measurements were not continued due to school break. 
 
Table 15: Size distribution and zeta potential for non-targeted and mu-opioid targeted NEs with increased PEG 
density. 
 
Table 16: Size distribution and zeta potential for alpha-7 nAChR NEs with increased PEG density. 
7.1.2 Nanoemulsion Fluorescence Uptake Study 
In Figure 18 the non-targeted condition showed much less uptake of the nanoemulsions 
as compared with the mu-opioid targeted NE at time points of 30 minutes, 1 hour, and 4 hours. 
As seen from Figure 19, the alpha-7 nAChR targeted and b2-bradykinin targeted NEs also show 
Non-Targeted NE
Day 0 7 14 21 0 7 14 21
Size Distribution (nm) PDI
138.7 0.033
Zeta Potential (mV) Standard Deviation (mV)
-46 6.69
Mu-Opioid Targeted NE 
Size Distribution (nm) PDI
134.9 0.073
Zeta Potential (mV) Standard Deviation (mV)
-45.7 9.52
Non-Targeted NE
Day 0 7 14 21 29 0 7 14 21 29
Size Distribution (nm) PDI
150.3 141.7 146.1 149.3 137.6 0.082 0.006 0.113 0.01 0.046
Zeta Potential (mV) Standard Deviation (mV)
-52.7 -47.9 -35.7 -39.7 -41.9 11.5 15.3 10.2 10.8 10.6
Mu-Opioid Targeted NE 
Size Distribution (nm) PDI
145.2 142.9 145.1 146.5 144.6 0.057 0.017 0.005 0.04 0.008
Zeta Potential (mV) Standard Deviation (mV)
-37.1 -43.5 -32.7 -47.1 -47.8 13.5 9.25 6.56 10.3 14.1
Alpha-7 nAChR Targeted NE
Day 0 7 14 21 0 7 14 21
Size Distribution (nm) PDI
150.9 143.9 146.6 148.9 0.006 0.065 0.03 0.023
Zeta Potential (mV) Standard Deviation (mV)
-40.1 -47.3 -36.1 -46 14.1 8.1 11.7 11.9
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comparable uptake by the U87MG cells at 4 hours. These nanoemulsions contained a low 
density of PEG. 
 
Figure 18: U87MG cells treated with untreated, non-targeted, and mu-opioid targeted NEs at time points 0.5 hours, 
1 hour, and 4 hours. 
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 Figure 19: U87MG cells treated with non-targeted, alpha-7 nAChR targeted (Alpha-7), and b2-bradykinin targeted 
(B2R) NEs at time intervals 0.5 hours, 1 hour, and 4 hours. 
7.1.3 Suspension Nanoemulsion Flow Cytometry Studies  
Figure 20 shows the flow cytometry data analysis for the U87MG cells targeted with the 
mu-opioid targeted and alpha-7 nAChR targeted NEs. The non-targeted NEs show a 0.48 fold 
increase in uptake by the cells. Both the mu-opioid targeted and the alpha-7 nAChR targeted NEs 
show a 0.5 fold increase in uptake and the alpha-7 nAChR targeted NE shows significance as 
compared with the non-targeted NEs. Overall, it seems that both the mu-opioid targeted and 
alpha-7 nAChR targeted NEs elicit a slight increase in uptake by the U87MG cells at the 1 hour 
time point. The tight error bars on the graphs indicate that the data is valuable and accurate. 
Further experiments can further explore into quantifying the presence of the targeted receptors as 
well as the ligand receptor interaction on the U87MG cells. 
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 Figure 20: The untreated cells were set a geometric mean fluoresce baseline of 2. Significance indicated by * is < 
0.05 and ** is < 0.005. 
The bEnd.3 cells have an increased uptake of the non-targeted nanoemulsions as 
compared with the targeted NEs as can be seen in Figure 21. There is a 1.43 fold increase in the 
uptake of the non-targeted NEs by the bEnd.3 cells and a 1.2 and 1.1 fold increase by the mu-
opioid targeted and alpha-7 nAChR targeted NEs respectively. Additionally, both the mu-opioid 
targeted and the alpha-7 nAChR targeted NEs show significance when compared to the non-
targeted NEs. Overall, in comparison with the U87MG cells, there is an increased uptake of the 
non-targeted and targeted NEs by the bEnd.3 cells at 1 hour. This may be due to the surface 
properties of the cell and the endocytosis mechanisms the cell employs. The tight error bars on 
the graphs indicate that the data is valuable and accurate. 
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 Figure 21: The untreated cells were set a geometric mean fluoresce baseline of 2. Significance 
indicated by * is < 0.05 and ** is < 0.005. 
The C6 cells show a 2.52 fold increase in the uptake of non-targeted NEs as compared to 
the untreated cells as can be seen in Figure 22. The mu-opioid targeted NEs show a 2 fold 
increase in uptake and the alpha-7 nAChR targeted NEs show a 2.2 fold increase in uptake by the 
cells. Both the mu-opioid targeted and the alpha-7 nAChR targeted NEs show significant uptake 
by the cells as compared to the non-targeted NE. Overall, the C6 cells exhibited greater uptake of 
both the targeted and non-targeted NEs at 1 hour as compared to the U87MG and the bEnd.3 
cells. Additionally the tight error bars on each bar indicates that the data is accurate and valuable. 
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 Figure 22: The untreated cells were set a geometric mean fluoresce baseline of 2. Significance indicated by * is < 
0.05 and ** is < 0.005. 
7.1.4 Binding Study 
The binding study did not confirm the uptake of the mu-opioid targeted-Alexa fluor tag 
by the C6 cells as can be seen in Figure 23. The concentration of the mu-opioid targeted-Alexa 
fluor tag was increased and although fluorescence is expressed at higher concentrations, the 
fluorescence cannot be correlated to binding to the cell. These nanoemulsions contained a higher 
density of PEG. 
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 Figure 23:C6 cells at 1 hour time point with various concentrations of mu-opioid targeted tagged with Alexa fluor 
568 fluorescence. 
 
7.2.0 3D Statistical Heatmap 
 The final design of the Statistical Analysis code has four major outputs. These are CSV 
files, three for the Specificity Index at all three scan time points for each rat and the other is the p 
values from the t-test at the 90% confidence. These files will be exported into the Matlab folder 
where the code and necessary data folders are stored as well, seen below in Figure 24. 
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 Figure 24: Folder Containing Code and CSV needed.  
 
Shown below is a sample from one of the specificity index CSV files in Figure 25.  
 
Figure 25:Sample of ROI CSV File. 
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The code is able to do all simultaneous analysis of all 174 anatomically defined regions 
of the rat brain for all three scan time points and the pre scan across the three rat study. This 
allows for voxel spatial weighting and normalization of the data to better represent where Gd3+ 
uptake is the highest and to find the significance of the uptake of targeted NEs.  
 The final design and result from the statistical 3D heatmap was composed of two 
products. The primary product is an exported CSV file containing computed statistical analysis. 
The secondary resulting output is the final reconstructed model of the 174 defined functional 
region rat brain model in MatLab which can be seen below in Figure’s 26, 27, and 28.  
This model was successfully able to reproduce the 63 portable network graphics provided by  
Figure 26: ¾ view of 174 functional regions of rat brain model comprised of 63 digitized PNG slices. 
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 Figure 27: Frontal view of 174 functional regions of rat brain model comprised of 63 digitized PNG slices. 
 
 
Figure 28: Top-down view of 174 functional regions of rat brain model comprised of 63 digitized PNG slices. 
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Northern University in MatLab. This visualization is created through a four step process. The 
primary process was to remove all text from each of the 63 PNGs and was conducted through 
Photoshop CS5. The second step was to import these images into MatLab and create a scrip that 
searched through each pixel to see if a coordinate denoting part of a line and corresponding 
designated color range. If the script came across this then it would save that coordinate in an 
array. Upon completion of this script across all slices, the coordinates where then plotted in 3D. 
If enough points were present, this verified that the script had worked correctly and was ready to 
proceed. By applying the Ramer-Douglas-Peuker algorithm the coordinate points were connect 
for each individual slice. So that viewing from the side view, the model displays 63 distinct 
slices. As seen in Figure 26 above, a cross sectional view allows the user to see all 63 slices with 
the defined functional regions as well. This skeletal model allows for a depth of view previously 
not found for this type of model which will allow for a greater range of pharmocodynamic 
visualization. 
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8.0.0 Conclusion and Recommendations 
Our initial nanoemulsions (NEs) that we created contained a relatively low density of 
PEG covering their surface and appeared to not be stable as they increased in size over a period 
of 4 week which is indicative of Oswald Ripening. By increasing the amount of PEG used in the 
manufacturing process we increased the density of PEG covering the surface of the NEs, which 
decreased their size and increased their stability.   
The fluorescent microscopy uptake studies of the low PEG density nanoemulsions 
against U87MG cells indicated targeting specificity was achieved with the mu opioid receptor 
targeted NEs. The uptake by the alpha-7 and B2 bradykinin receptor targeted NEs were not 
conclusive however there was comparable uptake by all nanoemulsions by the 4 hour time point. 
The flow cytometry studies using high density PEG NEs indicated that there is comparable 
uptake of the non-targeted and targeted NEs in the U87MG, bEnd.3, and C6 cell lines. Overall, 
there was higher fold uptake of the NEs by the C6 cells as compared with the U87MG and 
bEnd.3 cells.  
The mu-opioid targeting ligand fluorescent binding assay did not show successful 
binding of the mu opioid receptor ligand to the C6 cells at various concentrations. This assay was 
the last experiment to be performed and due to time constraints and, combined with a lack of 
positive control, does not provide convincing data for or against the targeting specificity of our 
selected ligand. In looking back at our series of experiments, our results indicate that the 
targeting specificity demonstrated in low density PEG NEs may be lost at higher concentrations 
of PEG on the surface of the nanoemulsions. Therefore, alternative methods of increasing NE 
stability should be looked at before moving forward with the project. 
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For future studies, we recommend looking into the pharmacodynamics uptake of the NEs 
by the various cell lines. The effect of the increased PEG density should be studied to determine 
possible negative impact on the uptake by the cells even though the size of the NEs may be 
stable. The specificity of the targeting moieties on the NEs should also be assessed and whether 
the PEG density disables having an effective ligand-receptor interaction. Next, the FACS 
analysis should be further investigated with various in vitro cell conditions to determine whether 
the trypsinization of the cells for suspension binding studies prior to FAC negatively affect the 
active portion of the intended receptor that the NEs are attempting to target. Additionally, the 
binding assay should be reiterated with research into whether the mu-opioid ligand used binds to 
the mu opioid receptor on mouse C6 cells. Overall, by continuing to investigate all possible 
mechanisms of uptake, the targeted nanoemulsions can be further improved with increased 
uptake as compared to non-targeted NEs.  
The statistical analysis code is very robust and can conduct simultaneous analysis, but 
more can be added in order to show higher specificity and testing. The code can be expanded 
upon to sort the exported CSV files be the desired p-value of 0.10 and to organize the specificity 
files by the top 25% that is done by quartile analysis function in MatLab. From the statistical 
analysis of the receptor studies and from our collaborators at Northeastern we know NEs 
targeting the mu-opioid receptor are ‘hitting’ regions known to be rich in the receptor based on 
Nemucore’s research. Due to the high specificity and affinity for μ-opioid receptor in these 
subsystems being picked up by statistics and specificity, by corollary we know that alpha7 and 
bradykinin are scientifically valid due to the same mathematical analysis. Alpha7 can potentially 
give a lot of drug exposure in the future based on its high specificity for locations of the brain 
where GBMs are known to reside. The statistical analysis can also be done on larger study sizes 
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based on the manipulative nature of the looping portions of the code. This will allow the user to 
select more folders while simultaneous analysis is being conducted. This has high clinical 
relevance because it will allow for larger sample sizes to be used for trial studies.  
Software programs will always have the capability of improving whether it is to enable 
new functionality, improve graphics, or optimize storage. For the visualization of the Rat Brain 
Atlas 63 PNGs for creation of a visual 3D statistical heatmap of T1 MRI signal and by 
association Gd3+ that a few very distinct lines of improvement. The primary means for 
improvement is creating an interface between the created wire-frame rat brain atlas and the 
output of the statistical heatmap. This could be accomplished through the use of an integrated 
heatmap. In order for this to be accomplished however, the Ramer-Douglas-Peucker algorithm 
should be modified further or a new algorithm should be applied to smooth the current wire-
frame. By doing so, edge detection could then be used to enable each of the 174 defined 
functional regions across the 63 PNG slices to be identified as its own object. As an object each 
region can be subjected to the application of a heatmap variable designation. This designation 
would denote a color gradient relative to a numerical scale spanning the statistical analysis 
output. Through this application of a statistical heatmap to the wire-frame model and integrative 
software program will enable ‘real time’ visualization of pharmacodynamics of Gd3+ annotated, 
receptor targeted NEs in rat brain studies. 
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9.0.0 Glossary 
Alpha-7 nicotinic Acetylcholine Receptor (Alpha-7 nAchR) – a type of nAchR that is a homo-
pentamer composed of five α-7 subunits. It is located in the brain, spleen, and lymph nodes and 
its activation increases Ca2+ permeability. It is located on the endothelial cells of the blood-brain 
barrier, and has been shown to be involved in angiogenesis and cancer mediation/proliferation. 
Rat Brain Atlas - a 3D, segmented, annotated atlas was developed from high resolution 
anatomical MRI images obtained from male adult rats. The output file delineates each region 
uniquely. They are suitable for further numerical analyses such as constructing pixel image data 
set (of any size) or surface mesh. 
Blood Brain Barrier - the mechanism that controls the passage of molecules from the blood into 
the cerebrospinal fluid and the tissue spaces surrounding the cells of the brain and thus protects 
the brain from the effects of substances harmful to it. The endothelial cells lining the walls of the 
brain capillaries are more tightly joined together at their edges than those lining capillaries 
supplying other parts of the body, which allows the passage of solutions and fat-soluble 
compounds but excludes particles and large molecules. 
B2 Bradykinin Receptor (B2BR) – a G-protein coupled receptor for Bradykinin. Activation of 
this receptor induces vasodilation, as well as increasing vascular permeability. It is expressed 
throughout most tissues in the brain to varying degrees. 
Flow Cytometry- a laser-based technology in which cells are passed single-file through a light 
beam that is set to excite fluorescent markers, while a detector analyzes fluorescent signals 
emitted from the cells. This system allows high throughput quantitative analysis of cells through 
the use of fluorescent markers. 
Glioblastoma multiforme- A glioma consisting chiefly of undifferentiated anaplastic cells 
frequently arranged radially about an irregular focus of necrosis, usually occurring in the 
cerebrum of adults. Also called grade IV astrocytoma 
Magnetic resonance Imaging (MRI) - diagnostic medical imaging technologies that uses strong 
magnets and pulses of radio waves to manipulate the natural magnetic properties in the body to 
generate a visible image.  
Mu-Opioid Receptor– a class of opioid receptors that distinguish themselves from other classes 
by their a high affinity for enkaphalins and low affinity for dynorphins. They are primarily found 
in the tissue of the CNS, with their secondary location in the intestines. They are G protein-
coupled receptors with opioids as their primary antagonist. 
Nanoemulsion- A nano-sized droplet of oil contained in water, with a surfactant phospholipid 
monolayer creating a barrier between the immiscible liquids, creating a micelle-like structure. 
They are created through a high stress, mechanical-extrusion process that creates droplets of 
uniform size. 
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Nontargeted- Having no receptor ligands on the surface, but still incorporating all other aspects 
of the drug delivery system, see Targeted for definition.  
Normalization- The normal distribution is one of the key distributions providing the basis for 
probability statistics, so that when a particular distribution is not normal, some transformation of 
the data may be attempted so as to achieve a normal distribution—for example charting the 
logarithms of values instead of the values themselves. This is known as normalizing the 
distribution. 
Ramer-Douglas-Peucker Algorithm - an algorithm for reducing the number of points in a 
curve that is approximated by a series of points. 
Region of Interest(ROI)- A specific geometrically defined area of the brain that serves a 
specific function based off of its location 
Subsystem of Brain- A grouping of region of interests that comprise a larger area of the brain 
that has a multitude of functions.  
Specificity Index- the condition of being peculiar to a particular individual, region, or group of 
organisms 
T1-weighted image -  A basic pulse sequences in MRI and demonstrates differences in the T1 
relaxation times of tissues, used with softer tissue types. 
Theranostic – development of more specific, individualized therapies for various diseases, and 
to combine diagnostic and therapeutic capabilities into a single agent. 
Transcytosis- A mechanism for transcellular transport in which a cell encloses extracellular 
material in an invagination of the cell membrane to form a vesicle, then moves the vesicle across 
the cell to eject the material through the opposite cell membrane by the reverse process. Also 
called vesicular transport .  
Targeted- The process whereby a newly synthesized molecule is directed to its correct location 
within the cell. Receptor targeting is determined by short sequences of ligands on the surface, 
which direct it to the correct destination 
T-test - A test to calculate the probability that mean values for a particular measurement are 
significantly different in two sets of data. 
Voxel - short for ‘volume element’, the volume of tissue in a body that is represented by a pixel 
in a cross-sectional image. 
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Appendixes 
Appendix 1: Functional Specifications 
Purpose: 
The purpose of this program is to create a sagittal and multilevel coronal view of the 3D 
visualization (through the use of a heatmap with corresponding color values) of drug dispersion 
through 174 small and 23 larger regions of the rat brain. 
 
Benefits:  
A visualization of drug dispersion over the 174 regions of a rat brain, with a color gradient 
depicting the amount of drug reacted by receptors.  
 
Pertinent Definitions 
 
Heatmap: A visualization that has a default color gradient which is set to have high values 
corresponding to a color and low values to another color with a gradient to corresponding colors 
and values between the extremes. 
Cite: http://custom-
analytics.thomsonreuterslifesciences.com/SpotfireWeb/Help/dxpwebclient/heat_what_is_a_heat
_map.htm 
 
Voxel: Also known as a Volume Pixel. A three-dimensional equivalent of a pixel in which the 
volume is representative of a specific grid value in 3D space. The coordinates however are not 
given via 3D space but rather inferred based on designated positions in relation to other 
surrounding voxels. 
Cite: http://www.techopedia.com/definition/2055/volume-pixel-volume-pixel-or-voxel 
 
T-Test: A statistical data analysis procedure used for testing hypotheses. There are many forms, 
this program will make use of a two-sample t-test format.  
Cite: http://www.statisticallysignificantconsulting.com/Ttest.htm 
 
Statistical Variance: A measurement of how data distributes itself about the mean or expected 
value. This will look at all data points, and then determine distribution.  
Cite: https://explorable.com/statistical-variance  
 
P-values: Measurement of how likely a spot of data is if no real difference existed. Meaning if 
the p-value is small (0.05) there is a corresponding small chance of getting this data if no real 
difference existed.  
Cite: http://www.totallab.com/products/samespots/support/faq/pq-values.aspx 
 
False Positive: Can occur when a positive is obtained but in reality no significant difference is 
encountered.  
Cite: http://www.totallab.com/products/samespots/support/faq/pq-values.aspx 
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False Discovery Rate: Determines the adjusted p-values for each test, by controlling the number 
of false discoveries.  
Cite:http://www.totallab.com/products/samespots/support/faq/pq-values.aspx 
 
Specificity Index:  
Specificity is the ability to measure desired outputs in comparison to controls. It relates to the 
proportion of negative results that are correctly identified as negative. This has to do with the 
value of targeted areas being considered negative in comparison to the controls which are the 
receptor distribution in that area, i.e. the number of receptors reacting to the NE over the total 
receptor response. To determine the specificity an average for the size of the group, n=3, must be 
taken at different time points for the experiment and then compared to the average of the control 
at the same time point for each of the three time points. 
 
The Specificity index will be used to test the specificity of the method in the presence of targeted 
nanoemulsions. The Specificity index (SI) is calculated as below: 
 
Specificity index (SI) = Average of Single Scan with Targeted NE/ Average of Single Scan with 
Control NE  
 
The Specificity index should equal one in the absence of targeted areas, i.e. control area 
comparisons. To test the significance of a specificity index other than one a two-sided t-test is 
used. For each targeted area calculate the average Specificity Index (SI) for each of the three 
scans and use the average of the control vs. targeted to determine confidence with a t test.  
 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959882/  
 
Product Description: 
• System Interfaces(how code is interpreted) 
• User Interfaces(data input into code) 
• MatLab environment 
• Gui constructed through MatLab 
• Software interfaces 
• MRI output in ParaVision  
• MRI Brain Atlas Program 
• MatLab  
• ITKSnap 
• possibly, still under consideration for embedding atlas to MRI 
staked scans 
• Communication Interfaces  
• Memory Constraints  
• MRI data file size 
• Output file size 
• Operations 
• Site Adaptation Requirements 
• compatible across user systems 
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• Windows 7 
• Windows 8 
• Mac 
 User characteristics 
• easy to use/understand with basic coding knowledge/knowledge of the 
data type and what it represents  
 Constraints, assumptions and dependencies 
• imaging capabilities 
• data output/input 
• file size and formatting  
Requirements:  
• External interface requirements 
• Uploading the data from an external source (NEU, CD, thumb drive, etc.) 
 Functional requirements 
• Showing data in visual and numerical forms  
 Performance requirements 
• Visualization 
• Data Organized per region 
• Specificity Index Shown for Voxel Weighted Data 
• T tests and confidence tests 
 Design constraints 
• Standards Compliance  
• Novel program, unknown compliance standards 
• Logical database requirement  
• NEU 
• Nemucore 
• CD 
 Software System attributes 
• Reliability 
• t tests and other confidence testing 
• compare to excel template for data results 
• Availability 
• MatLab license required 
• Data availability  
• Maintainability 
• debugging 
• system updates 
• Portability 
• access to researchers in various locations 
Walk through of Heatmap/ How the code works: 
Will be completed upon compilation of final code with accompanying “How to” guide. See 
Appendix 3: User Guide for Heatmap Code  
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Appendix 2: User Guide for Excel Template 
Step 1: Paste Data into Designated Sheets  
There are 6 tabs that have areas designated for the prescan and scan data at each time 
point for the targeted and nontargeted scans.  
 
 
Step 2: Pasting the Data 
The image below shows where the prescan data must be pasted for both the targeted and 
nontargeted scan time points. 
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The image below shows where the scan data for each rat is pasted for the 174 Regions of 
interest. 
 
The image below shows the pasted data values in the designated tab.  
 
Step 3: Analysis of Data 
In the Data Analysis tab shown below, the ROI names and ID are locked in place to allow 
for scrolling capabilities of the data analysis and viewing the process for the calculations of 
voxel weighting, specificity index and t-testing. 
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Below is the highlighted specificity index for the 174 Regions of interest. 
  
Below is the highlighted specificity index for the 22 subsystems. 
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 Below is the highlighted the p-values for t-testing of the 174 regions of interest.  
 
Below is the highlighted p-values for t-testing of 22 subsystems of the brain.  
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As seen in image above the areas with the most significant uptake are those with re or 
blue highlighted areas.  The analysis of the original MRI data from Northeastern in vivo rat study 
was done on targeted nanoemulsions and MRI T1 data. The values in the t-test columns 
correspond to the p values. When p-values are less than 0.10 it shows areas of significant 
difference between Nontargeted and Targeted nanoemulsion uptake in healthy rat brain tissue. 
The values in the specificity index are the average of the three scans of the targeted divided by 
the average of the three scans for the nontargeted. The highlighted values represents the top 25% 
of the specificity index, which shows where the highest concentration of targeted nanoemulsions 
are going based off of the specificity of Gd uptake in each region, due to the direct. There is a 
direct correlation between T1 signal and Gd uptake in the brain for enhanced MRI data. Most 
significant sections with uptake are where the specificity index is in the top 25% and the p-value 
is less than 0.10. 
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Appendix 3: User Guide for MatLab 3D Statistical Heatmap 
Step 1: Download Needed Filed and Code then Open Code  
The required files to run the Statistical Analysis Code are the CSV file ROI and the 
MatLab file Statistical_Analysis_Code 
 
Once the Statistical_Analysis_Code is opened in MatLab you will see a screen like this.  
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 Step 2: Select Run 
Once opened you will be able to run the program 
 
The code will ask you to select a the first folder  
Step 3: Select Desired Folders  
The code will ask you to select a the first folder  
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 A close up of the pop up selection window is shown below, as you can see it will tell you at the 
top which subject you are selecting data for.  
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Then select the folder needed  
 
Hitting the enter button will take you into the folder, be sure to click the Select Folder button as 
shown above. 
This is then repeated based on the number of Rats the desired output is for.  
Step 4: Open Exported Specificity and T-Test CSV Files  
After the code exports the desired files into the MatLab folder you can open them for further 
analysis.  
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 Below is a sample portion of one of the Specificity Index files with the last three columns being 
the three scan time points. 
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Step 5: Loading Visualization Code  
First select the file plotable in order to have the map of all 63 PNG files.  
 
Step 6: Load Hashes file 
After the plotable is loaded open the hashes.m to make the wire model of the rat brain.  
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Step 7: Run Visualization Program  
Select Run and allow code to go through for a few minutes.  
 
 
Step 8: Manipulate Wire Frame Model of Rat Brain  
Wait for output and once loaded it can be manipulate manually to show different angles, can also 
be manipulated before running by adding a view (x , y )line within the loop.  
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Below is a manipulated version of the outputted wire frame model.  
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Appendix 4: MatLab Script for Statistical Analysis of 3D Statistical Heatmap 
 
Import data from text file. for ROI ID and Names ............................................................................... 157 
Initialize variables. ................................................................................................................................ 157 
Format string for each line of text: ........................................................................................................ 157 
Open the text file. .................................................................................................................................. 157 
Read columns of data according to format string. ................................................................................ 157 
Close the text file. ................................................................................................................................. 157 
Post processing for unimportable data. ................................................................................................. 157 
Create output variable ........................................................................................................................... 157 
Clear temporary variables ..................................................................................................................... 157 
Load, Sort and Store ............................................................................................................................. 158 
create array titled with section and then populated from ...................................................................... 158 
Normalization of Data with Pre Scan and Specificity Indexing ........................................................... 167 
Quartile Analysis .................................................................................................................................. 192 
Making Arrays for T-Testing ................................................................................................................ 192 
T Tests ................................................................................................................................................... 200 
%Nemucore Medical Innovations Inc. and Worcester Polytechnic Institute 
 
%Load, Sort, Store data for 3 rat subjects worth of NMI-800 series Nanoemulsion data. 
 
%Please read the User Guide to this program prior to implamentation. 
 
%Usage: Run program, user is asked to select 3 folders containing original 
%filenames of all three rat subjects data (this should total to 8 .csv 
%files). Please do not alter filenames as this program calls them 
%specifically. 
clc; 
clear clf; 
clear all; 
clearvars; 
filename = 'C:\Users\jms\Documents\MATLAB\ROI.csv'; 
delimiter = ','; 
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Import data from text file. for ROI ID and Names 
Initialize variables. 
%location here needs to change for filename if computer changes 
filename = 'C:\Users\jms\Documents\MATLAB\ROI.csv'; 
delimiter = ','; 
Format string for each line of text: 
column1: double (%f) 
% column2: text (%s) 
% For more information, see the TEXTSCAN documentation. 
formatSpec = '%f%s%[^\n\r]'; 
Open the text file. 
fileID = fopen(filename,'r'); 
Read columns of data according to format string. 
This call is based on the structure of the file used to generate this code. If an error occurs for a different 
file, try regenerating the code from the Import Tool. 
dataArray = textscan(fileID, formatSpec, 'Delimiter', delimiter,  'ReturnOnError', false); 
Close the text file. 
fclose(fileID); 
Post processing for unimportable data. 
No unimportable data rules were applied during the import, so no post processing code is included. To 
generate code which works for unimportable data, select unimportable cells in a file and regenerate the 
script. 
Create output variable 
dataArray(1) = cellfun(@(x) num2cell(x), dataArray(1), 'UniformOutput', false); 
ROI = [dataArray{1:end-1}]; 
Clear temporary variables 
clearvars filename delimiter formatSpec fileID dataArray ans; 
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Load, Sort and Store 
filenames = {'\A3_Pre.csv', '\A_Pre_T1.csv', '\A3_post_20min.csv', '\A3_post_40min.csv', 
             '\A3_post_60min.csv', '\A_15min_T1.csv', '\A_40min_T1.csv', '\A_1Hr_T1Map.csv'}; 
shorthand = {'PST', 'PSC','S1T', 'S2T', 'S3T', 'S1C', 'S2C', 'S3C'}; 
shorthandweighted = {'WPST', 'WPSC', 'WS1T', 'WS2T', 'WS3T', 'WS1C', 'WS2C', 'WS3C'}; 
for index = 1:3 %if more than 3 subject increase ratio to desired number ie. 1:4 for four subjects 
    prompt = sprintf('Please select subject %d data', index); 
    directory{index} = uigetdir('C:\Users\edlacarra\Documents\MATLAB',prompt); 
    for i = 1:8 
        filename{i} = cat(2, directory{index}, filenames{i}); 
    end 
    data_set{index} = containers.Map(); 
    data_setw{index} = containers.Map(); 
for i = 1:8; %loop to ask/assign all 8 files and 
     [num_data, text_data, raw_data]= xlsread(filename{i}, 'A1:FS6'); 
     A = transpose(raw_data); % transpore horizontal -> vertical 
        B = A; 
        X= B(:,3); 
        Y= B(:,1); 
        Z= B(:,2); 
        B(:,1)=X; 
        B(:,2)=Y; 
        B(:,3)=Z; 
        header = B(1,:); %move scan title column to the front 
Create array titled with section and then populated from 
each spreadsheet through the 23 larger regions of the brain 
    %Olfactory Bulb 
    OB = cell(3,6); 
    OB(1,:) = B(58,:); 
    OB(2,:) = B(54,:); 
    OB(3,:) = B(60,:); 
    %Olfactory Area 
    OA = cell(4,6); 
    OA(1,:) = B(153,:); 
    OA(2,:) = B(21,:); 
    OA(3,:) = B(103,:); 
    OA(4,:) = B(104,:); 
    %Limbic Lobe 
    L = cell(3,6); 
    L(1,:) = B(32,:); 
    L(2,:) = B(126,:); 
    L(3,:) = B(127,:); 
    %Insular Cortex 
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    I = cell(1,6); 
    I(1,:) = B(65,:); 
    %Ocipital Lobe 
    OL = cell(2,6); 
    OL(1,:) = B(157,:); 
    OL(2,:) = B(158,:); 
    %Temporal Lobe 
    TL = cell(5,6); 
    TL(1,:) = B(151,:); 
    TL(2,:) = B(53,:); 
    TL(3,:) = B(24,:); 
    TL(4,:) = B(51,:); 
    TL(5,:) = B(115,:); 
    %Parietal Lob 
    PL = cell(9,6); 
    PL(1,:) =B(117,:); 
    PL(2,:) =B(131,:); 
    PL(3,:) =B(132,:); 
    PL(4,:) =B(133,:); 
    PL(5,:) =B(134,:); 
    PL(6,:) =B(135,:); 
    PL(7,:) =B(136,:); 
    PL(8,:) =B(137,:); 
    PL(9,:) =B(138,:); 
    %Frontal Lobe 
    FL = cell(8,6); 
    FL(1,:) =B(167,:); 
    FL(2,:) =B(89,:); 
    FL(3,:) =B(76,:); 
    FL(4,:) =B(64,:); 
    FL(5,:) =B(116,:); 
    FL(6,:) =B(56,:); 
    FL(7,:) =B(80,:); 
    FL(8,:) =B(81,:); 
    %Hippocampal Formation 
    HF = cell(9,6); 
    HF(1,:) =B(26,:); 
    HF(2,:) =B(27,:); 
    HF(3,:) =B(28,:); 
    HF(4,:) =B(29,:); 
    HF(5,:) =B(30,:); 
    HF(6,:) =B(49,:); 
    HF(7,:) =B(171,:); 
    HF(8,:) =B(41,:); 
    HF(9,:) =B(42,:); 
    %Amygdaloid Nuclear Complex 
    ANC = cell(8,6); 
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    ANC(1,:) =B(25,:); 
    ANC(2,:) =B(31,:); 
    ANC(3,:) =B(16,:); 
    ANC(4,:) =B(69,:); 
    ANC(5,:) =B(62,:); 
    ANC(6,:) =B(36,:); 
    ANC(7,:) =B(84,:); 
    ANC(8,:) =B(50,:); 
    %Basal Ganglia 
    BG = cell(13,6); 
    BG(1,:) = B(43,:); 
    BG(2,:) = B(45,:); 
    BG(3,:) = B(163,:); 
    BG(4,:) = B(166,:); 
    BG(5,:) = B(154,:); 
    BG(6,:) = B(17,:); 
    BG(7,:) = B(18,:); 
    BG(8,:) = B(59,:); 
    BG(9,:) = B(168,:); 
    BG(10,:) = B(147,:); 
    BG(11,:) = B(175,:); 
    BG(12,:) = B(112,:); 
    BG(13,:) = B(52,:); 
    %Basal Forebrain 
    BF = cell(5,6); 
    BF(1,:) = B(140,:); 
    BF(2,:) = B(34,:); 
    BF(3,:) = B(146,:); 
    BF(4,:) = B(79,:); 
    BF(5,:) = B(152,:); 
    %Septum 
    S = cell(2,6); 
    S(1,:) = B(92,:); 
    S(2,:) = B(40,:); 
    %Hypothalamus 
    H = cell(16,6); 
    H(1,:) = B(19,:); 
    H(2,:) = B(74,:); 
    H(3,:) = B(105,:); 
    H(4,:) = B(150,:); 
    H(5,:) = B(139,:); 
    H(6,:) = B(95,:); 
    H(7,:) = B(23,:); 
    H(8,:) = B(44,:); 
    H(9,:) = B(101,:); 
    H(10,:) = B(82,:); 
    H(11,:) = B(87,:); 
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    H(12,:) = B(144,:); 
    H(13,:) = B(165,:); 
    H(14,:) = B(78,:); 
    H(15,:) = B(90,:); 
    H(16,:) = B(120,:); 
    %Pituitary 
    PT = cell(2,6); 
    PT(1,:) = B(20,:); 
    PT(2,:) = B(93,:); 
    %Thalamus 
    TH = cell(17,6); 
    TH(1,:) = B(15,:); 
    TH(2,:) = B(35,:); 
    TH(3,:) = B(72,:); 
    TH(4,:) = B(77,:); 
    TH(5,:) = B(83,:); 
    TH(6,:) = B(99,:); 
    TH(7,:) = B(121,:); 
    TH(8,:) = B(159,:); 
    TH(9,:) = B(162,:); 
    TH(10,:) = B(164,:); 
    TH(11,:) = B(169,:); 
    TH(12,:) = B(170,:); 
    TH(13,:) = B(119,:); 
    TH(14,:) = B(110,:); 
    TH(15,:) = B(86,:); 
    TH(16,:) = B(73,:); 
    TH(17,:) = B(128,:); 
    %Epithalamus 
    E = cell(2,6); 
    E(1,:) = B(61,:); 
    E(2,:) = B(102,:); 
    %Cerebellum 
    C = cell(20,6); 
    C(1,:) = B(3,:); 
    C(2,:) = B(4,:); 
    C(3,:) = B(5,:); 
    C(4,:) = B(6,:); 
    C(5,:) = B(7,:); 
    C(6,:) = B(10,:); 
    C(7,:) = B(11,:); 
    C(8,:) = B(13,:); 
    C(9,:) = B(14,:); 
    C(10,:) = B(2,:); 
    C(11,:) = B(66,:); 
    C(12,:) = B(141,:); 
    C(13,:) = B(37,:); 
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    C(14,:) = B(100,:); 
    C(15,:) = B(38,:); 
    C(16,:) = B(39,:); 
    C(17,:) = B(55,:); 
    C(18,:) = B(70,:); 
    C(19,:) = B(85,:); 
    C(20,:) = B(106,:); 
    %Pons 
    P = cell(18,6); 
    P(1,:) = B(107,:); 
    P(2,:) = B(8,:); 
    P(3,:) = B(113,:); 
    P(4,:) = B(46,:); 
    P(5,:) = B(155,:); 
    P(6,:) = B(75,:); 
    P(7,:) = B(130,:); 
    P(8,:) = B(148,:); 
    P(9,:) = B(111,:); 
    P(10,:) = B(108,:); 
    P(11,:) = B(109,:); 
    P(12,:) = B(57,:); 
    P(13,:) = B(97,:); 
    P(14,:) = B(9,:); 
    P(15,:) = B(12,:); 
    P(16,:) = B(71,:); 
    P(17,:) = B(149,:); 
    P(18,:) = B(88,:); 
    %Tectum 
    T = cell(2,6); 
    T(1,:) = B(63,:); 
    T(2,:) = B(148,:); 
    %Cerebral Peduncle 
    CP = cell(13,6); 
    CP(1,:) = B(22,:); 
    CP(2,:) = B(91,:); 
    CP(3,:) = B(142,:); 
    CP(4,:) = B(143,:); 
    CP(5,:) = B(125,:); 
    CP(6,:) = B(172,:); 
    CP(7,:) = B(68,:); 
    CP(8,:) = B(96,:); 
    CP(9,:) = B(33,:); 
    CP(10,:) = B(129,:); 
    CP(11,:) = B(118,:); 
    CP(12,:) = B(48,:); 
    CP(13,:) = B(122,:); 
    %Medulla Oblongata 
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    MO = cell(12,6); 
    MO(1,:) = B(67,:); 
    MO(2,:) = B(145,:); 
    MO(3,:) = B(160,:); 
    MO(4,:) = B(161,:); 
    MO(5,:) = B(123,:); 
    MO(6,:) = B(124,:); 
    MO(7,:) = B(98,:); 
    MO(8,:) = B(47,:); 
    MO(9,:) = B(114,:); 
    MO(10,:) = B(156,:); 
    MO(11,:) = B(173,:); 
    MO(12,:) = B(174,:); 
    %voxel is in colum 4, need tosum this one column 
    %Olfactory Bulb 
    VWOB = cell(3,1); 
    NVOB=cell2mat(OB(:,4)); 
    SVOB=sum(NVOB,1); 
    MOB=cell2mat(OB(:,5)); 
        for a=1:3 
            VWOB(a,:) = num2cell((NVOB(a,:)/SVOB)*MOB(a,:)); 
        end 
        %Olfactory Area 
        VWOA = cell(4,1); 
        NVOA=cell2mat(OA(:,4)); 
        SVOA=sum(NVOA,1); 
        MOA=cell2mat(OA(:,5)); 
        for b=1:4 
            VWOA(b,:) = num2cell((NVOA(b,:)/SVOA)*MOA(b,:)); 
        end 
        %Limbic Lobe 
        VWL = cell(3,1); 
        NVL=cell2mat(L(:,4)); 
        SVL=sum(NVL,1); 
        ML=cell2mat(L(:,5)); 
        for c=1:3 
            VWL(c,:) = num2cell((NVL(c,:)/SVL)*ML(c,:)); 
        end 
        %Insular Cortex 
        VWI = cell(1,1); 
        NVI=cell2mat(I(:,4)); 
        SVI=sum(NVI,1); 
        MI=cell2mat(I(:,5)); 
        VWI(1,:) = num2cell((NVI(1,:)/SVI)*MI(1,:)); 
        %Ocipital Lobe 
        VWOL = cell(2,1); 
        NVOL=cell2mat(OL(:,4)); 
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        SVOL=sum(NVOL,1); 
        MOL=cell2mat(OL(:,5)); 
        VWOL(1,:) = num2cell((NVOL(1,:)/SVOL)*MOL(1,:)); 
        VWOL(2,:) = num2cell((NVOL(2,:)/SVOL)*MOL(2,:)); 
        %Temporal Lobe 
        VWTL = cell(5,1); 
        NVTL=cell2mat(TL(:,4)); 
        SVTL=sum(NVTL,1); 
        MTL=cell2mat(TL(:,5)); 
        for d=1:5 
            VWTL(d,:) = num2cell((NVTL(d,:)/SVTL)*MTL(d,:)); 
        end 
        %Parietal Lobe 
        VWPL = cell(9,1); 
        NVPL=cell2mat(PL(:,4)); 
        SVPL=sum(NVPL,1); 
        MPL=cell2mat(PL(:,5)); 
        for e=1:9 
            VWPL(e,:) = num2cell((NVPL(e,:)/SVPL)*MPL(e,:)); 
        end 
        %Frontal Lobe 
        VWFL = cell(8,1); 
        NVFL=cell2mat(FL(:,4)); 
        SVFL=sum(NVFL,1); 
        MFL=cell2mat(FL(:,5)); 
        for f=1:8 
            VWFL(f,:) = num2cell((NVFL(f,:)/SVFL)*MFL(f,:)); 
        end 
        %Hippocampal Formation 
        VWHF = cell(9,1); 
        NVHF=cell2mat(HF(:,4)); 
        SVHF=sum(NVHF,1); 
        MHF=cell2mat(HF(:,5)); 
        for g=1:9 
            VWHF(g,:) = num2cell((NVHF(g,:)/SVHF)*MHF(g,:)); 
        end 
        %Amygdaloid Nuclear Complex 
        VWANC = cell(8,1); 
        NVANC=cell2mat(ANC(:,4)); 
        SVANC=sum(NVANC,1); 
        MANC=cell2mat(ANC(:,5)); 
        for h=1:8 
            VWANC(h,:) = num2cell((NVANC(h,:)/SVANC)*MANC(h,:)); 
        end 
        %Basal Ganglia 
        VWBG = cell(13,1); 
        NVBG=cell2mat(BG(:,4)); 
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        SVBG=sum(NVBG,1); 
        MBG=cell2mat(BG(:,5)); 
        for j=1:13 
            VWBG(j,:) = num2cell((NVBG(j,:)/SVBG)*MBG(j,:)); 
        end 
        %Basal Forebrain 
        VWBF = cell(5,1); 
        NVBF=cell2mat(BF(:,4)); 
        SVBF=sum(NVBF,1); 
        MBF=cell2mat(BF(:,5)); 
        for k=1:5 
            VWBF(k,:) = num2cell((NVBF(k,:)/SVBF)*MBF(k,:)); 
        end 
        %Septum 
        VWS = cell(2,1); 
        NVS=cell2mat(S(:,4)); 
        SVS=sum(NVS,1); 
        MS=cell2mat(S(:,5)); 
        VWS(1,:) = num2cell((NVS(1,:)/SVS)*MS(1,:)); 
        VWS(2,:) = num2cell((NVS(2,:)/SVS)*MS(2,:)); 
        %Hypothalamus 
        VWH = cell(16,1); 
        NVH=cell2mat(H(:,4)); 
        SVH=sum(NVH,1); 
        MH=cell2mat(H(:,5)); 
        for l=1:16 
            VWH(l,:) = num2cell((NVH(l,:)/SVH)*MH(l,:)); 
        end 
        %Pituitary 
        VWPT = cell(2,1); 
        NVPT=cell2mat(PT(:,4)); 
        SVPT=sum(NVPT,1); 
        MPT=cell2mat(PT(:,5)); 
        VWPT(1,:) = num2cell((NVPT(1,:)/SVPT)*MPT(1,:)); 
        VWPT(2,:) = num2cell((NVPT(2,:)/SVPT)*MPT(2,:)); 
        %Thalamus 
        VWTH = cell(17,1); 
        NVTH=cell2mat(TH(:,4)); 
        SVTH=sum(NVTH,1); 
        MTH=cell2mat(TH(:,5)); 
        for m=1:17 
            VWTH(m,:) = num2cell((NVTH(m,:)/SVTH)*MTH(m,:)); 
        end 
        %Epithalamus 
        VWE = cell(2,1); 
        NVE=cell2mat(E(:,4)); 
        SVE=sum(NVE,1); 
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        ME=cell2mat(E(:,5)); 
        VWE(1,:) = num2cell((NVE(1,:)/SVE)*ME(1,:)); 
        VWE(2,:) = num2cell((NVE(2,:)/SVE)*ME(2,:)); 
        %Cerebellum 
        VWC = cell(20,1); 
        NVC=cell2mat(C(:,4)); 
        SVC=sum(NVC,1); 
        MC=cell2mat(C(:,5)); 
        for n=1:20 
            VWC(n,:) = num2cell((NVC(n,:)/SVC)*MC(n,:)); 
        end 
        %Pons 
        VWP = cell(18,1); 
        NVP=cell2mat(P(:,4)); 
        SVP=sum(NVP,1); 
        MP=cell2mat(P(:,5)); 
        for o=1:18 
            VWP(o,:) = num2cell((NVP(o,:)/SVP)*MP(o,:)); 
        end 
        %Tectum 
        VWT = cell(2,1); 
        NVT=cell2mat(T(:,4)); 
        SVT=sum(NVT,1); 
        MT=cell2mat(T(:,5)); 
        VWT(1,:) = num2cell((NVT(1,:)/SVT)*MT(1,:)); 
        VWT(2,:) = num2cell((NVT(2,:)/SVT)*MT(2,:)); 
        %Cerebral Peduncle 
        VWCP = cell(13,1); 
        NVCP=cell2mat(CP(:,4)); 
        SVCP=sum(NVCP,1); 
        MCP=cell2mat(CP(:,5)); 
        for p=1:13 
            VWCP(p,:) = num2cell((NVCP(p,:)/SVCP)*MCP(p,:)); 
        end 
        %Medulla Oblongata 
        VWMO=cell(12,1); 
        NVMO=cell2mat(MO(:,4)); 
        SVMO=sum(NVMO,1); 
        MMO=cell2mat(MO(:,5)); 
        for q=1:12 
            VWMO(q,:) = num2cell((NVMO(q,:)/SVMO)*MMO(q,:)); 
        end 
    rat = containers.Map ({'Olfactory_Bulb','Olfactory_Area','Limbic_Lobe', 'Insular_Cortex', 'Ocipital_Lobe', 'Temporal_Lobe', 'Parietal_Lobe', 
'Frontal_Lobe', 'Hippocampal_Formation', 'Amygdaloid_Nuclear_Complex', 'Basal_Ganglia','Basal_Forebrain', 'Septum', 'Hypothalamus', 
'Pituitary', 'Thalamus', 'Epithalamus', 'Cerebellum', 'Pons', 'Tectum', 'Cerebral_Peduncle', 'Medullar_Oblongata'}, {OB, OA, L, I, OL, TL, PL, FL, 
HF, ANC, BG, BF, S, H, PT, TH, E, C, P, T, CP, MO}); 
        data_set{index}(shorthand{i}) = rat; 
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    wrat = containers.Map ({'Weighted_Olfactory_Bulb','Weighted_Olfactory_Area','Weighted_Limbic_Lobe', 'Weighted_Insular_Cortex', 
'Weighted_Ocipital_Lobe', 'Weighted_Temporal_Lobe', 'Weighted_Parietal_Lobe', 'Weighted_Frontal_Lobe', 
'Weighted_Hippocampal_Formation', 'Weighted_Amygdaloid_Nuclear_Complex', 'Weighted_Basal_Ganglia','Weighted_Basal_Forebrain', 
'Weighted_Septum', 'Weighted_Hypothalamus', 'Weighted_Pituitary', 'Weighted_Thalamus', 'Weighted_Epithalamus', 'Weighted_Cerebellum', 
'Weighted_Pons', 'Weighted_Tectum', 'Weighted_Cerebral_Peduncle', 'Weighted_Medulla_Oblongata'}, {VWOB, VWOA, VWL, VWI, VWOL, 
VWTL, VWPL, VWFL, VWHF, VWANC, VWBG, VWBF, VWS, VWH, VWP, VWTH, VWE, VWC, VWP, VWT, VWCP, VWMO}); 
        data_setw{index}(shorthandweighted{i}) = wrat; 
 end 
end 
Normalization of Data with Pre Scan and Specificity Indexing 
%Call files from voxel weighted maps 
for k=1:3 
    data_normalized1{k} = containers.Map(); 
    data_normalized2{k} = containers.Map(); 
    data_normalized3{k} = containers.Map(); 
    disp(data_setw{k}.keys()) 
    disp(data_setw{k}.values()) 
    call{1} = data_setw{k}('WPST'); 
    call{2} = data_setw{k}('WPSC'); 
    call{3} = data_setw{k}('WS1T'); 
    call{4} = data_setw{k}('WS2T'); 
    call{5} = data_setw{k}('WS3T'); 
    call{6} = data_setw{k}('WS1C'); 
    call{7} = data_setw{k}('WS2C'); 
    call{8} = data_setw{k}('WS3C'); 
%for loop for the titles of the 22 regions 
    for l=1:8; 
        COB{l} = call{l}('Weighted_Olfactory_Bulb'); 
        COA{l} = call{l}('Weighted_Olfactory_Area'); 
        CL{l} = call{l}('Weighted_Limbic_Lobe'); 
        CI{l} = call{l}('Weighted_Insular_Cortex'); 
        COL{l} = call{l}('Weighted_Ocipital_Lobe'); 
        CTL{l} = call{l}('Weighted_Temporal_Lobe'); 
        CPL{l} = call{l}('Weighted_Parietal_Lobe'); 
        CFL{l} = call{l}('Weighted_Frontal_Lobe'); 
        CHF{l} = call{l}('Weighted_Hippocampal_Formation'); 
        CANC{l} = call{l}('Weighted_Amygdaloid_Nuclear_Complex'); 
        CBG{l} = call{l}('Weighted_Basal_Ganglia'); 
        CBF{l} = call{l}('Weighted_Basal_Forebrain'); 
        CS{l} = call{l}('Weighted_Septum'); 
        CH{l} = call{l}('Weighted_Hypothalamus'); 
        CPT{l} = call{l}('Weighted_Pituitary'); 
        CTH{l} = call{l}('Weighted_Thalamus'); 
        CE{l} = call{l}('Weighted_Epithalamus'); 
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        CC{l} = call{l}('Weighted_Cerebellum'); 
        CP{l} = call{l}('Weighted_Pons'); 
        CT{l} = call{l}('Weighted_Tectum'); 
        CCP{l} = call{l}('Weighted_Cerebral_Peduncle'); 
        CMO{l} = call{l}('Weighted_Medulla_Oblongata'); 
    end 
%Subtracting Voxcel Weighted PreScan from Voxcel Weighted Means 
    for j=1:3; 
        %Targeted Scans Normalized_Weighted_Olfactory_Bulb_Targeted 
        DiffOBS{j}=cell(3,1); 
        DOB=cell2mat(COB{1}(:,1)); 
        DOBS{j}=cell2mat(COB{j+2}(:,1)); 
        DiffOBS{j}(1,:)=num2cell((abs(DOB(1,:)-DOBS{j}(1,:)))); 
        DiffOBS{j}(2,:)=num2cell((abs(DOB(2,:)-DOBS{j}(2,:)))); 
        DiffOBS{j}(3,:)=num2cell((abs(DOB(3,:)-DOBS{j}(3,:)))); 
        AOB{j}=mean(cell2mat(DiffOBS{j})); 
        %Control Scans Normalized_Weighted_Olfactory_Bulb_NonTargeted 
        DiffOBCS{j}=cell(3,1); 
        DOBC=cell2mat(COB{2}(:,1)); 
        DOBCS{j}=cell2mat(COB{j+5}(:,1)); 
        DiffOBCS{j}(1,:)=num2cell((abs(DOBC(1,:)-DOBCS{j}(1,:)))); 
        DiffOBCS{j}(2,:)=num2cell((abs(DOBC(2,:)-DOBCS{j}(2,:)))); 
        DiffOBCS{j}(3,:)=num2cell((abs(DOBC(3,:)-DOBCS{j}(3,:)))); 
        AOBC{j}=mean(cell2mat(DiffOBCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI57S{j}=cell2mat(DiffOBS{j}(1,:))/cell2mat(DiffOBCS{j}(1,:)); 
        ROI53S{j}=cell2mat(DiffOBS{j}(2,:))/cell2mat(DiffOBCS{j}(2,:)); 
        ROI59S{j}=cell2mat(DiffOBS{j}(3,:))/cell2mat(DiffOBCS{j}(3,:)); 
        %For larger regions 
        OBSI{j}=AOB{j}/AOBC{j}; 
        %Olfactory Area Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Olfactory_Area_Targeted 
        DiffOAS{j}=cell(4,1); 
        DOA=cell2mat(COA{1}(:,1)); 
        DOAS{j}=cell2mat(COA{j+2}(:,1)); 
        DiffOAS{j}(1,:)=num2cell((abs(DOA(1,:)-DOAS{j}(1,:)))); 
        DiffOAS{j}(2,:)=num2cell((abs(DOA(2,:)-DOAS{j}(2,:)))); 
        DiffOAS{j}(3,:)=num2cell((abs(DOA(3,:)-DOAS{j}(3,:)))); 
        DiffOAS{j}(4,:)=num2cell((abs(DOA(4,:)-DOAS{j}(4,:)))); 
        AOAS{j}=mean(cell2mat(DiffOAS{j})); 
        %Control Scans Normalized_Weighted_Olfactory_Area_NonTargeted 
        DiffOACS{j}=cell(4,1); 
        DOAC=cell2mat(COA{2}(:,1)); 
        DOACS{j}=cell2mat(COA{j+5}(:,1)); 
        DiffOACS{j}(1,:)=num2cell((abs(DOAC(1,:)-DOACS{j}(1,:)))); 
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        DiffOACS{j}(2,:)=num2cell((abs(DOAC(2,:)-DOACS{j}(2,:)))); 
        DiffOACS{j}(3,:)=num2cell((abs(DOAC(3,:)-DOACS{j}(3,:)))); 
        DiffOACS{j}(4,:)=num2cell((abs(DOAC(4,:)-DOACS{j}(4,:)))); 
        AOACS{j}=mean(cell2mat(DiffOACS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI152S{j}=cell2mat(DiffOAS{j}(1,:))/cell2mat(DiffOACS{j}(1,:)); 
        ROI20S{j}=cell2mat(DiffOAS{j}(2,:))/cell2mat(DiffOACS{j}(2,:)); 
        ROI102S{j}=cell2mat(DiffOAS{j}(3,:))/cell2mat(DiffOACS{j}(3,:)); 
        ROI103S{j}=cell2mat(DiffOAS{j}(4,:))/cell2mat(DiffOACS{j}(4,:)); 
        %For larger regions 
        OASI{j}=AOAS{j}/AOACS{j}; 
        %Limbic Lobe Pre-Scan and Average of Scan 
        %Targeted Scans Normailized_Weighted_Limbic_Lobe_Targeted 
        DiffLS{j}=cell(3,1); 
        DL=cell2mat(CL{1}(:,1)); 
        DLS{j}=cell2mat(CL{j+2}(:,1)); 
        DiffLS{j}(1,:)=num2cell((abs(DL(1,:)-DLS{j}(1,:)))); 
        DiffLS{j}(2,:)=num2cell((abs(DL(2,:)-DLS{j}(2,:)))); 
        DiffLS{j}(3,:)=num2cell((abs(DL(3,:)-DLS{j}(3,:)))); 
        ALS{j}=mean(cell2mat(DiffLS{j})); 
        %Control Scans Normailized_Weighted_Limbic_Lobe_NonTargeted 
        DiffLCS{j}=cell(3,1); 
        DLC=cell2mat(CL{2}(:,1)); 
        DLCS{j}=cell2mat(CL{j+5}(:,1)); 
        DiffLCS{j}(1,:)=num2cell((abs(DLC(1,:)-DLCS{j}(1,:)))); 
        DiffLCS{j}(2,:)=num2cell((abs(DLC(2,:)-DLCS{j}(2,:)))); 
        DiffLCS{j}(3,:)=num2cell((abs(DLC(3,:)-DLCS{j}(3,:)))); 
        ALCS{j}=mean(cell2mat(DiffLCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI31S{j}=cell2mat(DiffLS{j}(1,:))/cell2mat(DiffLCS{j}(1,:)); 
        ROI125S{j}=cell2mat(DiffLS{j}(2,:))/cell2mat(DiffLCS{j}(2,:)); 
        ROI126S{j}=cell2mat(DiffLS{j}(3,:))/cell2mat(DiffLCS{j}(3,:)); 
        %For larger regions 
        LSI{j}=ALS{j}/ALCS{j}; 
        %Insular Cortex Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Insular_Cortex_Targeted 
        DiffIS{j}=cell(1,1); 
        DI=cell2mat(CI{1}(:,1)); 
        DIS{j}=cell2mat(CI{j+2}(:,1)); 
        DiffIS{j}(1,:)=num2cell((abs(DI(1,:)-DIS{j}(1,:)))); 
        AIS{j}=mean(cell2mat(DiffIS{j})); 
        %Control Scans Normalized_Weighted_Insular_Cortex_NonTargeted 
        DiffIS{j}=cell(1,1); 
        DIC=cell2mat(CI{2}(:,1)); 
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        DICS{j}=cell2mat(CI{j+5}(:,1)); 
        DiffICS{j}(1,:)=num2cell((abs(DIC(1,:)-DICS{j}(1,:)))); 
        AICS{j}=mean(cell2mat(DiffICS{j})); 
        %Specificity Index 
        %The individual ROI is the same as the larger region since only one 
        ISI{j}=AIS{j}/AICS{j}; 
        ROI64S{j}=ISI{j}; 
        %Ocipital Lobe Pre-Scan and Average of Scan 
        %Targeted Scans 'Normalized_Weighted_Ocipital_Lobe_Targeted' 
        DOL=cell2mat(COL{1}(:,1)); 
        DiffOLS1=cell(2,1); 
        DOLS{j}=cell2mat(COL{j+2}(:,1)); 
        DiffOLS{j}(1,:)=num2cell((abs(DOL(1,:)-DOLS{j}(1,:)))); 
        DiffOLS{j}(2,:)=num2cell((abs(DOL(2,:)-DOLS{j}(2,:)))); 
        AOLS{j}=mean(cell2mat(DiffOLS{j})); 
        %Control Scans Normalized_Weighted_Ocipital_Lobe_NonTargeted 
        DOLC=cell2mat(COL{2}(:,1)); 
        DiffOLCS1=cell(2,1); 
        DOLCS{j}=cell2mat(COL{j+5}(:,1)); 
        DiffOLCS{j}(1,:)=num2cell((abs(DOLC(1,:)-DOLCS{j}(1,:)))); 
        DiffOLCS{j}(2,:)=num2cell((abs(DOLC(2,:)-DOLCS{j}(2,:)))); 
        AOLCS{j}=mean(cell2mat(DiffOLCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI156S{j}=cell2mat(DiffOLS{j}(1,:))/cell2mat(DiffOLCS{j}(1,:)); 
        ROI157S{j}=cell2mat(DiffOLS{j}(2,:))/cell2mat(DiffOLCS{j}(2,:)); 
        %For larger regions 
        OLSI{j}=AOLS{j}/AOLCS{j}; 
        %Scan # 1 tailed 
        [hOLS{j},pOLS{j}] = ttest(cell2mat(DiffOLS{j}),cell2mat(DiffOLCS{j})); 
        %Temporal Lobe Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Temporal_Lobe_Targeted 
        DTL=cell2mat(CTL{1}(:,1)); 
        DiffTLS{j}=cell(5,1); 
        DTLS{j}=cell2mat(CTL{j+2}(:,1)); 
        DiffTLS{j}(1,:)=num2cell((abs(DTL(1,:)-DTLS{j}(1,:)))); 
        DiffTLS{j}(2,:)=num2cell((abs(DTL(2,:)-DTLS{j}(2,:)))); 
        DiffTLS{j}(3,:)=num2cell((abs(DTL(3,:)-DTLS{j}(3,:)))); 
        DiffTLS{j}(4,:)=num2cell((abs(DTL(4,:)-DTLS{j}(4,:)))); 
        DiffTLS{j}(5,:)=num2cell((abs(DTL(5,:)-DTLS{j}(5,:)))); 
        ATLS{j}=mean(cell2mat(DiffTLS{j})); 
        %Control Scans Normalized_Weighted_Temporal_Lobe_NonTargeted 
        DTLC=cell2mat(CTL{2}(:,1)); 
        DiffTLCS1=cell(5,1); 
        DTLCS{j}=cell2mat(CTL{j+5}(:,1)); 
        DiffTLCS{j}(1,:)=num2cell((abs(DTLC(1,:)-DTLCS{j}(1,:)))); 
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        DiffTLCS{j}(2,:)=num2cell((abs(DTLC(2,:)-DTLCS{j}(2,:)))); 
        DiffTLCS{j}(3,:)=num2cell((abs(DTLC(3,:)-DTLCS{j}(3,:)))); 
        DiffTLCS{j}(4,:)=num2cell((abs(DTLC(4,:)-DTLCS{j}(4,:)))); 
        DiffTLCS{j}(5,:)=num2cell((abs(DTLC(5,:)-DTLCS{j}(5,:)))); 
        ATLCS{j}=mean(cell2mat(DiffTLCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI150S{j}=cell2mat(DiffTLS{j}(1,:))/cell2mat(DiffTLCS{j}(1,:)); 
        ROI52S{j}=cell2mat(DiffTLS{j}(2,:))/cell2mat(DiffTLCS{j}(2,:)); 
        ROI23S{j}=cell2mat(DiffTLS{j}(3,:))/cell2mat(DiffTLCS{j}(3,:)); 
        ROI50S{j}=cell2mat(DiffTLS{j}(4,:))/cell2mat(DiffTLCS{j}(4,:)); 
        ROI114S{j}=cell2mat(DiffTLS{j}(5,:))/cell2mat(DiffTLCS{j}(5,:)); 
        %For larger regions 
        TLSI{j}=ATLS{j}/ATLCS{j}; 
        %Parietal Lobe Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Parietal_Lobe_Targeted 
        DPL=cell2mat(CPL{1}(:,1)); 
        DiffPLS{j}=cell(9,1); 
        DPLS{j}=cell2mat(CPL{j+2}(:,1)); 
        DiffPLS{j}(1,:)=num2cell((abs(DPL(1,:)-DPLS{j}(1,:)))); 
        DiffPLS{j}(2,:)=num2cell((abs(DPL(2,:)-DPLS{j}(2,:)))); 
        DiffPLS{j}(3,:)=num2cell((abs(DPL(3,:)-DPLS{j}(3,:)))); 
        DiffPLS{j}(4,:)=num2cell((abs(DPL(4,:)-DPLS{j}(4,:)))); 
        DiffPLS{j}(5,:)=num2cell((abs(DPL(5,:)-DPLS{j}(5,:)))); 
        DiffPLS{j}(6,:)=num2cell((abs(DPL(6,:)-DPLS{j}(6,:)))); 
        DiffPLS{j}(7,:)=num2cell((abs(DPL(7,:)-DPLS{j}(7,:)))); 
        DiffPLS{j}(8,:)=num2cell((abs(DPL(8,:)-DPLS{j}(8,:)))); 
        DiffPLS{j}(9,:)=num2cell((abs(DPL(9,:)-DPLS{j}(9,:)))); 
        APLS{j}=mean(cell2mat(DiffPLS{j})); 
        %Control Scans Normalized_Weighted_Parietal_Lobe_Targeted 
        DPLC=cell2mat(CPL{2}(:,1)); 
        DiffPLCS{j}=cell(9,1); 
        DPLCS{j}=cell2mat(CPL{j+5}(:,1)); 
        DiffPLCS{j}(1,:)=num2cell((abs(DPLC(1,:)-DPLCS{j}(1,:)))); 
        DiffPLCS{j}(2,:)=num2cell((abs(DPLC(2,:)-DPLCS{j}(2,:)))); 
        DiffPLCS{j}(3,:)=num2cell((abs(DPLC(3,:)-DPLCS{j}(3,:)))); 
        DiffPLCS{j}(4,:)=num2cell((abs(DPLC(4,:)-DPLCS{j}(4,:)))); 
        DiffPLCS{j}(5,:)=num2cell((abs(DPLC(5,:)-DPLCS{j}(5,:)))); 
        DiffPLCS{j}(6,:)=num2cell((abs(DPLC(6,:)-DPLCS{j}(6,:)))); 
        DiffPLCS{j}(7,:)=num2cell((abs(DPLC(7,:)-DPLCS{j}(7,:)))); 
        DiffPLCS{j}(8,:)=num2cell((abs(DPLC(8,:)-DPLCS{j}(8,:)))); 
        DiffPLCS{j}(9,:)=num2cell((abs(DPLC(9,:)-DPLCS{j}(9,:)))); 
        APLCS{j}=mean(cell2mat(DiffPLCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI116S{j}=cell2mat(DiffPLS{j}(1,:))/cell2mat(DiffPLCS{j}(1,:)); 
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        ROI130S{j}=cell2mat(DiffPLS{j}(2,:))/cell2mat(DiffPLCS{j}(2,:)); 
        ROI131S{j}=cell2mat(DiffPLS{j}(3,:))/cell2mat(DiffPLCS{j}(3,:)); 
        ROI132S{j}=cell2mat(DiffPLS{j}(4,:))/cell2mat(DiffPLCS{j}(4,:)); 
        ROI133S{j}=cell2mat(DiffPLS{j}(5,:))/cell2mat(DiffPLCS{j}(5,:)); 
        ROI134S{j}=cell2mat(DiffPLS{j}(6,:))/cell2mat(DiffPLCS{j}(6,:)); 
        ROI135S{j}=cell2mat(DiffPLS{j}(7,:))/cell2mat(DiffPLCS{j}(7,:)); 
        ROI136S{j}=cell2mat(DiffPLS{j}(8,:))/cell2mat(DiffPLCS{j}(8,:)); 
        ROI137S{j}=cell2mat(DiffPLS{j}(9,:))/cell2mat(DiffPLCS{j}(9,:)); 
        %For larger regions 
        PLSI{j}=APLS{j}/APLCS{j}; 
        %Frontal  Lobe Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Frontal_Lobe_Targeted 
        DFL=cell2mat(CFL{1}(:,1)); 
        DiffFLS{j}=cell(8,1); 
        DFLS{j}=cell2mat(CFL{j+2}(:,1)); 
        DiffFLS{j}(1,:)=num2cell((abs(DFL(1,:)-DFLS{j}(1,:)))); 
        DiffFLS{j}(2,:)=num2cell((abs(DFL(2,:)-DFLS{j}(2,:)))); 
        DiffFLS{j}(3,:)=num2cell((abs(DFL(3,:)-DFLS{j}(3,:)))); 
        DiffFLS{j}(4,:)=num2cell((abs(DFL(4,:)-DFLS{j}(4,:)))); 
        DiffFLS{j}(5,:)=num2cell((abs(DFL(5,:)-DFLS{j}(5,:)))); 
        DiffFLS{j}(6,:)=num2cell((abs(DFL(6,:)-DFLS{j}(6,:)))); 
        DiffFLS{j}(7,:)=num2cell((abs(DFL(7,:)-DFLS{j}(7,:)))); 
        DiffFLS{j}(8,:)=num2cell((abs(DFL(8,:)-DFLS{j}(8,:)))); 
        AFLS{j}=mean(cell2mat(DiffFLS{j})); 
        %Control Scans Normalized_Weighted_Frontal_Lobe_NonTargeted 
        DFLC=cell2mat(CFL{2}(:,1)); 
        DiffFLCS{j}=cell(8,1); 
        DFLCS{j}=cell2mat(CFL{j+5}(:,1)); 
        DiffFLCS{j}(1,:)=num2cell((abs(DFLC(1,:)-DFLCS{j}(1,:)))); 
        DiffFLCS{j}(2,:)=num2cell((abs(DFLC(2,:)-DFLCS{j}(2,:)))); 
        DiffFLCS{j}(3,:)=num2cell((abs(DFLC(3,:)-DFLCS{j}(3,:)))); 
        DiffFLCS{j}(4,:)=num2cell((abs(DFLC(4,:)-DFLCS{j}(4,:)))); 
        DiffFLCS{j}(5,:)=num2cell((abs(DFLC(5,:)-DFLCS{j}(5,:)))); 
        DiffFLCS{j}(6,:)=num2cell((abs(DFLC(6,:)-DFLCS{j}(6,:)))); 
        DiffFLCS{j}(7,:)=num2cell((abs(DFLC(7,:)-DFLCS{j}(7,:)))); 
        DiffFLCS{j}(8,:)=num2cell((abs(DFLC(8,:)-DFLCS{j}(8,:)))); 
        AFLCS{j}=mean(cell2mat(DiffFLCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI166S{j}=cell2mat(DiffFLS{j}(1,:))/cell2mat(DiffFLCS{j}(1,:)); 
        ROI88S{j}=cell2mat(DiffFLS{j}(2,:))/cell2mat(DiffFLCS{j}(2,:)); 
        ROI75S{j}=cell2mat(DiffFLS{j}(3,:))/cell2mat(DiffFLCS{j}(3,:)); 
        ROI63S{j}=cell2mat(DiffFLS{j}(4,:))/cell2mat(DiffFLCS{j}(4,:)); 
        ROI115S{j}=cell2mat(DiffFLS{j}(5,:))/cell2mat(DiffFLCS{j}(5,:)); 
        ROI55S{j}=cell2mat(DiffFLS{j}(6,:))/cell2mat(DiffFLCS{j}(6,:)); 
        ROI79S{j}=cell2mat(DiffFLS{j}(7,:))/cell2mat(DiffFLCS{j}(7,:)); 
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        ROI80S{j}=cell2mat(DiffFLS{j}(8,:))/cell2mat(DiffFLCS{j}(8,:)); 
        %For larger regions 
        FLSI{j}=AFLS{j}/AFLCS{j}; 
        %Hippocampal Formation Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Hippocampal_Formation_Targeted 
        DHF=cell2mat(CHF{1}(:,1)); 
        DiffHFS{j}=cell(9,1); 
        DHFS{j}=cell2mat(CHF{j+2}(:,1)); 
        DiffHFS{j}(1,:)=num2cell((abs(DHF(1,:)-DHFS{j}(1,:)))); 
        DiffHFS{j}(2,:)=num2cell((abs(DHF(2,:)-DHFS{j}(2,:)))); 
        DiffHFS{j}(3,:)=num2cell((abs(DHF(3,:)-DHFS{j}(3,:)))); 
        DiffHFS{j}(4,:)=num2cell((abs(DHF(4,:)-DHFS{j}(4,:)))); 
        DiffHFS{j}(5,:)=num2cell((abs(DHF(5,:)-DHFS{j}(5,:)))); 
        DiffHFS{j}(6,:)=num2cell((abs(DHF(6,:)-DHFS{j}(6,:)))); 
        DiffHFS{j}(7,:)=num2cell((abs(DHF(7,:)-DHFS{j}(7,:)))); 
        DiffHFS{j}(8,:)=num2cell((abs(DHF(8,:)-DHFS{j}(8,:)))); 
        DiffHFS{j}(9,:)=num2cell((abs(DHF(9,:)-DHFS{j}(9,:)))); 
        AHFS{j}=mean(cell2mat(DiffHFS{j})); 
        %Control Scans 'Normalized_Weighted_Hippocampal_Formation_NonTargeted 
        DHFC=cell2mat(CHF{2}(:,1)); 
        DiffHFCS{j}=cell(9,1); 
        DHFCS{j}=cell2mat(CHF{j+5}(:,1)); 
        DiffHFCS{j}(1,:)=num2cell((abs(DHFC(1,:)-DHFCS{j}(1,:)))); 
        DiffHFCS{j}(2,:)=num2cell((abs(DHFC(2,:)-DHFCS{j}(2,:)))); 
        DiffHFCS{j}(3,:)=num2cell((abs(DHFC(3,:)-DHFCS{j}(3,:)))); 
        DiffHFCS{j}(4,:)=num2cell((abs(DHFC(4,:)-DHFCS{j}(4,:)))); 
        DiffHFCS{j}(5,:)=num2cell((abs(DHFC(5,:)-DHFCS{j}(5,:)))); 
        DiffHFCS{j}(6,:)=num2cell((abs(DHFC(6,:)-DHFCS{j}(6,:)))); 
        DiffHFCS{j}(7,:)=num2cell((abs(DHFC(7,:)-DHFCS{j}(7,:)))); 
        DiffHFCS{j}(8,:)=num2cell((abs(DHFC(8,:)-DHFCS{j}(8,:)))); 
        DiffHFCS{j}(9,:)=num2cell((abs(DHFC(9,:)-DHFCS{j}(9,:)))); 
        AHFCS{j}=mean(cell2mat(DiffHFCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI25S{j}=cell2mat(DiffHFS{j}(1,:))/cell2mat(DiffHFCS{j}(1,:)); 
        ROI26S{j}=cell2mat(DiffHFS{j}(2,:))/cell2mat(DiffHFCS{j}(2,:)); 
        ROI27S{j}=cell2mat(DiffHFS{j}(3,:))/cell2mat(DiffHFCS{j}(3,:)); 
        ROI28S{j}=cell2mat(DiffHFS{j}(4,:))/cell2mat(DiffHFCS{j}(4,:)); 
        ROI29S{j}=cell2mat(DiffHFS{j}(5,:))/cell2mat(DiffHFCS{j}(5,:)); 
        ROI48S{j}=cell2mat(DiffHFS{j}(6,:))/cell2mat(DiffHFCS{j}(6,:)); 
        ROI170S{j}=cell2mat(DiffHFS{j}(7,:))/cell2mat(DiffHFCS{j}(7,:)); 
        ROI40S{j}=cell2mat(DiffHFS{j}(8,:))/cell2mat(DiffHFCS{j}(8,:)); 
        ROI41S{j}=cell2mat(DiffHFS{j}(9,:))/cell2mat(DiffHFCS{j}(9,:)); 
        %For larger regions 
        HFSI{j}=AHFS{j}/AHFCS{j}; 
        %Amygdaloid Nuclear Complex Pre-Scan and Average of Scan 
173 
 
        %Targeted Scans Normalized_Weighted_Amygdaloid_Nuclear_Complex_Targeted 
        DANC=cell2mat(CANC{1}(:,1)); 
        DiffANCS{j}=cell(8,1); 
        DANCS{j}=cell2mat(CANC{j+2}(:,1)); 
        DiffANCS{j}(1,:)=num2cell((abs(DANC(1,:)-DANCS{j}(1,:)))); 
        DiffANCS{j}(2,:)=num2cell((abs(DANC(2,:)-DANCS{j}(2,:)))); 
        DiffANCS{j}(3,:)=num2cell((abs(DANC(3,:)-DANCS{j}(3,:)))); 
        DiffANCS{j}(4,:)=num2cell((abs(DANC(4,:)-DANCS{j}(4,:)))); 
        DiffANCS{j}(5,:)=num2cell((abs(DANC(5,:)-DANCS{j}(5,:)))); 
        DiffANCS{j}(6,:)=num2cell((abs(DANC(6,:)-DANCS{j}(6,:)))); 
        DiffANCS{j}(7,:)=num2cell((abs(DANC(7,:)-DANCS{j}(7,:)))); 
        DiffANCS{j}(8,:)=num2cell((abs(DANC(8,:)-DANCS{j}(8,:)))); 
        AANCS{j}=mean(cell2mat(DiffANCS{j})); 
        %ConrtolScans Normalized_Weighted_Amygdaloid_Nuclear_Complex_NonTargeted 
        DANCC=cell2mat(CANC{2}(:,1)); 
        DiffANCCS{j}=cell(8,1); 
        DANCCS{j}=cell2mat(CANC{j+5}(:,1)); 
        DiffANCCS{j}(1,:)=num2cell((abs(DANCC(1,:)-DANCCS{j}(1,:)))); 
        DiffANCCS{j}(2,:)=num2cell((abs(DANCC(2,:)-DANCCS{j}(2,:)))); 
        DiffANCCS{j}(3,:)=num2cell((abs(DANCC(3,:)-DANCCS{j}(3,:)))); 
        DiffANCCS{j}(4,:)=num2cell((abs(DANCC(4,:)-DANCCS{j}(4,:)))); 
        DiffANCCS{j}(5,:)=num2cell((abs(DANCC(5,:)-DANCCS{j}(5,:)))); 
        DiffANCCS{j}(6,:)=num2cell((abs(DANCC(6,:)-DANCCS{j}(6,:)))); 
        DiffANCCS{j}(7,:)=num2cell((abs(DANCC(7,:)-DANCCS{j}(7,:)))); 
        DiffANCCS{j}(8,:)=num2cell((abs(DANCC(8,:)-DANCCS{j}(8,:)))); 
        AANCCS{j}=mean(cell2mat(DiffANCCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI24S{j}=cell2mat(DiffANCS{j}(1,:))/cell2mat(DiffANCCS{j}(1,:)); 
        ROI30S{j}=cell2mat(DiffANCS{j}(2,:))/cell2mat(DiffANCCS{j}(2,:)); 
        ROI15S{j}=cell2mat(DiffANCS{j}(3,:))/cell2mat(DiffANCCS{j}(3,:)); 
        ROI68S{j}=cell2mat(DiffANCS{j}(4,:))/cell2mat(DiffANCCS{j}(4,:)); 
        ROI61S{j}=cell2mat(DiffANCS{j}(5,:))/cell2mat(DiffANCCS{j}(5,:)); 
        ROI35S{j}=cell2mat(DiffANCS{j}(6,:))/cell2mat(DiffANCCS{j}(6,:)); 
        ROI83S{j}=cell2mat(DiffANCS{j}(7,:))/cell2mat(DiffANCCS{j}(7,:)); 
        ROI49S{j}=cell2mat(DiffANCS{j}(8,:))/cell2mat(DiffANCCS{j}(8,:)); 
        %For larger regions 
        ANCSI{j}=AANCS{j}/AANCCS{j}; 
        %Basal Ganglia Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Basal_Ganglia_Targeted 
        DBG=cell2mat(CBG{1}(:,1)); 
        DiffBGS{j}=cell(13,1); 
        DBGS{j}=cell2mat(CBG{j+2}(:,1)); 
        DiffBGS{j}(1,:)=num2cell((abs(DBG(1,:)-DBGS{j}(1,:)))); 
        DiffBGS{j}(2,:)=num2cell((abs(DBG(2,:)-DBGS{j}(2,:)))); 
        DiffBGS{j}(3,:)=num2cell((abs(DBG(3,:)-DBGS{j}(3,:)))); 
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        DiffBGS{j}(4,:)=num2cell((abs(DBG(4,:)-DBGS{j}(4,:)))); 
        DiffBGS{j}(5,:)=num2cell((abs(DBG(5,:)-DBGS{j}(5,:)))); 
        DiffBGS{j}(6,:)=num2cell((abs(DBG(6,:)-DBGS{j}(6,:)))); 
        DiffBGS{j}(7,:)=num2cell((abs(DBG(7,:)-DBGS{j}(7,:)))); 
        DiffBGS{j}(8,:)=num2cell((abs(DBG(8,:)-DBGS{j}(8,:)))); 
        DiffBGS{j}(9,:)=num2cell((abs(DBG(9,:)-DBGS{j}(9,:)))); 
        DiffBGS{j}(10,:)=num2cell((abs(DBG(10,:)-DBGS{j}(10,:)))); 
        DiffBGS{j}(11,:)=num2cell((abs(DBG(11,:)-DBGS{j}(11,:)))); 
        DiffBGS{j}(12,:)=num2cell((abs(DBG(12,:)-DBGS{j}(12,:)))); 
        DiffBGS{j}(13,:)=num2cell((abs(DBG(13,:)-DBGS{j}(13,:)))); 
        ABGS{j}=mean(cell2mat(DiffBGS{j})); 
        %Control Scans Normalized_Weighted_Basal_Ganglia_NonTargeted 
        DBGC=cell2mat(CBG{2}(:,1)); 
        DiffBGCS{j}=cell(13,1); 
        DBGCS{j}=cell2mat(CBG{j+5}(:,1)); 
        DiffBGCS{j}(1,:)=num2cell((abs(DBGC(1,:)-DBGCS{j}(1,:)))); 
        DiffBGCS{j}(2,:)=num2cell((abs(DBGC(2,:)-DBGCS{j}(2,:)))); 
        DiffBGCS{j}(3,:)=num2cell((abs(DBGC(3,:)-DBGCS{j}(3,:)))); 
        DiffBGCS{j}(4,:)=num2cell((abs(DBGC(4,:)-DBGCS{j}(4,:)))); 
        DiffBGCS{j}(5,:)=num2cell((abs(DBGC(5,:)-DBGCS{j}(5,:)))); 
        DiffBGCS{j}(6,:)=num2cell((abs(DBGC(6,:)-DBGCS{j}(6,:)))); 
        DiffBGCS{j}(7,:)=num2cell((abs(DBGC(7,:)-DBGCS{j}(7,:)))); 
        DiffBGCS{j}(8,:)=num2cell((abs(DBGC(8,:)-DBGCS{j}(8,:)))); 
        DiffBGCS{j}(9,:)=num2cell((abs(DBGC(9,:)-DBGCS{j}(9,:)))); 
        DiffBGCS{j}(10,:)=num2cell((abs(DBGC(10,:)-DBGCS{j}(10,:)))); 
        DiffBGCS{j}(11,:)=num2cell((abs(DBGC(11,:)-DBGCS{j}(11,:)))); 
        DiffBGCS{j}(12,:)=num2cell((abs(DBGC(12,:)-DBGCS{j}(12,:)))); 
        DiffBGCS{j}(13,:)=num2cell((abs(DBGC(13,:)-DBGCS{j}(13,:)))); 
        ABGCS{j}=mean(cell2mat(DiffBGCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI42S{j}=cell2mat(DiffBGS{j}(1,:))/cell2mat(DiffBGCS{j}(1,:)); 
        ROI44S{j}=cell2mat(DiffBGS{j}(2,:))/cell2mat(DiffBGCS{j}(2,:)); 
        ROI162S{j}=cell2mat(DiffBGS{j}(3,:))/cell2mat(DiffBGCS{j}(3,:)); 
        ROI165S{j}=cell2mat(DiffBGS{j}(4,:))/cell2mat(DiffBGCS{j}(4,:)); 
        ROI153S{j}=cell2mat(DiffBGS{j}(5,:))/cell2mat(DiffBGCS{j}(5,:)); 
        ROI16S{j}=cell2mat(DiffBGS{j}(6,:))/cell2mat(DiffBGCS{j}(6,:)); 
        ROI17S{j}=cell2mat(DiffBGS{j}(7,:))/cell2mat(DiffBGCS{j}(7,:)); 
        ROI58S{j}=cell2mat(DiffBGS{j}(8,:))/cell2mat(DiffBGCS{j}(8,:)); 
        ROI167S{j}=cell2mat(DiffBGS{j}(9,:))/cell2mat(DiffBGCS{j}(9,:)); 
        ROI146S{j}=cell2mat(DiffBGS{j}(10,:))/cell2mat(DiffBGCS{j}(10,:)); 
        ROI174S{j}=cell2mat(DiffBGS{j}(11,:))/cell2mat(DiffBGCS{j}(11,:)); 
        ROI111S{j}=cell2mat(DiffBGS{j}(12,:))/cell2mat(DiffBGCS{j}(12,:)); 
        ROI51S{j}=cell2mat(DiffBGS{j}(13,:))/cell2mat(DiffBGCS{j}(13,:)); 
        %For larger regions 
        BGSI{j}=ABGS{j}/ABGCS{j}; 
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        %Basal Forebrain Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Basal_Forebrain_Targeted 
        DBF=cell2mat(CBF{1}(:,1)); 
        DiffBFS{j}=cell(5,1); 
        DBFS{j}=cell2mat(CBF{j+2}(:,1)); 
        DiffBFS{j}(1,:)=num2cell((abs(DBF(1,:)-DBFS{j}(1,:)))); 
        DiffBFS{j}(2,:)=num2cell((abs(DBF(2,:)-DBFS{j}(2,:)))); 
        DiffBFS{j}(3,:)=num2cell((abs(DBF(3,:)-DBFS{j}(3,:)))); 
        DiffBFS{j}(4,:)=num2cell((abs(DBF(4,:)-DBFS{j}(4,:)))); 
        DiffBFS{j}(5,:)=num2cell((abs(DBF(5,:)-DBFS{j}(5,:)))); 
        ABFS{j}=mean(cell2mat(DiffBFS{j})); 
        %Control Scans Normalized_Weighted_Basal_Forebrain_NonTargeted 
        DBFC=cell2mat(CBF{2}(:,1)); 
        DiffBFCS{j}=cell(5,1); 
        DBFCS{j}=cell2mat(CBF{j+5}(:,1)); 
        DiffBFCS{j}(1,:)=num2cell((abs(DBFC(1,:)-DBFCS{j}(1,:)))); 
        DiffBFCS{j}(2,:)=num2cell((abs(DBFC(2,:)-DBFCS{j}(2,:)))); 
        DiffBFCS{j}(3,:)=num2cell((abs(DBFC(3,:)-DBFCS{j}(3,:)))); 
        DiffBFCS{j}(4,:)=num2cell((abs(DBFC(4,:)-DBFCS{j}(4,:)))); 
        DiffBFCS{j}(5,:)=num2cell((abs(DBFC(5,:)-DBFCS{j}(5,:)))); 
        disp(DiffBFCS{j}) 
        ABFCS{j}=mean(cell2mat(DiffBFCS{j})); 
        disp(ABFCS{j}) 
        %Specificity Index 
        %For Individual ROIs 
        ROI139S{j}=cell2mat(DiffBFS{j}(1,:))/cell2mat(DiffBFCS{j}(1,:)); 
        ROI33S{j}=cell2mat(DiffBFS{j}(2,:))/cell2mat(DiffBFCS{j}(2,:)); 
        ROI145S{j}=cell2mat(DiffBFS{j}(3,:))/cell2mat(DiffBFCS{j}(3,:)); 
        ROI78S{j}=cell2mat(DiffBFS{j}(4,:))/cell2mat(DiffBFCS{j}(4,:)); 
        ROI151S{j}=cell2mat(DiffBFS{j}(5,:))/cell2mat(DiffBFCS{j}(5,:)); 
        %For larger regions 
        BSI{j}=ABFS{j}/ABFCS{j}; 
        %Septum Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Septum_Targeted 
        DS=cell2mat(CS{1}(:,1)); 
        DiffSS{j}=cell(2,1); 
        DSS{j}=cell2mat(CS{j+2}(:,1)); 
        DiffSS{j}(1,:)=num2cell((abs(DS(1,:)-DSS{j}(1,:)))); 
        DiffSS{j}(2,:)=num2cell((abs(DS(2,:)-DSS{j}(2,:)))); 
        ASS{j}=mean(cell2mat(DiffSS{j})); 
        %Control Scans Normalized_Weighted_Septum_NonTargeted 
        DSC=cell2mat(CS{2}(:,1)); 
        DiffSCS{j}=cell(2,1); 
        DSCS{j}=cell2mat(CS{j+5}(:,1)); 
        DiffSCS{j}(1,:)=num2cell((abs(DSC(1,:)-DSCS{j}(1,:)))); 
        DiffSCS{j}(2,:)=num2cell((abs(DSC(2,:)-DSCS{j}(2,:)))); 
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        ASCS{j}=mean(cell2mat(DiffSCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI91S{j}=cell2mat(DiffSS{j}(1,:))/cell2mat(DiffSCS{j}(1,:)); 
        ROI39S{j}=cell2mat(DiffSS{j}(2,:))/cell2mat(DiffSCS{j}(2,:)); 
        %For larger regions 
        SSI{j}=ASS{j}/ASCS{j}; 
        %Hypothalamus Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Hypothalamus_Targeted 
        DH=cell2mat(CH{1}(:,1)); 
        DiffHS{j}=cell(16,1); 
        DHS{j}=cell2mat(CH{j+2}(:,1)); 
        DiffHS{j}(1,:)=num2cell((abs(DH(1,:)-DHS{j}(1,:)))); 
        DiffHS{j}(2,:)=num2cell((abs(DH(2,:)-DHS{j}(2,:)))); 
        DiffHS{j}(3,:)=num2cell((abs(DH(3,:)-DHS{j}(3,:)))); 
        DiffHS{j}(4,:)=num2cell((abs(DH(4,:)-DHS{j}(4,:)))); 
        DiffHS{j}(5,:)=num2cell((abs(DH(5,:)-DHS{j}(5,:)))); 
        DiffHS{j}(6,:)=num2cell((abs(DH(6,:)-DHS{j}(6,:)))); 
        DiffHS{j}(7,:)=num2cell((abs(DH(7,:)-DHS{j}(7,:)))); 
        DiffHS{j}(8,:)=num2cell((abs(DH(8,:)-DHS{j}(8,:)))); 
        DiffHS{j}(9,:)=num2cell((abs(DH(9,:)-DHS{j}(9,:)))); 
        DiffHS{j}(10,:)=num2cell((abs(DH(10,:)-DHS{j}(10,:)))); 
        DiffHS{j}(11,:)=num2cell((abs(DH(11,:)-DHS{j}(11,:)))); 
        DiffHS{j}(12,:)=num2cell((abs(DH(12,:)-DHS{j}(12,:)))); 
        DiffHS{j}(13,:)=num2cell((abs(DH(13,:)-DHS{j}(13,:)))); 
        DiffHS{j}(14,:)=num2cell((abs(DH(14,:)-DHS{j}(14,:)))); 
        DiffHS{j}(15,:)=num2cell((abs(DH(15,:)-DHS{j}(15,:)))); 
        DiffHS{j}(16,:)=num2cell((abs(DH(16,:)-DHS{j}(16,:)))); 
        AHS{j}=mean(cell2mat(DiffHS{j})); 
        %Control Scans 'Normalized_Weighted_Hypothalamus_NonTargeted' 
        DHC=cell2mat(CH{2}(:,1)); 
        DiffHCS{j}=cell(16,1); 
        DHCS{j}=cell2mat(CH{j+5}(:,1)); 
        DiffHCS{j}(1,:)=num2cell((abs(DHC(1,:)-DHCS{j}(1,:)))); 
        DiffHCS{j}(2,:)=num2cell((abs(DHC(2,:)-DHCS{j}(2,:)))); 
        DiffHCS{j}(3,:)=num2cell((abs(DHC(3,:)-DHCS{j}(3,:)))); 
        DiffHCS{j}(4,:)=num2cell((abs(DHC(4,:)-DHCS{j}(4,:)))); 
        DiffHCS{j}(5,:)=num2cell((abs(DHC(5,:)-DHCS{j}(5,:)))); 
        DiffHCS{j}(6,:)=num2cell((abs(DHC(6,:)-DHCS{j}(6,:)))); 
        DiffHCS{j}(7,:)=num2cell((abs(DHC(7,:)-DHCS{j}(7,:)))); 
        DiffHCS{j}(8,:)=num2cell((abs(DHC(8,:)-DHCS{j}(8,:)))); 
        DiffHCS{j}(9,:)=num2cell((abs(DHC(9,:)-DHCS{j}(9,:)))); 
        DiffHCS{j}(10,:)=num2cell((abs(DHC(10,:)-DHCS{j}(10,:)))); 
        DiffHCS{j}(11,:)=num2cell((abs(DHC(11,:)-DHCS{j}(11,:)))); 
        DiffHCS{j}(12,:)=num2cell((abs(DHC(12,:)-DHCS{j}(12,:)))); 
        DiffHCS{j}(13,:)=num2cell((abs(DHC(13,:)-DHCS{j}(13,:)))); 
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        DiffHCS{j}(14,:)=num2cell((abs(DHC(14,:)-DHCS{j}(14,:)))); 
        DiffHCS{j}(15,:)=num2cell((abs(DHC(15,:)-DHCS{j}(15,:)))); 
        DiffHCS{j}(16,:)=num2cell((abs(DHC(16,:)-DHCS{j}(16,:)))); 
        AHCS{j}=mean(cell2mat(DiffHCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI18S{j}=cell2mat(DiffHS{j}(1,:))/cell2mat(DiffHCS{j}(1,:)); 
        ROI73S{j}=cell2mat(DiffHS{j}(2,:))/cell2mat(DiffHCS{j}(2,:)); 
        ROI104S{j}=cell2mat(DiffHS{j}(3,:))/cell2mat(DiffHCS{j}(3,:)); 
        ROI149S{j}=cell2mat(DiffHS{j}(4,:))/cell2mat(DiffHCS{j}(4,:)); 
        ROI138S{j}=cell2mat(DiffHS{j}(5,:))/cell2mat(DiffHCS{j}(5,:)); 
        ROI94S{j}=cell2mat(DiffHS{j}(6,:))/cell2mat(DiffHCS{j}(6,:)); 
        ROI22S{j}=cell2mat(DiffHS{j}(7,:))/cell2mat(DiffHCS{j}(7,:)); 
        ROI43S{j}=cell2mat(DiffHS{j}(8,:))/cell2mat(DiffHCS{j}(8,:)); 
        ROI100S{j}=cell2mat(DiffHS{j}(9,:))/cell2mat(DiffHCS{j}(9,:)); 
        ROI81S{j}=cell2mat(DiffHS{j}(10,:))/cell2mat(DiffHCS{j}(10,:)); 
        ROI86S{j}=cell2mat(DiffHS{j}(11,:))/cell2mat(DiffHCS{j}(11,:)); 
        ROI143S{j}=cell2mat(DiffHS{j}(12,:))/cell2mat(DiffHCS{j}(12,:)); 
        ROI164S{j}=cell2mat(DiffHS{j}(13,:))/cell2mat(DiffHCS{j}(13,:)); 
        ROI77S{j}=cell2mat(DiffHS{j}(14,:))/cell2mat(DiffHCS{j}(14,:)); 
        ROI89S{j}=cell2mat(DiffHS{j}(15,:))/cell2mat(DiffHCS{j}(15,:)); 
        ROI119S{j}=cell2mat(DiffHS{j}(16,:))/cell2mat(DiffHCS{j}(16,:)); 
        %For larger regions 
        HSI{j}=AHS{j}/AHCS{j}; 
        %Pituitary Pre-Scan and Average of Scan 
        %Targeted Scans 'Normalized_Weighted_Pituitary_Targeted' 
        DPT=cell2mat(CPT{1}(:,1)); 
        DiffPTS{j}=cell(2,1); 
        DPTS{j}=cell2mat(CPT{j+2}(:,1)); 
        DiffPTS{j}(1,:)=num2cell((abs(DPT(1,:)-DPTS{j}(1,:)))); 
        DiffPTS{j}(2,:)=num2cell((abs(DPT(2,:)-DPTS{j}(2,:)))); 
        APTS{j}=mean(cell2mat(DiffPTS{j})); 
        %Control Scans 'Normalized_Weighted_Pituitary_NonTargeted' 
        DPTC=cell2mat(CPT{2}(:,1)); 
        DiffPTCS{j}=cell(2,1); 
        DPTCS{j}=cell2mat(CPT{j+5}(:,1)); 
        DiffPTCS{j}(1,:)=num2cell((abs(DPTC(1,:)-DPTCS{j}(1,:)))); 
        DiffPTCS{j}(2,:)=num2cell((abs(DPTC(2,:)-DPTCS{j}(2,:)))); 
        APTCS{j}=mean(cell2mat(DiffPTCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI19S{j}=cell2mat(DiffPTS{j}(1,:))/cell2mat(DiffPTCS{j}(1,:)); 
        ROI92S{j}=cell2mat(DiffPTS{j}(2,:))/cell2mat(DiffPTCS{j}(2,:)); 
        %For larger regions 
        PTSI{j}=APTS{j}/APTCS{j}; 
        %Thalamus Pre-Scan and Average of Scan 
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        %Targeted Scans Normalized_Weighted_Thalamus_Targeted 
        DTH=cell2mat(CTH{1}(:,1)); 
        DiffTHS{j}=cell(17,1); 
        DTHS{j}=cell2mat(CTH{j+2}(:,1)); 
        DiffTHS{j}(1,:)=num2cell((abs(DTH(1,:)-DTHS{j}(1,:)))); 
        DiffTHS{j}(2,:)=num2cell((abs(DTH(2,:)-DTHS{j}(2,:)))); 
        DiffTHS{j}(3,:)=num2cell((abs(DTH(3,:)-DTHS{j}(3,:)))); 
        DiffTHS{j}(4,:)=num2cell((abs(DTH(4,:)-DTHS{j}(4,:)))); 
        DiffTHS{j}(5,:)=num2cell((abs(DTH(5,:)-DTHS{j}(5,:)))); 
        DiffTHS{j}(6,:)=num2cell((abs(DTH(6,:)-DTHS{j}(6,:)))); 
        DiffTHS{j}(7,:)=num2cell((abs(DTH(7,:)-DTHS{j}(7,:)))); 
        DiffTHS{j}(8,:)=num2cell((abs(DTH(8,:)-DTHS{j}(8,:)))); 
        DiffTHS{j}(9,:)=num2cell((abs(DTH(9,:)-DTHS{j}(9,:)))); 
        DiffTHS{j}(10,:)=num2cell((abs(DTH(10,:)-DTHS{j}(10,:)))); 
        DiffTHS{j}(11,:)=num2cell((abs(DTH(11,:)-DTHS{j}(11,:)))); 
        DiffTHS{j}(12,:)=num2cell((abs(DTH(12,:)-DTHS{j}(12,:)))); 
        DiffTHS{j}(13,:)=num2cell((abs(DTH(13,:)-DTHS{j}(13,:)))); 
        DiffTHS{j}(14,:)=num2cell((abs(DTH(14,:)-DTHS{j}(14,:)))); 
        DiffTHS{j}(15,:)=num2cell((abs(DTH(15,:)-DTHS{j}(15,:)))); 
        DiffTHS{j}(16,:)=num2cell((abs(DTH(16,:)-DTHS{j}(16,:)))); 
        DiffTHS{j}(17,:)=num2cell((abs(DTH(17,:)-DTHS{j}(17,:)))); 
        ATHS{j}=mean(cell2mat(DiffTHS{j})); 
        %Control Scans Normalized_Weighted_Thalamus_NonTargeted 
        DTHC=cell2mat(CTH{2}(:,1)); 
        DiffTHCS{j}=cell(17,1); 
        DTHCS{j}=cell2mat(CTH{j+5}(:,1)); 
        DiffTHCS{j}(1,:)=num2cell((abs(DTHC(1,:)-DTHCS{j}(1,:)))); 
        DiffTHCS{j}(2,:)=num2cell((abs(DTHC(2,:)-DTHCS{j}(2,:)))); 
        DiffTHCS{j}(3,:)=num2cell((abs(DTHC(3,:)-DTHCS{j}(3,:)))); 
        DiffTHCS{j}(4,:)=num2cell((abs(DTHC(4,:)-DTHCS{j}(4,:)))); 
        DiffTHCS{j}(5,:)=num2cell((abs(DTHC(5,:)-DTHCS{j}(5,:)))); 
        DiffTHCS{j}(6,:)=num2cell((abs(DTHC(6,:)-DTHCS{j}(6,:)))); 
        DiffTHCS{j}(7,:)=num2cell((abs(DTHC(7,:)-DTHCS{j}(7,:)))); 
        DiffTHCS{j}(8,:)=num2cell((abs(DTHC(8,:)-DTHCS{j}(8,:)))); 
        DiffTHCS{j}(9,:)=num2cell((abs(DTHC(9,:)-DTHCS{j}(9,:)))); 
        DiffTHCS{j}(10,:)=num2cell((abs(DTHC(10,:)-DTHCS{j}(10,:)))); 
        DiffTHCS{j}(11,:)=num2cell((abs(DTHC(11,:)-DTHCS{j}(11,:)))); 
        DiffTHCS{j}(12,:)=num2cell((abs(DTHC(12,:)-DTHCS{j}(12,:)))); 
        DiffTHCS{j}(13,:)=num2cell((abs(DTHC(13,:)-DTHCS{j}(13,:)))); 
        DiffTHCS{j}(14,:)=num2cell((abs(DTHC(14,:)-DTHCS{j}(14,:)))); 
        DiffTHCS{j}(15,:)=num2cell((abs(DTHC(15,:)-DTHCS{j}(15,:)))); 
        DiffTHCS{j}(16,:)=num2cell((abs(DTHC(16,:)-DTHCS{j}(16,:)))); 
        DiffTHCS{j}(17,:)=num2cell((abs(DTHC(17,:)-DTHCS{j}(17,:)))); 
        ATHCS{j}=mean(cell2mat(DiffTHCS{j})); 
        %Specificity Index 
        %For Individual ROIs 
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        ROI14S{j}=cell2mat(DiffTHS{j}(1,:))/cell2mat(DiffTHCS{j}(1,:)); 
        ROI34S{j}=cell2mat(DiffTHS{j}(2,:))/cell2mat(DiffTHCS{j}(2,:)); 
        ROI71S{j}=cell2mat(DiffTHS{j}(3,:))/cell2mat(DiffTHCS{j}(3,:)); 
        ROI76S{j}=cell2mat(DiffTHS{j}(4,:))/cell2mat(DiffTHCS{j}(4,:)); 
        ROI82S{j}=cell2mat(DiffTHS{j}(5,:))/cell2mat(DiffTHCS{j}(5,:)); 
        ROI98S{j}=cell2mat(DiffTHS{j}(6,:))/cell2mat(DiffTHCS{j}(6,:)); 
        ROI120S{j}=cell2mat(DiffTHS{j}(7,:))/cell2mat(DiffTHCS{j}(7,:)); 
        ROI158S{j}=cell2mat(DiffTHS{j}(8,:))/cell2mat(DiffTHCS{j}(8,:)); 
        ROI161S{j}=cell2mat(DiffTHS{j}(9,:))/cell2mat(DiffTHCS{j}(9,:)); 
        ROI163S{j}=cell2mat(DiffTHS{j}(10,:))/cell2mat(DiffTHCS{j}(10,:)); 
        ROI168S{j}=cell2mat(DiffTHS{j}(11,:))/cell2mat(DiffTHCS{j}(11,:)); 
        ROI169S{j}=cell2mat(DiffTHS{j}(12,:))/cell2mat(DiffTHCS{j}(12,:)); 
        ROI118S{j}=cell2mat(DiffTHS{j}(13,:))/cell2mat(DiffTHCS{j}(13,:)); 
        ROI109S{j}=cell2mat(DiffTHS{j}(14,:))/cell2mat(DiffTHCS{j}(14,:)); 
        ROI85S{j}=cell2mat(DiffTHS{j}(15,:))/cell2mat(DiffTHCS{j}(15,:)); 
        ROI72S{j}=cell2mat(DiffTHS{j}(16,:))/cell2mat(DiffTHCS{j}(16,:)); 
        ROI127S{j}=cell2mat(DiffTHS{j}(17,:))/cell2mat(DiffTHCS{j}(17,:)); 
        %For larger regions 
        THSI{j}=ATHS{j}/ATHCS{j}; 
        %Epithalamus Pre-Scan and Average of Scan 
        %Targeted Scans 'Normalized_Weighted_Epithalamus_Targeted' 
        DE=cell2mat(CE{1}(:,1)); 
        DiffES{j}=cell(2,1); 
        DES{j}=cell2mat(CE{j+2}(:,1)); 
        DiffES{j}(1,:)=num2cell((abs(DE(1,:)-DES{j}(1,:)))); 
        DiffES{j}(2,:)=num2cell((abs(DE(2,:)-DES{j}(2,:)))); 
        AES{j}=mean(cell2mat(DiffES{j})); 
        %Control Scans Normalized_Weighted_Epithalamus_NonTargeted' 
        DEC=cell2mat(CE{2}(:,1)); 
        DiffECS{j}=cell(2,1); 
        DECS{j}=cell2mat(CE{j+5}(:,1)); 
        DiffECS{j}(1,:)=num2cell((abs(DEC(1,:)-DECS{j}(1,:)))); 
        DiffECS{j}(2,:)=num2cell((abs(DEC(2,:)-DECS{j}(2,:)))); 
        AECS{j}=mean(cell2mat(DiffECS{j})); 
        %Specificity Index 
        %For Individual ROIs 
        ROI60S{j}=cell2mat(DiffES{j}(1,:))/cell2mat(DiffECS{j}(1,:)); 
        ROI101S{j}=cell2mat(DiffES{j}(2,:))/cell2mat(DiffECS{j}(2,:)); 
        %For Larger Regions 
        ESI{j}=AES{j}/AECS{j}; 
        %Cerebellum Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Cerebellum_Targeted' 
        DC=cell2mat(CC{1}(:,1)); 
        DiffCS{j}=cell(20,1); 
        DCS{j}=cell2mat(CC{j+2}(:,1)); 
        DiffCS{j}(1,:)=num2cell((abs(DC(1,:)-DCS{j}(1,:)))); 
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        DiffCS{j}(2,:)=num2cell((abs(DC(2,:)-DCS{j}(2,:)))); 
        DiffCS{j}(3,:)=num2cell((abs(DC(3,:)-DCS{j}(3,:)))); 
        DiffCS{j}(4,:)=num2cell((abs(DC(4,:)-DCS{j}(4,:)))); 
        DiffCS{j}(5,:)=num2cell((abs(DC(5,:)-DCS{j}(5,:)))); 
        DiffCS{j}(6,:)=num2cell((abs(DC(6,:)-DCS{j}(6,:)))); 
        DiffCS{j}(7,:)=num2cell((abs(DC(7,:)-DCS{j}(7,:)))); 
        DiffCS{j}(8,:)=num2cell((abs(DC(8,:)-DCS{j}(8,:)))); 
        DiffCS{j}(9,:)=num2cell((abs(DC(9,:)-DCS{j}(9,:)))); 
        DiffCS{j}(10,:)=num2cell((abs(DC(10,:)-DCS{j}(10,:)))); 
        DiffCS{j}(11,:)=num2cell((abs(DC(11,:)-DCS{j}(11,:)))); 
        DiffCS{j}(12,:)=num2cell((abs(DC(12,:)-DCS{j}(12,:)))); 
        DiffCS{j}(13,:)=num2cell((abs(DC(13,:)-DCS{j}(13,:)))); 
        DiffCS{j}(14,:)=num2cell((abs(DC(14,:)-DCS{j}(14,:)))); 
        DiffCS{j}(15,:)=num2cell((abs(DC(15,:)-DCS{j}(15,:)))); 
        DiffCS{j}(16,:)=num2cell((abs(DC(16,:)-DCS{j}(16,:)))); 
        DiffCS{j}(17,:)=num2cell((abs(DC(17,:)-DCS{j}(17,:)))); 
        DiffCS{j}(18,:)=num2cell((abs(DC(18,:)-DCS{j}(18,:)))); 
        DiffCS{j}(19,:)=num2cell((abs(DC(19,:)-DCS{j}(19,:)))); 
        DiffCS{j}(20,:)=num2cell((abs(DC(20,:)-DCS{j}(20,:)))); 
        ACS{j}=mean(cell2mat(DiffCS{j})); 
        %Control Scans Normalized_Weighted_Cerebellum_NonTargeted 
        DCC=cell2mat(CC{2}(:,1)); 
        DiffCCS{j}=cell(20,1); 
        DCCS{j}=cell2mat(CC{j+5}(:,1)); 
        DiffCCS{j}(1,:)=num2cell((abs(DCC(1,:)-DCCS{j}(1,:)))); 
        DiffCCS{j}(2,:)=num2cell((abs(DCC(2,:)-DCCS{j}(2,:)))); 
        DiffCCS{j}(3,:)=num2cell((abs(DCC(3,:)-DCCS{j}(3,:)))); 
        DiffCCS{j}(4,:)=num2cell((abs(DCC(4,:)-DCCS{j}(4,:)))); 
        DiffCCS{j}(5,:)=num2cell((abs(DCC(5,:)-DCCS{j}(5,:)))); 
        DiffCCS{j}(6,:)=num2cell((abs(DCC(6,:)-DCCS{j}(6,:)))); 
        DiffCCS{j}(7,:)=num2cell((abs(DCC(7,:)-DCCS{j}(7,:)))); 
        DiffCCS{j}(8,:)=num2cell((abs(DCC(8,:)-DCCS{j}(8,:)))); 
        DiffCCS{j}(9,:)=num2cell((abs(DCC(9,:)-DCCS{j}(9,:)))); 
        DiffCCS{j}(10,:)=num2cell((abs(DCC(10,:)-DCCS{j}(10,:)))); 
        DiffCCS{j}(11,:)=num2cell((abs(DCC(11,:)-DCCS{j}(11,:)))); 
        DiffCCS{j}(12,:)=num2cell((abs(DCC(12,:)-DCCS{j}(12,:)))); 
        DiffCCS{j}(13,:)=num2cell((abs(DCC(13,:)-DCCS{j}(13,:)))); 
        DiffCCS{j}(14,:)=num2cell((abs(DCC(14,:)-DCCS{j}(14,:)))); 
        DiffCCS{j}(15,:)=num2cell((abs(DCC(15,:)-DCCS{j}(15,:)))); 
        DiffCCS{j}(16,:)=num2cell((abs(DCC(16,:)-DCCS{j}(16,:)))); 
        DiffCCS{j}(17,:)=num2cell((abs(DCC(17,:)-DCCS{j}(17,:)))); 
        DiffCCS{j}(18,:)=num2cell((abs(DCC(18,:)-DCCS{j}(18,:)))); 
        DiffCCS{j}(19,:)=num2cell((abs(DCC(19,:)-DCCS{j}(19,:)))); 
        DiffCCS{j}(20,:)=num2cell((abs(DCC(20,:)-DCCS{j}(20,:)))); 
        ACCS{j}=mean(cell2mat(DiffCCS{j})); 
        %Specificity Index 
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        %For Individual ROIs 
        ROI2S{j}=cell2mat(DiffCS{j}(1,:))/cell2mat(DiffCCS{j}(1,:)); 
        ROI3S{j}=cell2mat(DiffCS{j}(2,:))/cell2mat(DiffCCS{j}(2,:)); 
        ROI4S{j}=cell2mat(DiffCS{j}(3,:))/cell2mat(DiffCCS{j}(3,:)); 
        ROI5S{j}=cell2mat(DiffCS{j}(4,:))/cell2mat(DiffCCS{j}(4,:)); 
        ROI6S{j}=cell2mat(DiffCS{j}(5,:))/cell2mat(DiffCCS{j}(5,:)); 
        ROI9S{j}=cell2mat(DiffCS{j}(6,:))/cell2mat(DiffCCS{j}(6,:)); 
        ROI10S{j}=cell2mat(DiffCS{j}(7,:))/cell2mat(DiffCCS{j}(7,:)); 
        ROI12S{j}=cell2mat(DiffCS{j}(8,:))/cell2mat(DiffCCS{j}(8,:)); 
        ROI13S{j}=cell2mat(DiffCS{j}(9,:))/cell2mat(DiffCCS{j}(9,:)); 
        ROI1S{j}=cell2mat(DiffCS{j}(10,:))/cell2mat(DiffCCS{j}(10,:)); 
        ROI65S{j}=cell2mat(DiffCS{j}(11,:))/cell2mat(DiffCCS{j}(11,:)); 
        ROI140S{j}=cell2mat(DiffCS{j}(12,:))/cell2mat(DiffCCS{j}(12,:)); 
        ROI36S{j}=cell2mat(DiffCS{j}(13,:))/cell2mat(DiffCCS{j}(13,:)); 
        ROI99S{j}=cell2mat(DiffCS{j}(14,:))/cell2mat(DiffCCS{j}(14,:)); 
        ROI37S{j}=cell2mat(DiffCS{j}(15,:))/cell2mat(DiffCCS{j}(15,:)); 
        ROI38S{j}=cell2mat(DiffCS{j}(16,:))/cell2mat(DiffCCS{j}(16,:)); 
        ROI54S{j}=cell2mat(DiffCS{j}(17,:))/cell2mat(DiffCCS{j}(17,:)); 
        ROI69S{j}=cell2mat(DiffCS{j}(18,:))/cell2mat(DiffCCS{j}(18,:)); 
        ROI84S{j}=cell2mat(DiffCS{j}(19,:))/cell2mat(DiffCCS{j}(19,:)); 
        ROI105S{j}=cell2mat(DiffCS{j}(20,:))/cell2mat(DiffCCS{j}(20,:)); 
        %For larger regions 
        CSI{j}=ACS{j}/ACCS{j}; 
        %Pons Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Pons_Targeted 
        DP=cell2mat(CP{1}(:,1)); 
        DiffPS1=cell(18,1); 
        DPS{j}=cell2mat(CP{j+2}(:,1)); 
        DiffPS{j}(1,:)=num2cell((abs(DP(1,:)-DPS{j}(1,:)))); 
        DiffPS{j}(2,:)=num2cell((abs(DP(2,:)-DPS{j}(2,:)))); 
        DiffPS{j}(3,:)=num2cell((abs(DP(3,:)-DPS{j}(3,:)))); 
        DiffPS{j}(4,:)=num2cell((abs(DP(4,:)-DPS{j}(4,:)))); 
        DiffPS{j}(5,:)=num2cell((abs(DP(5,:)-DPS{j}(5,:)))); 
        DiffPS{j}(6,:)=num2cell((abs(DP(6,:)-DPS{j}(6,:)))); 
        DiffPS{j}(7,:)=num2cell((abs(DP(7,:)-DPS{j}(7,:)))); 
        DiffPS{j}(8,:)=num2cell((abs(DP(8,:)-DPS{j}(8,:)))); 
        DiffPS{j}(9,:)=num2cell((abs(DP(9,:)-DPS{j}(9,:)))); 
        DiffPS{j}(10,:)=num2cell((abs(DP(10,:)-DPS{j}(10,:)))); 
        DiffPS{j}(11,:)=num2cell((abs(DP(11,:)-DPS{j}(11,:)))); 
        DiffPS{j}(12,:)=num2cell((abs(DP(12,:)-DPS{j}(12,:)))); 
        DiffPS{j}(13,:)=num2cell((abs(DP(13,:)-DPS{j}(13,:)))); 
        DiffPS{j}(14,:)=num2cell((abs(DP(14,:)-DPS{j}(14,:)))); 
        DiffPS{j}(15,:)=num2cell((abs(DP(15,:)-DPS{j}(15,:)))); 
        DiffPS{j}(16,:)=num2cell((abs(DP(16,:)-DPS{j}(16,:)))); 
        DiffPS{j}(17,:)=num2cell((abs(DP(17,:)-DPS{j}(17,:)))); 
        DiffPS{j}(18,:)=num2cell((abs(DP(18,:)-DPS{j}(18,:)))); 
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        APS{j}=mean(cell2mat(DiffPS{j})); 
        %Conrtol Scans Normalized_Weighted_Pons_NonTargeted 
        DPC=cell2mat(CP{2}(:,1)); 
        DiffPCS{j}=cell(18,1); 
        DPCS{j}=cell2mat(CP{j+5}(:,1)); 
        DiffPCS{j}(1,:)=num2cell((abs(DPC(1,:)-DPCS{j}(1,:)))); 
        DiffPCS{j}(2,:)=num2cell((abs(DPC(2,:)-DPCS{j}(2,:)))); 
        DiffPCS{j}(3,:)=num2cell((abs(DPC(3,:)-DPCS{j}(3,:)))); 
        DiffPCS{j}(4,:)=num2cell((abs(DPC(4,:)-DPCS{j}(4,:)))); 
        DiffPCS{j}(5,:)=num2cell((abs(DPC(5,:)-DPCS{j}(5,:)))); 
        DiffPCS{j}(6,:)=num2cell((abs(DPC(6,:)-DPCS{j}(6,:)))); 
        DiffPCS{j}(7,:)=num2cell((abs(DPC(7,:)-DPCS{j}(7,:)))); 
        DiffPCS{j}(8,:)=num2cell((abs(DPC(8,:)-DPCS{j}(8,:)))); 
        DiffPCS{j}(9,:)=num2cell((abs(DPC(9,:)-DPCS{j}(9,:)))); 
        DiffPCS{j}(10,:)=num2cell((abs(DPC(10,:)-DPCS{j}(10,:)))); 
        DiffPCS{j}(11,:)=num2cell((abs(DPC(11,:)-DPCS{j}(11,:)))); 
        DiffPCS{j}(12,:)=num2cell((abs(DPC(12,:)-DPCS{j}(12,:)))); 
        DiffPCS{j}(13,:)=num2cell((abs(DPC(13,:)-DPCS{j}(13,:)))); 
        DiffPCS{j}(14,:)=num2cell((abs(DPC(14,:)-DPCS{j}(14,:)))); 
        DiffPCS{j}(15,:)=num2cell((abs(DPC(15,:)-DPCS{j}(15,:)))); 
        DiffPCS{j}(16,:)=num2cell((abs(DPC(16,:)-DPCS{j}(16,:)))); 
        DiffPCS{j}(17,:)=num2cell((abs(DPC(17,:)-DPCS{j}(17,:)))); 
        DiffPCS{j}(18,:)=num2cell((abs(DPC(18,:)-DPCS{j}(18,:)))); 
        APCS{j}=mean(cell2mat(DiffPCS{j})); 
        %Specificity Index 
        %For individual ROIs 
        ROI106S{j}=cell2mat(DiffPS{j}(1,:))/cell2mat(DiffPCS{j}(1,:)); 
        ROI7S{j}=cell2mat(DiffPS{j}(2,:))/cell2mat(DiffPCS{j}(2,:)); 
        ROI112S{j}=cell2mat(DiffPS{j}(3,:))/cell2mat(DiffPCS{j}(3,:)); 
        ROI45S{j}=cell2mat(DiffPS{j}(4,:))/cell2mat(DiffPCS{j}(4,:)); 
        ROI154S{j}=cell2mat(DiffPS{j}(5,:))/cell2mat(DiffPCS{j}(5,:)); 
        ROI74S{j}=cell2mat(DiffPS{j}(6,:))/cell2mat(DiffPCS{j}(6,:)); 
        ROI129S{j}=cell2mat(DiffPS{j}(7,:))/cell2mat(DiffPCS{j}(7,:)); 
        ROI93S{j}=cell2mat(DiffPS{j}(8,:))/cell2mat(DiffPCS{j}(8,:)); 
        ROI110S{j}=cell2mat(DiffPS{j}(9,:))/cell2mat(DiffPCS{j}(9,:)); 
        ROI107S{j}=cell2mat(DiffPS{j}(10,:))/cell2mat(DiffPCS{j}(10,:)); 
        ROI108S{j}=cell2mat(DiffPS{j}(11,:))/cell2mat(DiffPCS{j}(11,:)); 
        ROI56S{j}=cell2mat(DiffPS{j}(12,:))/cell2mat(DiffPCS{j}(12,:)); 
        ROI96S{j}=cell2mat(DiffPS{j}(13,:))/cell2mat(DiffPCS{j}(13,:)); 
        ROI8S{j}=cell2mat(DiffPS{j}(14,:))/cell2mat(DiffPCS{j}(14,:)); 
        ROI11S{j}=cell2mat(DiffPS{j}(15,:))/cell2mat(DiffPCS{j}(15,:)); 
        ROI70S{j}=cell2mat(DiffPS{j}(16,:))/cell2mat(DiffPCS{j}(16,:)); 
        ROI148S{j}=cell2mat(DiffPS{j}(17,:))/cell2mat(DiffPCS{j}(17,:)); 
        ROI87S{j}=cell2mat(DiffPS{j}(18,:))/cell2mat(DiffPCS{j}(18,:)); 
        %For larger region 
        PSI{j}=APS{j}/APCS{j}; 
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        %Tectum Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Tectum_Targeted 
        DT=cell2mat(CT{1}(:,1)); 
        DiffTS{j}=cell(2,1); 
        DTS{j}=cell2mat(CT{j+2}(:,1)); 
        DiffTS{j}(1,:)=num2cell((abs(DT(1,:)-DTS{j}(1,:)))); 
        DiffTS{j}(2,:)=num2cell((abs(DT(2,:)-DTS{j}(2,:)))); 
        ATS{j}=mean(cell2mat(DiffTS{j})); 
        %Control Scans Normalized_Weighted_Tectum_NonTargeted 
        DTC=cell2mat(CT{2}(:,1)); 
        DiffTCS1=cell(2,1); 
        DTCS{j}=cell2mat(CT{j+5}(:,1)); 
        DiffTCS{j}(1,:)=num2cell((abs(DTC(1,:)-DTCS{j}(1,:)))); 
        DiffTCS{j}(2,:)=num2cell((abs(DTC(2,:)-DTCS{j}(2,:)))); 
        ATCS{j}=mean(cell2mat(DiffTCS{j})); 
        %Specificity Index 
        %For the individual ROI's 
        ROI62S{j}=cell2mat(DiffTS{j}(1,:))/cell2mat(DiffTCS{j}(1,:)); 
        ROI147S{j}=cell2mat(DiffTS{j}(2,:))/cell2mat(DiffTCS{j}(2,:)); 
        %For the larger regions 
        TSI{j}=ATS{j}/ATCS{j}; 
        %Cerebral Peduncle  Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Cerebral_Peduncle_Targeted 
        DCP=cell2mat(CCP{1}(:,1)); 
        DiffCPS{j}=cell(13,1); 
        DCPS{j}=cell2mat(CCP{j+2}(:,1)); 
        DiffCPS{j}(1,:)=num2cell((abs(DCP(1,:)-DCPS{j}(1,:)))); 
        DiffCPS{j}(2,:)=num2cell((abs(DCP(2,:)-DCPS{j}(2,:)))); 
        DiffCPS{j}(3,:)=num2cell((abs(DCP(3,:)-DCPS{j}(3,:)))); 
        DiffCPS{j}(4,:)=num2cell((abs(DCP(4,:)-DCPS{j}(4,:)))); 
        DiffCPS{j}(5,:)=num2cell((abs(DCP(5,:)-DCPS{j}(5,:)))); 
        DiffCPS{j}(6,:)=num2cell((abs(DCP(6,:)-DCPS{j}(6,:)))); 
        DiffCPS{j}(7,:)=num2cell((abs(DCP(7,:)-DCPS{j}(7,:)))); 
        DiffCPS{j}(8,:)=num2cell((abs(DCP(8,:)-DCPS{j}(8,:)))); 
        DiffCPS{j}(9,:)=num2cell((abs(DCP(9,:)-DCPS{j}(9,:)))); 
        DiffCPS{j}(10,:)=num2cell((abs(DCP(10,:)-DCPS{j}(10,:)))); 
        DiffCPS{j}(11,:)=num2cell((abs(DCP(11,:)-DCPS{j}(11,:)))); 
        DiffCPS{j}(12,:)=num2cell((abs(DCP(12,:)-DCPS{j}(12,:)))); 
        DiffCPS{j}(13,:)=num2cell((abs(DCP(13,:)-DCPS{j}(13,:)))); 
        ACPS{j}=mean(cell2mat(DiffCPS{j})); 
        %Control Scans Normalized_Weighted_Cerebral_Peduncle_NonTargeted 
        DCPC=cell2mat(CCP{2}(:,1)); 
        DiffCPCS{j}=cell(13,1); 
        DCPCS{j}=cell2mat(CCP{j+5}(:,1)); 
        DiffCPCS{j}(1,:)=num2cell((abs(DCPC(1,:)-DCPCS{j}(1,:)))); 
        DiffCPCS{j}(2,:)=num2cell((abs(DCPC(2,:)-DCPCS{j}(2,:)))); 
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        DiffCPCS{j}(3,:)=num2cell((abs(DCPC(3,:)-DCPCS{j}(3,:)))); 
        DiffCPCS{j}(4,:)=num2cell((abs(DCPC(4,:)-DCPCS{j}(4,:)))); 
        DiffCPCS{j}(5,:)=num2cell((abs(DCPC(5,:)-DCPCS{j}(5,:)))); 
        DiffCPCS{j}(6,:)=num2cell((abs(DCPC(6,:)-DCPCS{j}(6,:)))); 
        DiffCPCS{j}(7,:)=num2cell((abs(DCPC(7,:)-DCPCS{j}(7,:)))); 
        DiffCPCS{j}(8,:)=num2cell((abs(DCPC(8,:)-DCPCS{j}(8,:)))); 
        DiffCPCS{j}(9,:)=num2cell((abs(DCPC(9,:)-DCPCS{j}(9,:)))); 
        DiffCPCS{j}(10,:)=num2cell((abs(DCPC(10,:)-DCPCS{j}(10,:)))); 
        DiffCPCS{j}(11,:)=num2cell((abs(DCPC(11,:)-DCPCS{j}(11,:)))); 
        DiffCPCS{j}(12,:)=num2cell((abs(DCPC(12,:)-DCPCS{j}(12,:)))); 
        DiffCPCS{j}(13,:)=num2cell((abs(DCPC(13,:)-DCPCS{j}(13,:)))); 
        ACPCS{j}=mean(cell2mat(DiffCPCS{j})); 
        %Specificity Index 
        %For the individual ROIs 
        ROI21S{j}=cell2mat(DiffCPS{j}(1,:))/cell2mat(DiffCPCS{j}(1,:)); 
        ROI90S{j}=cell2mat(DiffCPS{j}(2,:))/cell2mat(DiffCPCS{j}(2,:)); 
        ROI141S{j}=cell2mat(DiffCPS{j}(3,:))/cell2mat(DiffCPCS{j}(3,:)); 
        ROI142S{j}=cell2mat(DiffCPS{j}(4,:))/cell2mat(DiffCPCS{j}(4,:)); 
        ROI124S{j}=cell2mat(DiffCPS{j}(5,:))/cell2mat(DiffCPCS{j}(5,:)); 
        ROI171S{j}=cell2mat(DiffCPS{j}(6,:))/cell2mat(DiffCPCS{j}(6,:)); 
        ROI67S{j}=cell2mat(DiffCPS{j}(7,:))/cell2mat(DiffCPCS{j}(7,:)); 
        ROI95S{j}=cell2mat(DiffCPS{j}(8,:))/cell2mat(DiffCPCS{j}(8,:)); 
        ROI32S{j}=cell2mat(DiffCPS{j}(9,:))/cell2mat(DiffCPCS{j}(9,:)); 
        ROI128S{j}=cell2mat(DiffCPS{j}(10,:))/cell2mat(DiffCPCS{j}(10,:)); 
        ROI117S{j}=cell2mat(DiffCPS{j}(11,:))/cell2mat(DiffCPCS{j}(11,:)); 
        ROI47S{j}=cell2mat(DiffCPS{j}(12,:))/cell2mat(DiffCPCS{j}(12,:)); 
        ROI121S{j}=cell2mat(DiffCPS{j}(13,:))/cell2mat(DiffCPCS{j}(13,:)); 
        %For larger region 
        CPSI{j}=ACPS{j}/ACPCS{j}; 
        %Medulla Oblongata Pre-Scan and Average of Scan 
        %Targeted Scans Normalized_Weighted_Medulla_Oblongata_Targeted 
        DMO=cell2mat(CMO{1}(:,1)); 
        DiffMOS{j}=cell(12,1); 
        DMOS{j}=cell2mat(CMO{j+2}(:,1)); 
        DiffMOS{j}(1,:)=num2cell((abs(DMO(1,:)-DMOS{j}(1,:)))); 
        DiffMOS{j}(2,:)=num2cell((abs(DMO(2,:)-DMOS{j}(2,:)))); 
        DiffMOS{j}(3,:)=num2cell((abs(DMO(3,:)-DMOS{j}(3,:)))); 
        DiffMOS{j}(4,:)=num2cell((abs(DMO(4,:)-DMOS{j}(4,:)))); 
        DiffMOS{j}(5,:)=num2cell((abs(DMO(5,:)-DMOS{j}(5,:)))); 
        DiffMOS{j}(6,:)=num2cell((abs(DMO(6,:)-DMOS{j}(6,:)))); 
        DiffMOS{j}(7,:)=num2cell((abs(DMO(7,:)-DMOS{j}(7,:)))); 
        DiffMOS{j}(8,:)=num2cell((abs(DMO(8,:)-DMOS{j}(8,:)))); 
        DiffMOS{j}(9,:)=num2cell((abs(DMO(9,:)-DMOS{j}(9,:)))); 
        DiffMOS{j}(10,:)=num2cell((abs(DMO(10,:)-DMOS{j}(10,:)))); 
        DiffMOS{j}(11,:)=num2cell((abs(DMO(11,:)-DMOS{j}(11,:)))); 
        DiffMOS{j}(12,:)=num2cell((abs(DMO(12,:)-DMOS{j}(12,:)))); 
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        AMOS{j}=mean(cell2mat(DiffMOS{j})); 
        %Control Scans Normalized_Weighted_Medulla_Oblongata_NonTargeted 
        DMOC=cell2mat(CMO{2}(:,1)); 
        DiffMOCS{j}=cell(12,1); 
        DMOCS{j}=cell2mat(CMO{j+5}(:,1)); 
        DiffMOCS{j}(1,:)=num2cell((abs(DMOC(1,:)-DMOCS{j}(1,:)))); 
        DiffMOCS{j}(2,:)=num2cell((abs(DMOC(2,:)-DMOCS{j}(2,:)))); 
        DiffMOCS{j}(3,:)=num2cell((abs(DMOC(3,:)-DMOCS{j}(3,:)))); 
        DiffMOCS{j}(4,:)=num2cell((abs(DMOC(4,:)-DMOCS{j}(4,:)))); 
        DiffMOCS{j}(5,:)=num2cell((abs(DMOC(5,:)-DMOCS{j}(5,:)))); 
        DiffMOCS{j}(6,:)=num2cell((abs(DMOC(6,:)-DMOCS{j}(6,:)))); 
        DiffMOCS{j}(7,:)=num2cell((abs(DMOC(7,:)-DMOCS{j}(7,:)))); 
        DiffMOCS{j}(8,:)=num2cell((abs(DMOC(8,:)-DMOCS{j}(8,:)))); 
        DiffMOCS{j}(9,:)=num2cell((abs(DMOC(9,:)-DMOCS{j}(9,:)))); 
        DiffMOCS{j}(10,:)=num2cell((abs(DMOC(10,:)-DMOCS{j}(10,:)))); 
        DiffMOCS{j}(11,:)=num2cell((abs(DMOC(11,:)-DMOCS{j}(11,:)))); 
        DiffMOCS{j}(12,:)=num2cell((abs(DMOC(12,:)-DMOCS{j}(12,:)))); 
        AMOCS{j}=mean(cell2mat(DiffMOCS{j})); 
        %Specificity Index 
        %For smaller region 
        ROI66S{j}=cell2mat(DiffMOS{j}(1,:))/cell2mat(DiffMOCS{j}(1,:)); 
        ROI144S{j}=cell2mat(DiffMOS{j}(2,:))/cell2mat(DiffMOCS{j}(2,:)); 
        ROI159S{j}=cell2mat(DiffMOS{j}(3,:))/cell2mat(DiffMOCS{j}(3,:)); 
        ROI160S{j}=cell2mat(DiffMOS{j}(4,:))/cell2mat(DiffMOCS{j}(4,:)); 
        ROI122S{j}=cell2mat(DiffMOS{j}(5,:))/cell2mat(DiffMOCS{j}(5,:)); 
        ROI123S{j}=cell2mat(DiffMOS{j}(6,:))/cell2mat(DiffMOCS{j}(6,:)); 
        ROI97S{j}=cell2mat(DiffMOS{j}(7,:))/cell2mat(DiffMOCS{j}(7,:)); 
        ROI46S{j}=cell2mat(DiffMOS{j}(8,:))/cell2mat(DiffMOCS{j}(8,:)); 
        ROI113S{j}=cell2mat(DiffMOS{j}(9,:))/cell2mat(DiffMOCS{j}(9,:)); 
        ROI155S{j}=cell2mat(DiffMOS{j}(10,:))/cell2mat(DiffMOCS{j}(10,:)); 
        ROI172S{j}=cell2mat(DiffMOS{j}(11,:))/cell2mat(DiffMOCS{j}(11,:)); 
        ROI173S{j}=cell2mat(DiffMOS{j}(12,:))/cell2mat(DiffMOCS{j}(12,:)); 
        %For Overall Larger Region 
        MOSI{j}=AMOS{j}/AMOCS{j}; 
    end 
        normalized1 = containers.Map ({'Normalized_Weighted_Olfactory_Bulb_Targeted','Normalized_Weighted_Olfactory_Bulb_NonTargeted', 
'Normalized_Weighted_Olfactory_Area_Targeted', 'Normalized_Weighted_Olfactory_Area_NonTargeted', 
'Normalized_Weighted_Limbic_Lobe_Targeted', 'Normalized_Weighted_Limbic_Lobe_NonTargeted', 
'Normalized_Weighted_Insular_Cortex_Targeted', 'Normalized_Weighted_Insular_Cortex_NonTargeted', 
'Normalized_Weighted_Ocipital_Lobe_Targeted', 'Normalized_Weighted_Ocipital_Lobe_NonTargeted', 
'Normalized_Weighted_Temporal_Lobe_Targeted', 'Normalized_Weighted_Temporal_Lobe_NonTargeted', 
'Normalized_Weighted_Parietal_Lobe_Targeted', 'Normalized_Weighted_Parietal_Lobe_NonTargeted', 
'Normalized_Weighted_Frontal_Lobe_Targeted', 'Normalized_Weighted_Frontal_Lobe_NonTargeted', 
'Normalized_Weighted_Hippocampal_Formation_Targeted', 'Normalized_Weighted_Hippocampal_Formation_NonTargeted', 
'Normalized_Weighted_Amygdaloid_Nuclear_Complex_Targeted', 'Normalized_Weighted_Amygdaloid_Nuclear_Complex_NonTargeted', 
'Normalized_Weighted_Basal_Ganglia_Targeted', 'Normalized_Weighted_Basal_Ganglia_NonTargeted', 
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'Normalized_Weighted_Basal_Forebrain_Targeted', 'Normalized_Weighted_Basal_Forebrain_NonTargeted', 
'Normalized_Weighted_Septum_Targeted', 'Normalized_Weighted_Septum_NonTargeted', 'Normalized_Weighted_Hypothalamus_Targeted', 
'Normalized_Weighted_Hypothalamus_NonTargeted', 'Normalized_Weighted_Pituitary_Targeted', 
'Normalized_Weighted_Pituitary_NonTargeted', 'Normalized_Weighted_Thalamus_Targeted', 'Normalized_Weighted_Thalamus_NonTargeted', 
'Normalized_Weighted_Epithalamus_Targeted', 'Normalized_Weighted_Epithalamus_NonTargeted', 
'Normalized_Weighted_Cerebellum_Targeted', 'Normalized_Weighted_Cerebellum_NonTargeted', 'Normalized_Weighted_Pons_Targeted', 
'Normalized_Weighted_Pons_NonTargeted', 'Normalized_Weighted_Tectum_Targeted', 'Normalized_Weighted_Tectum_NonTargeted', 
'Normalized_Weighted_Cerebral_Peduncle_Targeted', 'Normalized_Weighted_Cerebral_Peduncle_NonTargeted', 
'Normalized_Weighted_Medulla_Oblongata_Targeted', 'Normalized_Weighted_Medulla_Oblongata_NonTargeted'}, {DiffOBS{1}, 
DiffOBCS{1}, DiffOAS{1}, DiffOACS{1}, DiffLS{1}, DiffLCS{1}, DiffIS{1}, DiffICS{1}, DiffOLS{1}, DiffOLCS{1}, DiffTLS{1}, 
DiffTLCS{1}, DiffPLS{1}, DiffPLCS{1},  DiffFLS{1}, DiffFLCS{1}, DiffHFS{1}, DiffHFCS{1}, DiffANCS{1}, DiffANCCS{1}, 
DiffBGS{1}, DiffBGCS{1}, DiffBFS{1}, DiffBFCS{1}, DiffSS{1}, DiffSCS{1}, DiffHS{1}, DiffHCS{1}, DiffPS{1}, DiffPCS{1}, 
DiffTHS{1}, DiffTHCS{1}, DiffES{1}, DiffECS{1}, DiffCS{1}, DiffCCS{1}, DiffPS{1}, DiffPCS{1}, DiffTS{1}, DiffTCS{1}, DiffCPS{1}, 
DiffCPCS{1}, DiffMOS{1},DiffMOCS{1}}); 
        normalized2 = containers.Map ({'Normalized_Weighted_Olfactory_Bulb_Targeted','Normalized_Weighted_Olfactory_Bulb_NonTargeted', 
'Normalized_Weighted_Olfactory_Area_Targeted', 'Normalized_Weighted_Olfactory_Area_NonTargeted', 
'Normalized_Weighted_Limbic_Lobe_Targeted', 'Normalized_Weighted_Limbic_Lobe_NonTargeted', 
'Normalized_Weighted_Insular_Cortex_Targeted', 'Normalized_Weighted_Insular_Cortex_NonTargeted', 
'Normalized_Weighted_Ocipital_Lobe_Targeted', 'Normalized_Weighted_Ocipital_Lobe_NonTargeted', 
'Normalized_Weighted_Temporal_Lobe_Targeted', 'Normalized_Weighted_Temporal_Lobe_NonTargeted', 
'Normalized_Weighted_Parietal_Lobe_Targeted', 'Normalized_Weighted_Parietal_Lobe_NonTargeted', 
'Normalized_Weighted_Frontal_Lobe_Targeted', 'Normalized_Weighted_Frontal_Lobe_NonTargeted', 
'Normalized_Weighted_Hippocampal_Formation_Targeted', 'Normalized_Weighted_Hippocampal_Formation_NonTargeted', 
'Normalized_Weighted_Amygdaloid_Nuclear_Complex_Targeted', 'Normalized_Weighted_Amygdaloid_Nuclear_Complex_NonTargeted', 
'Normalized_Weighted_Basal_Ganglia_Targeted', 'Normalized_Weighted_Basal_Ganglia_NonTargeted', 
'Normalized_Weighted_Basal_Forebrain_Targeted', 'Normalized_Weighted_Basal_Forebrain_NonTargeted', 
'Normalized_Weighted_Septum_Targeted', 'Normalized_Weighted_Septum_NonTargeted', 'Normalized_Weighted_Hypothalamus_Targeted', 
'Normalized_Weighted_Hypothalamus_NonTargeted', 'Normalized_Weighted_Pituitary_Targeted', 
'Normalized_Weighted_Pituitary_NonTargeted', 'Normalized_Weighted_Thalamus_Targeted', 'Normalized_Weighted_Thalamus_NonTargeted', 
'Normalized_Weighted_Epithalamus_Targeted', 'Normalized_Weighted_Epithalamus_NonTargeted', 
'Normalized_Weighted_Cerebellum_Targeted', 'Normalized_Weighted_Cerebellum_NonTargeted', 'Normalized_Weighted_Pons_Targeted', 
'Normalized_Weighted_Pons_NonTargeted', 'Normalized_Weighted_Tectum_Targeted', 'Normalized_Weighted_Tectum_NonTargeted', 
'Normalized_Weighted_Cerebral_Peduncle_Targeted', 'Normalized_Weighted_Cerebral_Peduncle_NonTargeted', 
'Normalized_Weighted_Medulla_Oblongata_Targeted', 'Normalized_Weighted_Medulla_Oblongata_NonTargeted'}, {DiffOBS{2}, 
DiffOBCS{2}, DiffOAS{2}, DiffOACS{2}, DiffLS{2}, DiffLCS{2}, DiffIS{2}, DiffICS{2}, DiffOLS{2}, DiffOLCS{2}, DiffTLS{2}, 
DiffTLCS{2}, DiffPLS{2}, DiffPLCS{2},  DiffFLS{2}, DiffFLCS{2}, DiffHFS{2}, DiffHFCS{2}, DiffANCS{2}, DiffANCCS{2}, 
DiffBGS{2}, DiffBGCS{2}, DiffBFS{2}, DiffBFCS{2}, DiffSS{2}, DiffSCS{2}, DiffHS{2}, DiffHCS{2}, DiffPS{2}, DiffPCS{2}, 
DiffTHS{2}, DiffTHCS{2}, DiffES{2}, DiffECS{2}, DiffCS{2}, DiffCCS{2}, DiffPS{2}, DiffPCS{2}, DiffTS{2}, DiffTCS{2}, DiffCPS{2}, 
DiffCPCS{2}, DiffMOS{2},DiffMOCS{2}}); 
        normalized3 = containers.Map ({'Normalized_Weighted_Olfactory_Bulb_Targeted','Normalized_Weighted_Olfactory_Bulb_NonTargeted', 
'Normalized_Weighted_Olfactory_Area_Targeted', 'Normalized_Weighted_Olfactory_Area_NonTargeted', 
'Normalized_Weighted_Limbic_Lobe_Targeted', 'Normalized_Weighted_Limbic_Lobe_NonTargeted', 
'Normalized_Weighted_Insular_Cortex_Targeted', 'Normalized_Weighted_Insular_Cortex_NonTargeted', 
'Normalized_Weighted_Ocipital_Lobe_Targeted', 'Normalized_Weighted_Ocipital_Lobe_NonTargeted', 
'Normalized_Weighted_Temporal_Lobe_Targeted', 'Normalized_Weighted_Temporal_Lobe_NonTargeted', 
'Normalized_Weighted_Parietal_Lobe_Targeted', 'Normalized_Weighted_Parietal_Lobe_NonTargeted', 
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'Normalized_Weighted_Frontal_Lobe_Targeted', 'Normalized_Weighted_Frontal_Lobe_NonTargeted', 
'Normalized_Weighted_Hippocampal_Formation_Targeted', 'Normalized_Weighted_Hippocampal_Formation_NonTargeted', 
'Normalized_Weighted_Amygdaloid_Nuclear_Complex_Targeted', 'Normalized_Weighted_Amygdaloid_Nuclear_Complex_NonTargeted', 
'Normalized_Weighted_Basal_Ganglia_Targeted', 'Normalized_Weighted_Basal_Ganglia_NonTargeted', 
'Normalized_Weighted_Basal_Forebrain_Targeted', 'Normalized_Weighted_Basal_Forebrain_NonTargeted', 
'Normalized_Weighted_Septum_Targeted', 'Normalized_Weighted_Septum_NonTargeted', 'Normalized_Weighted_Hypothalamus_Targeted', 
'Normalized_Weighted_Hypothalamus_NonTargeted', 'Normalized_Weighted_Pituitary_Targeted', 
'Normalized_Weighted_Pituitary_NonTargeted', 'Normalized_Weighted_Thalamus_Targeted', 'Normalized_Weighted_Thalamus_NonTargeted', 
'Normalized_Weighted_Epithalamus_Targeted', 'Normalized_Weighted_Epithalamus_NonTargeted', 
'Normalized_Weighted_Cerebellum_Targeted', 'Normalized_Weighted_Cerebellum_NonTargeted', 'Normalized_Weighted_Pons_Targeted', 
'Normalized_Weighted_Pons_NonTargeted', 'Normalized_Weighted_Tectum_Targeted', 'Normalized_Weighted_Tectum_NonTargeted', 
'Normalized_Weighted_Cerebral_Peduncle_Targeted', 'Normalized_Weighted_Cerebral_Peduncle_NonTargeted', 
'Normalized_Weighted_Medulla_Oblongata_Targeted', 'Normalized_Weighted_Medulla_Oblongata_NonTargeted'}, {DiffOBS{3}, 
DiffOBCS{3}, DiffOAS{3}, DiffOACS{3}, DiffLS{3}, DiffLCS{3}, DiffIS{3}, DiffICS{3}, DiffOLS{3}, DiffOLCS{3}, DiffTLS{3}, 
DiffTLCS{3}, DiffPLS{3}, DiffPLCS{3},  DiffFLS{3}, DiffFLCS{3}, DiffHFS{3}, DiffHFCS{3}, DiffANCS{3}, DiffANCCS{3}, 
DiffBGS{3}, DiffBGCS{3}, DiffBFS{3}, DiffBFCS{3}, DiffSS{3}, DiffSCS{3}, DiffHS{3}, DiffHCS{3}, DiffPS{3}, DiffPCS{3}, 
DiffTHS{3}, DiffTHCS{3}, DiffES{3}, DiffECS{3}, DiffCS{3}, DiffCCS{3}, DiffPS{3}, DiffPCS{3}, DiffTS{3}, DiffTCS{3}, DiffCPS{3}, 
DiffCPCS{3}, DiffMOS{3},DiffMOCS{3}}); 
 
%Matrix of all Specificity Indexes for the 174 ROIs 
    for i = 1:3; 
            SI174S(1,i)=ROI57S{i}; 
            SI174S(2,i)=ROI53S{i}; 
            SI174S(3,i)=ROI59S{i}; 
            SI174S(4,i)=ROI152S{i}; 
            SI174S(5,i)=ROI20S{i}; 
            SI174S(6,i)=ROI102S{i}; 
            SI174S(7,i)=ROI103S{i}; 
            SI174S(8,i)=ROI31S{i}; 
            SI174S(9,i)=ROI125S{i}; 
            SI174S(10,i)=ROI126S{i}; 
            SI174S(11,i)=ROI64S{i}; 
            SI174S(12,i)=ROI156S{i}; 
            SI174S(13,i)=ROI157S{i}; 
            SI174S(14,i)=ROI150S{i}; 
            SI174S(15,i)=ROI52S{i}; 
            SI174S(16,i)=ROI23S{i}; 
            SI174S(17,i)=ROI50S{i}; 
            SI174S(18,i)=ROI114S{i}; 
            SI174S(19,i)=ROI116S{i}; 
            SI174S(20,i)=ROI130S{i}; 
            SI174S(21,i)=ROI131S{i}; 
            SI174S(22,i)=ROI132S{i}; 
            SI174S(23,i)=ROI133S{i}; 
            SI174S(24,i)=ROI134S{i}; 
            SI174S(25,i)=ROI135S{i}; 
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            SI174S(26,i)=ROI136S{i}; 
            SI174S(27,i)=ROI137S{i}; 
            SI174S(28,i)=ROI166S{i}; 
            SI174S(29,i)=ROI88S{i}; 
            SI174S(30,i)=ROI75S{i}; 
            SI174S(31,i)=ROI63S{i}; 
            SI174S(32,i)=ROI115S{i}; 
            SI174S(33,i)=ROI55S{i}; 
            SI174S(34,i)=ROI79S{i}; 
            SI174S(35,i)=ROI80S{i}; 
            SI174S(36,i)=ROI25S{i}; 
            SI174S(37,i)=ROI26S{i}; 
            SI174S(38,i)=ROI27S{i}; 
            SI174S(39,i)=ROI28S{i}; 
            SI174S(40,i)=ROI29S{i}; 
            SI174S(41,i)=ROI48S{i}; 
            SI174S(42,i)=ROI170S{i}; 
            SI174S(43,i)=ROI40S{i}; 
            SI174S(44,i)=ROI41S{i}; 
            SI174S(45,i)=ROI24S{i}; 
            SI174S(46,i)=ROI30S{i}; 
            SI174S(47,i)=ROI15S{i}; 
            SI174S(48,i)=ROI68S{i}; 
            SI174S(49,i)=ROI61S{i}; 
            SI174S(50,i)=ROI35S{i}; 
            SI174S(51,i)=ROI83S{i}; 
            SI174S(52,i)=ROI49S{i}; 
            SI174S(53,i)=ROI42S{i}; 
            SI174S(54,i)=ROI44S{i}; 
            SI174S(55,i)=ROI162S{i}; 
            SI174S(56,i)=ROI165S{i}; 
            SI174S(57,i)=ROI153S{i}; 
            SI174S(58,i)=ROI16S{i}; 
            SI174S(59,i)=ROI17S{i}; 
            SI174S(60,i)=ROI58S{i}; 
            SI174S(61,i)=ROI167S{i}; 
            SI174S(62,i)=ROI146S{i}; 
            SI174S(63,i)=ROI174S{i}; 
            SI174S(64,i)=ROI111S{i}; 
            SI174S(65,i)=ROI51S{i}; 
            SI174S(66,i)=ROI139S{i}; 
            SI174S(67,i)=ROI33S{i}; 
            SI174S(68,i)=ROI145S{i}; 
            SI174S(69,i)=ROI78S{i}; 
            SI174S(70,i)=ROI151S{i}; 
            SI174S(71,i)=ROI91S{i}; 
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            SI174S(72,i)=ROI39S{i}; 
            SI174S(73,i)=ROI18S{i}; 
            SI174S(74,i)=ROI73S{i}; 
            SI174S(75,i)=ROI104S{i}; 
            SI174S(76,i)=ROI149S{i}; 
            SI174S(77,i)=ROI138S{i}; 
            SI174S(78,i)=ROI94S{i}; 
            SI174S(79,i)=ROI22S{i}; 
            SI174S(80,i)=ROI43S{i}; 
            SI174S(81,i)=ROI100S{i}; 
            SI174S(82,i)=ROI81S{i}; 
            SI174S(83,i)=ROI86S{i}; 
            SI174S(84,i)=ROI143S{i}; 
            SI174S(85,i)=ROI164S{i}; 
            SI174S(86,i)=ROI77S{i}; 
            SI174S(87,i)=ROI89S{i}; 
            SI174S(88,i)=ROI119S{i}; 
            SI174S(89,i)=ROI19S{i}; 
            SI174S(90,i)=ROI92S{i}; 
            SI174S(91,i)=ROI14S{i}; 
            SI174S(92,i)=ROI34S{i}; 
            SI174S(93,i)=ROI71S{i}; 
            SI174S(94,i)=ROI76S{i}; 
            SI174S(95,i)=ROI82S{i}; 
            SI174S(96,i)=ROI98S{i}; 
            SI174S(97,i)=ROI120S{i}; 
            SI174S(98,i)=ROI158S{i}; 
            SI174S(99,i)=ROI161S{i}; 
            SI174S(100,i)=ROI163S{i}; 
            SI174S(101,i)=ROI168S{i}; 
            SI174S(102,i)=ROI169S{i}; 
            SI174S(103,i)=ROI118S{i}; 
            SI174S(104,i)=ROI109S{i}; 
            SI174S(105,i)=ROI85S{i}; 
            SI174S(106,i)=ROI72S{i}; 
            SI174S(107,i)=ROI127S{i}; 
            SI174S(108,i)=ROI60S{i}; 
            SI174S(109,i)=ROI101S{i}; 
            SI174S(110,i)=ROI2S{i}; 
            SI174S(111,i)=ROI3S{i}; 
            SI174S(112,i)=ROI4S{i}; 
            SI174S(113,i)=ROI5S{i}; 
            SI174S(114,i)=ROI6S{i}; 
            SI174S(115,i)=ROI9S{i}; 
            SI174S(116,i)=ROI10S{i}; 
            SI174S(117,i)=ROI12S{i}; 
190 
 
            SI174S(118,i)=ROI13S{i}; 
            SI174S(119,i)=ROI1S{i}; 
            SI174S(120,i)=ROI65S{i}; 
            SI174S(121,i)=ROI140S{i}; 
            SI174S(122,i)=ROI36S{i}; 
            SI174S(123,i)=ROI99S{i}; 
            SI174S(124,i)=ROI37S{i}; 
            SI174S(125,i)=ROI38S{i}; 
            SI174S(126,i)=ROI54S{i}; 
            SI174S(127,i)=ROI69S{i}; 
            SI174S(128,i)=ROI84S{i}; 
            SI174S(129,i)=ROI105S{i}; 
            SI174S(130,i)=ROI106S{i}; 
            SI174S(131,i)=ROI7S{i}; 
            SI174S(132,i)=ROI112S{i}; 
            SI174S(133,i)=ROI45S{i}; 
            SI174S(134,i)=ROI154S{i}; 
            SI174S(135,i)=ROI74S{i}; 
            SI174S(136,i)=ROI129S{i}; 
            SI174S(137,i)=ROI93S{i}; 
            SI174S(138,i)=ROI110S{i}; 
            SI174S(139,i)=ROI107S{i}; 
            SI174S(140,i)=ROI108S{i}; 
            SI174S(141,i)=ROI56S{i}; 
            SI174S(142,i)=ROI96S{i}; 
            SI174S(143,i)=ROI8S{i}; 
            SI174S(144,i)=ROI11S{i}; 
            SI174S(145,i)=ROI70S{i}; 
            SI174S(146,i)=ROI148S{i}; 
            SI174S(147,i)=ROI87S{i}; 
            SI174S(148,i)=ROI62S{i}; 
            SI174S(149,i)=ROI147S{i}; 
            SI174S(150,i)=ROI21S{i}; 
            SI174S(151,i)=ROI90S{i}; 
            SI174S(152,i)=ROI141S{i}; 
            SI174S(153,i)=ROI142S{i}; 
            SI174S(154,i)=ROI124S{i}; 
            SI174S(155,i)=ROI171S{i}; 
            SI174S(156,i)=ROI67S{i}; 
            SI174S(157,i)=ROI95S{i}; 
            SI174S(158,i)=ROI32S{i}; 
            SI174S(159,i)=ROI128S{i}; 
            SI174S(160,i)=ROI117S{i}; 
            SI174S(161,i)=ROI47S{i}; 
            SI174S(162,i)=ROI121S{i}; 
            SI174S(163,i)=ROI66S{i}; 
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            SI174S(164,i)=ROI144S{i}; 
            SI174S(165,i)=ROI159S{i}; 
            SI174S(166,i)=ROI160S{i}; 
            SI174S(167,i)=ROI122S{i}; 
            SI174S(168,i)=ROI123S{i}; 
            SI174S(169,i)=ROI97S{i}; 
            SI174S(170,i)=ROI46S{i}; 
            SI174S(171,i)=ROI113S{i}; 
            SI174S(172,i)=ROI155S{i}; 
            SI174S(173,i)=ROI172S{i}; 
            SI174S(174,i)=ROI173S{i}; 
            disp(SI174S); 
    end 
            SI=cell(174,5); 
            SI(1:174,1:2)=ROI; 
            SI(1:174,3:5)=num2cell(SI174S); 
        for s=1:8 
            data_normalized1{k}(shorthandweighted{s}) = normalized1; 
            data_normalized2{k}(shorthandweighted{s}) = normalized2; 
            data_normalized3{k}(shorthandweighted{s}) = normalized3; 
        end 
        xlswrite((sprintf('Specificity Index Rat %d.csv', k)),SI); 
end 
Quartile Analysis 
QRTS1=quantile(cell2mat(SI174S{1}),[0.25 0.50 0.75]); disp(QRTS1); 
QRTS2=quantile(cell2mat(SI174S{2}),[0.25 0.50 0.75]); disp(QRTS2); 
QRTS3=quantile(cell2mat(SI174S{3}),[0.25 0.50 0.75]); disp(QRTS3); 
Making Arrays for T-Testing 
%calling normalized data from map 
for q=1:3 
    r=q; 
    TS1{r} = data_normalized1{q}('WS1T'); 
    TS2{r} = data_normalized2{q}('WS2T'); 
    TS3{r} = data_normalized3{q}('WS3T'); 
    NTS1{r} = data_normalized1{q}('WS1C'); 
    NTS2{r} = data_normalized2{q}('WS2C'); 
    NTS3{r} = data_normalized3{q}('WS3C'); 
end 
    %calls data for each of three scans Targeted v. Nontargeted 
    for t=1:3 
        %calls data for 22 larger regions from the 8 scans 
        for scan = 1:3 
            eval(sprintf('CTOBS%d{t} = TS%d{t}(''Normalized_Weighted_Olfactory_Bulb_Targeted'');',scan,scan)); 
            eval(sprintf('CNTOBS%d{t} = NTS%d{t}(''Normalized_Weighted_Olfactory_Bulb_NonTargeted'');',scan,scan)); 
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            eval(sprintf('CTOAS%d{t} = TS%d{t}(''Normalized_Weighted_Olfactory_Area_Targeted'');',scan,scan)); 
            eval(sprintf('CNTOAS%d{t} = NTS%d{t}(''Normalized_Weighted_Olfactory_Area_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTLS%d{t} = TS%d{t}(''Normalized_Weighted_Limbic_Lobe_Targeted'');',scan,scan)); 
            eval(sprintf('CNTLS%d{t} = NTS%d{t}(''Normalized_Weighted_Limbic_Lobe_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTIS%d{t} = TS%d{t}(''Normalized_Weighted_Insular_Cortex_Targeted'');',scan,scan)); 
            eval(sprintf('CNTIS%d{t} = NTS%d{t}(''Normalized_Weighted_Insular_Cortex_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTOLS%d{t} = TS%d{t}(''Normalized_Weighted_Ocipital_Lobe_Targeted'');',scan,scan)); 
            eval(sprintf('CNTOLS%d{t} = NTS%d{t}(''Normalized_Weighted_Ocipital_Lobe_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTTLS%d{t} = TS%d{t}(''Normalized_Weighted_Temporal_Lobe_Targeted'');',scan,scan)); 
            eval(sprintf('CNTTLS%d{t} = NTS%d{t}(''Normalized_Weighted_Temporal_Lobe_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTPLS%d{t} = TS%d{t}(''Normalized_Weighted_Parietal_Lobe_Targeted'');',scan,scan)); 
            eval(sprintf('CNTPLS%d{t} = NTS%d{t}(''Normalized_Weighted_Parietal_Lobe_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTFLS%d{t} = TS%d{t}(''Normalized_Weighted_Frontal_Lobe_Targeted'');',scan,scan)); 
            eval(sprintf('CNTFLS%d{t} = NTS%d{t}(''Normalized_Weighted_Frontal_Lobe_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTHFS%d{t} = TS%d{t}(''Normalized_Weighted_Hippocampal_Formation_Targeted'');',scan,scan)); 
            eval(sprintf('CNTHFS%d{t} = NTS%d{t}(''Normalized_Weighted_Hippocampal_Formation_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTANCS%d{t} = TS%d{t}(''Normalized_Weighted_Amygdaloid_Nuclear_Complex_Targeted'');',scan,scan)); 
            eval(sprintf('CNTANCS%d{t} = NTS%d{t}(''Normalized_Weighted_Amygdaloid_Nuclear_Complex_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTBGS%d{t} = TS%d{t}(''Normalized_Weighted_Basal_Ganglia_Targeted'');',scan,scan)); 
            eval(sprintf('CNTBGS%d{t} = NTS%d{t}(''Normalized_Weighted_Basal_Ganglia_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTBFS%d{t} = TS%d{t}(''Normalized_Weighted_Basal_Forebrain_Targeted'');',scan,scan)); 
            eval(sprintf('CNTBFS%d{t} = NTS%d{t}(''Normalized_Weighted_Basal_Forebrain_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTSS%d{t} = TS%d{t}(''Normalized_Weighted_Septum_Targeted'');',scan,scan)); 
            eval(sprintf('CNTSS%d{t} = NTS%d{t}(''Normalized_Weighted_Septum_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTHS%d{t} = TS%d{t}(''Normalized_Weighted_Hypothalamus_Targeted'');',scan,scan)); 
            eval(sprintf('CNTHS%d{t} = NTS%d{t}(''Normalized_Weighted_Hypothalamus_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTPTS%d{t} = TS%d{t}(''Normalized_Weighted_Pituitary_Targeted'');',scan,scan)); 
            eval(sprintf('CNTPTS%d{t} = NTS%d{t}(''Normalized_Weighted_Pituitary_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTTHS%d{t} = TS%d{t}(''Normalized_Weighted_Thalamus_Targeted'');',scan,scan)); 
            eval(sprintf('CNTTHS%d{t} = NTS%d{t}(''Normalized_Weighted_Thalamus_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTES%d{t} = TS%d{t}(''Normalized_Weighted_Epithalamus_Targeted'');',scan,scan)); 
            eval(sprintf('CNTES%d{t} = NTS%d{t}(''Normalized_Weighted_Epithalamus_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTCS%d{t} = TS%d{t}(''Normalized_Weighted_Cerebellum_Targeted'');',scan,scan)); 
            eval(sprintf('CNTCS%d{t} = NTS%d{t}(''Normalized_Weighted_Cerebellum_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTPS%d{t} = TS%d{t}(''Normalized_Weighted_Pons_Targeted'');',scan,scan)); 
            eval(sprintf('CNTPS%d{t} = NTS%d{t}(''Normalized_Weighted_Pons_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTTS%d{t} = TS%d{t}(''Normalized_Weighted_Tectum_Targeted'');',scan,scan)); 
            eval(sprintf('CNTTS%d{t} = NTS%d{t}(''Normalized_Weighted_Tectum_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTCPS%d{t} = TS%d{t}(''Normalized_Weighted_Cerebral_Peduncle_Targeted'');',scan,scan)); 
            eval(sprintf('CNTCPS%d{t} = NTS%d{t}(''Normalized_Weighted_Cerebral_Peduncle_NonTargeted'');',scan,scan)); 
            eval(sprintf('CTMOS%d{t} = TS%d{t}(''Normalized_Weighted_Medulla_Oblongata_Targeted'');',scan,scan)); 
            eval(sprintf('CNTMOS%d{t} = NTS%d{t}(''Normalized_Weighted_Medulla_Oblongata_NonTargeted'');',scan,scan)); 
        end 
    end 
    %makes array of the scana data for same scan but all three rats 
for scan=1:3 
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    eval(sprintf('OBTS%d = cell(3,3)',scan)); 
    eval(sprintf('OBNTS%d = cell(3,3)',scan)); 
    eval(sprintf('OATS%d = cell(4,3)',scan)); 
    eval(sprintf('OANTS%d = cell(4,3)',scan)); 
    eval(sprintf('LTS%d = cell(3,3)',scan)); 
    eval(sprintf('LNTS%d = cell(3,3)',scan)); 
    eval(sprintf('ITS%d = cell(1,3)',scan)); 
    eval(sprintf('INTS%d = cell(1,3)',scan)); 
    eval(sprintf('OLTS%d = cell(2,3)',scan)); 
    eval(sprintf('OLNTS%d = cell(2,3)',scan)); 
    eval(sprintf('TLTS%d = cell(5,3)',scan)); 
    eval(sprintf('TLNTS%d = cell(5,3)',scan)); 
    eval(sprintf('PLTS%d = cell(9,3)',scan)); 
    eval(sprintf('PLNTS%d = cell(9,3)',scan)); 
    eval(sprintf('FLTS%d = cell(8,3)',scan)); 
    eval(sprintf('FLNTS%d = cell(8,3)',scan)); 
    eval(sprintf('HFTS%d = cell(9,3)',scan)); 
    eval(sprintf('HFNTS%d = cell(9,3)',scan)); 
    eval(sprintf('ANCTS%d = cell(8,3)',scan)); 
    eval(sprintf('ANCNTS%d = cell(8,3)',scan)); 
    eval(sprintf('BGTS%d = cell(13,3)',scan)); 
    eval(sprintf('BGNTS%d = cell(13,3)',scan)); 
    eval(sprintf('BFTS%d = cell(5,3)',scan)); 
    eval(sprintf('BFNTS%d = cell(5,3)',scan)); 
    eval(sprintf('STS%d = cell(2,3)',scan)); 
    eval(sprintf('SNTS%d = cell(2,3)',scan)); 
    eval(sprintf('HTS%d = cell(16,3)',scan)); 
    eval(sprintf('HNTS%d = cell(16,3)',scan)); 
    eval(sprintf('PTTS%d = cell(2,3)',scan)); 
    eval(sprintf('PTNTS%d = cell(2,3)',scan)); 
    eval(sprintf('THTS%d = cell(17,3)',scan)); 
    eval(sprintf('THNTS%d = cell(17,3)',scan)); 
    eval(sprintf('ETS%d = cell(2,3)',scan)); 
    eval(sprintf('ENTS%d = cell(2,3)',scan)); 
    eval(sprintf('CTS%d = cell(20,3)',scan)); 
    eval(sprintf('CNTS%d = cell(20,3)',scan)); 
    eval(sprintf('PTS%d = cell(18,3)',scan)); 
    eval(sprintf('PNTS%d = cell(18,3)',scan)); 
    eval(sprintf('TTS%d = cell(2,3)',scan)); 
    eval(sprintf('TNTS%d = cell(2,3)',scan)); 
    eval(sprintf('CPTS%d = cell(13,3)',scan)); 
    eval(sprintf('CPNTS%d = cell(13,3)',scan)); 
    eval(sprintf('MOTS%d = cell(12,3)',scan)); 
    eval(sprintf('MONTS%d = cell(12,3)',scan)); 
end 
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    for a=1:3 
       %Olfactory Bulb 
        OBTS1(a,:) = [CTOBS1{1}(a,1), CTOBS1{2}(a,1), CTOBS1{3}(a,1)]; 
        OBNTS1(a,:) =[CNTOBS1{1}(a,1), CNTOBS1{2}(a,1), CNTOBS1{3}(a,1)]; 
        OBTS2(a,:) = [CTOBS2{1}(a,1), CTOBS2{2}(a,1), CTOBS2{3}(a,1)]; 
        OBNTS2(a,:) =[CNTOBS2{1}(a,1), CNTOBS2{2}(a,1), CNTOBS2{3}(a,1)]; 
        OBTS3(a,:) = [CTOBS3{1}(a,1), CTOBS3{2}(a,1), CTOBS3{3}(a,1)]; 
        OBNTS3(a,:) =[CNTOBS3{1}(a,1), CNTOBS3{2}(a,1), CNTOBS3{3}(a,1)]; 
        [hOBS1,pOBS1(a)] = ttest2(cell2mat(OBTS1(a,:)),cell2mat(OBNTS1(a,:))); 
        [hOBS2,pOBS2(a)] = ttest2(cell2mat(OBTS2(a,:)),cell2mat(OBNTS2(a,:))); 
        [hOBS3,pOBS3(a)] = ttest2(cell2mat(OBTS3(a,:)),cell2mat(OBNTS3(a,:))); 
              %loop for all 22 regions but make a loop for each array size 
       %Limbic Lobe becuase it also has 3 ROI's in it 
        LTS1(a,:) = [CTLS1{1}(a,1), CTLS1{2}(a,1), CTLS1{3}(a,1)]; 
        LNTS1(a,:) =[CNTLS1{1}(a,1), CNTLS1{2}(a,1), CNTLS1{3}(a,1)]; 
        LTS2(a,:) = [CTLS2{1}(a,1), CTLS2{2}(a,1), CTLS2{3}(a,1)]; 
        LNTS2(a,:) =[CNTLS2{1}(a,1), CNTLS2{2}(a,1), CNTLS2{3}(a,1)]; 
        LTS3(a,:) = [CTLS3{1}(a,1), CTLS3{2}(a,1), CTLS3{3}(a,1)]; 
        LNTS3(a,:) =[CNTLS3{1}(a,1), CNTLS3{2}(a,1), CNTLS3{3}(a,1)]; 
        [hLS1,pLS1(a)] = ttest2(cell2mat(LTS1(a,:)),cell2mat(LNTS1(a,:))); 
        [hLS2,pLS2(a)] = ttest2(cell2mat(LTS2(a,:)),cell2mat(LNTS2(a,:))); 
        [hLS3,pLS3(a)] = ttest2(cell2mat(LTS3(a,:)),cell2mat(LNTS3(a,:))); 
    end 
    for b=1:4 
        OATS1(b,:) = [CTOAS1{1}(b,1), CTOAS1{2}(b,1), CTOAS1{3}(b,1)]; 
        OANTS1(b,:) =[CNTOAS1{1}(b,1), CNTOAS1{2}(b,1), CNTOAS1{3}(b,1)]; 
        OATS2(b,:) = [CTOAS2{1}(b,1), CTOAS2{2}(b,1), CTOAS2{3}(b,1)]; 
        OANTS2(b,:) =[CNTOAS2{1}(b,1), CNTOAS2{2}(b,1), CNTOAS2{3}(b,1)]; 
        OATS3(b,:) = [CTOAS3{1}(b,1), CTOAS3{2}(b,1), CTOAS3{3}(b,1)]; 
        OANTS3(b,:) =[CNTOAS3{1}(b,1), CNTOAS3{2}(b,1), CNTOAS3{3}(b,1)]; 
        [hOAS1,pOAS1(b)] = ttest2(cell2mat(OATS1(b,:)),cell2mat(OANTS1(b,:))); 
        [hOAS2,pOAS2(b)] = ttest2(cell2mat(OATS2(b,:)),cell2mat(OANTS2(b,:))); 
        [hOAS3,pOAS3(b)] = ttest2(cell2mat(OATS3(b,:)),cell2mat(OANTS3(b,:))); 
    end 
    ITS1(1,:) = [CTIS1{1}(1,1), CTIS1{2}(1,1), CTIS1{3}(1,1)]; 
    INTS1(1,:) =[CNTIS1{1}(1,1), CNTIS1{2}(1,1), CNTIS1{3}(1,1)]; 
    ITS2(1,:) = [CTIS2{1}(1,1), CTIS2{2}(1,1), CTIS2{3}(1,1)]; 
    INTS2(1,:) =[CNTIS2{1}(1,1), CNTIS2{2}(1,1), CNTIS2{3}(1,1)]; 
    ITS3(1,:) = [CTIS3{1}(1,1), CTIS3{2}(1,1), CTIS3{3}(1,1)]; 
    INTS3(1,:) =[CNTIS3{1}(1,1), CNTIS3{2}(1,1), CNTIS3{3}(1,1)]; 
    %[hIS1,pIS1(1)] = ttest2(cell2mat(ITS1(1,:)),cell2mat(INTS1(1,:))); 
    %[hIS2,pIS2(1)] = ttest2(cell2mat(ITS2(1,:)),cell2mat(INTS2(1,:))); 
    %[hIS3,pIS3(1)] = ttest2(cell2mat(ITS3(1,:)),cell2mat(INTS3(1,:))); 
    for c=1:2 
        OLTS1(c,:) = [CTOLS1{1}(c,1), CTOLS1{2}(c,1), CTOLS1{3}(c,1)]; 
        OLNTS1(c,:) =[CNTOLS1{1}(c,1), CNTOLS1{2}(c,1), CNTOLS1{3}(c,1)]; 
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        OLTS2(c,:) = [CTOLS2{1}(c,1), CTOLS2{2}(c,1), CTOLS2{3}(c,1)]; 
        OLNTS2(c,:) =[CNTOLS2{1}(c,1), CNTOLS2{2}(c,1), CNTOLS2{3}(c,1)]; 
        OLTS3(c,:) = [CTOLS3{1}(c,1), CTOLS3{2}(c,1), CTOLS3{3}(c,1)]; 
        OLNTS3(c,:) =[CNTOLS3{1}(c,1), CNTOLS3{2}(c,1), CNTOLS3{3}(c,1)]; 
        [hOLS1,pOLS1(c)] = ttest2(cell2mat(OLTS1(c,:)),cell2mat(OLNTS1(c,:))); 
        [hOLS2,pOLS2(c)] = ttest2(cell2mat(OLTS2(c,:)),cell2mat(OLNTS2(c,:))); 
        [hOLS3,pOLS3(c)] = ttest2(cell2mat(OLTS3(c,:)),cell2mat(OLNTS3(c,:))); 
        %septum 
        STS1(c,:) = [CTSS1{1}(c,1), CTSS1{2}(c,1), CTSS1{3}(c,1)]; 
        SNTS1(c,:) =[CNTSS1{1}(c,1), CNTSS1{2}(c,1), CNTSS1{3}(c,1)]; 
        STS2(c,:) = [CTSS2{1}(c,1), CTSS2{2}(c,1), CTSS2{3}(c,1)]; 
        SNTS2(c,:) =[CNTSS2{1}(c,1), CNTSS2{2}(c,1), CNTSS2{3}(c,1)]; 
        STS3(c,:) = [CTSS3{1}(c,1), CTSS3{2}(c,1), CTSS3{3}(c,1)]; 
        SNTS3(c,:) =[CNTSS3{1}(c,1), CNTSS3{2}(c,1), CNTSS3{3}(c,1)]; 
        [hSS1,pSS1(c)] = ttest2(cell2mat(STS1(c,:)),cell2mat(SNTS1(c,:))); 
        [hSS2,pSS2(c)] = ttest2(cell2mat(STS2(c,:)),cell2mat(SNTS2(c,:))); 
        [hSS3,pSS3(c)] = ttest2(cell2mat(STS3(c,:)),cell2mat(SNTS3(c,:))); 
        %PT 
        PTTS1(c,:) = [CTPTS1{1}(c,1), CTPTS1{2}(c,1), CTPTS1{3}(c,1)]; 
        PTNTS1(c,:) =[CNTPTS1{1}(c,1), CNTPTS1{2}(c,1), CNTPTS1{3}(c,1)]; 
        PTTS2(c,:) = [CTPTS2{1}(c,1), CTPTS2{2}(c,1), CTPTS2{3}(c,1)]; 
        PTNTS2(c,:) =[CNTPTS2{1}(c,1), CNTPTS2{2}(c,1), CNTPTS2{3}(c,1)]; 
        PTTS3(c,:) = [CTPTS3{1}(c,1), CTPTS3{2}(c,1), CTPTS3{3}(c,1)]; 
        PTNTS3(c,:) =[CNTPTS3{1}(c,1), CNTPTS3{2}(c,1), CNTPTS3{3}(c,1)]; 
        [hPTS1,pPTS1(c)] = ttest2(cell2mat(PTTS1(c,:)),cell2mat(PTNTS1(c,:))); 
        [hPTS2,pPTS2(c)] = ttest2(cell2mat(PTTS2(c,:)),cell2mat(PTNTS2(c,:))); 
        [hPTS3,pPTS3(c)] = ttest2(cell2mat(PTTS3(c,:)),cell2mat(PTNTS3(c,:))); 
        %epithalmus 
        ETS1(c,:) = [CTES1{1}(c,1), CTES1{2}(c,1), CTES1{3}(c,1)]; 
        ENTS1(c,:) =[CNTES1{1}(c,1), CNTES1{2}(c,1), CNTES1{3}(c,1)]; 
        ETS2(c,:) = [CTES2{1}(c,1), CTES2{2}(c,1), CTES2{3}(c,1)]; 
        ENTS2(c,:) =[CNTES2{1}(c,1), CNTES2{2}(c,1), CNTES2{3}(c,1)]; 
        ETS3(c,:) = [CTES3{1}(c,1), CTES3{2}(c,1), CTES3{3}(c,1)]; 
        ENTS3(c,:) =[CNTES3{1}(c,1), CNTES3{2}(c,1), CNTES3{3}(c,1)]; 
        [hES1,pES1(c)] = ttest2(cell2mat(ETS1(c,:)),cell2mat(ENTS1(c,:))); 
        [hES2,pES2(c)] = ttest2(cell2mat(ETS2(c,:)),cell2mat(ENTS2(c,:))); 
        [hES3,pES3(c)] = ttest2(cell2mat(ETS3(c,:)),cell2mat(ENTS3(c,:))); 
        %tectum 
        TTS1(c,:) = [CTTS1{1}(c,1), CTTS1{2}(c,1), CTTS1{3}(c,1)]; 
        TNTS1(c,:) =[CNTTS1{1}(c,1), CNTTS1{2}(c,1), CNTTS1{3}(c,1)]; 
        TTS2(c,:) = [CTTS2{1}(c,1), CTTS2{2}(c,1), CTTS2{3}(c,1)]; 
        TNTS2(c,:) =[CNTTS2{1}(c,1), CNTTS2{2}(c,1), CNTTS2{3}(c,1)]; 
        TTS3(c,:) = [CTTS3{1}(c,1), CTTS3{2}(c,1), CTTS3{3}(c,1)]; 
        TNTS3(c,:) =[CNTTS3{1}(c,1), CNTTS3{2}(c,1), CNTTS3{3}(c,1)]; 
        [hTS1,pTS1(c)] = ttest2(cell2mat(TTS1(c,:)),cell2mat(TNTS1(c,:))); 
        [hTS2,pTS2(c)] = ttest2(cell2mat(TTS2(c,:)),cell2mat(TNTS2(c,:))); 
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        [hTS3,pTS3(c)] = ttest2(cell2mat(TTS3(c,:)),cell2mat(TNTS3(c,:))); 
    end 
    for d=1:5 
        TLTS1(d,:) = [CTTLS1{1}(d,1), CTTLS1{2}(d,1), CTTLS1{3}(d,1)]; 
        TLNTS1(d,:) =[CNTTLS1{1}(d,1), CNTTLS1{2}(d,1), CNTTLS1{3}(d,1)]; 
        TLTS2(d,:) = [CTTLS2{1}(d,1), CTTLS2{2}(d,1), CTTLS2{3}(d,1)]; 
        TLNTS2(d,:) =[CNTTLS2{1}(d,1), CNTTLS2{2}(d,1), CNTTLS2{3}(d,1)]; 
        TLTS3(d,:) = [CTTLS3{1}(d,1), CTTLS3{2}(d,1), CTTLS3{3}(d,1)]; 
        TLNTS3(d,:) =[CNTTLS3{1}(d,1), CNTTLS3{2}(d,1), CNTTLS3{3}(d,1)]; 
        [hTLS1,pTLS1(d)] = ttest2(cell2mat(TLTS1(d,:)),cell2mat(TLNTS1(d,:))); 
        [hTLS2,pTLS2(d)] = ttest2(cell2mat(TLTS2(d,:)),cell2mat(TLNTS2(d,:))); 
        [hTLS3,pTLS3(d)] = ttest2(cell2mat(TLTS3(d,:)),cell2mat(TLNTS3(d,:))); 
        %Basal Forebrain 
        BFTS1(d,:) = [CTBFS1{1}(d,1), CTBFS1{2}(d,1), CTBFS1{3}(d,1)]; 
        BFNTS1(d,:) =[CNTBFS1{1}(d,1), CNTBFS1{2}(d,1), CNTBFS1{3}(d,1)]; 
        BFTS2(d,:) = [CTBFS2{1}(d,1), CTBFS2{2}(d,1), CTBFS2{3}(d,1)]; 
        BFNTS2(d,:) =[CNTBFS2{1}(d,1), CNTBFS2{2}(d,1), CNTBFS2{3}(d,1)]; 
        BFTS3(d,:) = [CTBFS3{1}(d,1), CTBFS3{2}(d,1), CTBFS3{3}(d,1)]; 
        BFNTS3(d,:) =[CNTBFS3{1}(d,1), CNTBFS3{2}(d,1), CNTBFS3{3}(d,1)]; 
        [hBFS1,pBFS1(d)] = ttest2(cell2mat(BFTS1(d,:)),cell2mat(BFNTS1(d,:))); 
        [hBFS2,pBFS2(d)] = ttest2(cell2mat(BFTS2(d,:)),cell2mat(BFNTS2(d,:))); 
        [hBFS3,pBFS3(d)] = ttest2(cell2mat(BFTS3(d,:)),cell2mat(BFNTS3(d,:))); 
    end 
    for e=1:9 
        PLTS1(e,:) = [CTPLS1{1}(e,1), CTPLS1{2}(e,1), CTPLS1{3}(e,1)]; 
        PLNTS1(e,:) =[CNTPLS1{1}(e,1), CNTPLS1{2}(e,1), CNTPLS1{3}(e,1)]; 
        PLTS2(e,:) = [CTPLS2{1}(e,1), CTPLS2{2}(e,1), CTPLS2{3}(e,1)]; 
        PLNTS2(e,:) =[CNTPLS2{1}(e,1), CNTPLS2{2}(e,1), CNTPLS2{3}(e,1)]; 
        PLTS3(e,:) = [CTPLS3{1}(e,1), CTPLS3{2}(e,1), CTPLS3{3}(e,1)]; 
        PLNTS3(e,:) =[CNTPLS3{1}(e,1), CNTPLS3{2}(e,1), CNTPLS3{3}(e,1)]; 
        [hPLS1,pPLS1(e)] = ttest2(cell2mat(PLTS1(e,:)),cell2mat(PLNTS1(e,:))); 
        [hPLS2,pPLS2(e)] = ttest2(cell2mat(PLTS2(e,:)),cell2mat(PLNTS2(e,:))); 
        [hPLS3,pPLS3(e)] = ttest2(cell2mat(PLTS3(e,:)),cell2mat(PLNTS3(e,:))); 
        %Hippocampul Formation 
        HFTS1(e,:) = [CTHFS1{1}(e,1), CTHFS1{2}(e,1), CTHFS1{3}(e,1)]; 
        HFNTS1(e,:) =[CNTHFS1{1}(e,1), CNTHFS1{2}(e,1), CNTHFS1{3}(e,1)]; 
        HFTS2(e,:) = [CTHFS2{1}(e,1), CTHFS2{2}(e,1), CTHFS2{3}(e,1)]; 
        HFNTS2(e,:) =[CNTHFS2{1}(e,1), CNTHFS2{2}(e,1), CNTHFS2{3}(e,1)]; 
        HFTS3(e,:) = [CTHFS3{1}(e,1), CTHFS3{2}(e,1), CTHFS3{3}(e,1)]; 
        HFNTS3(e,:) =[CNTHFS3{1}(e,1), CNTHFS3{2}(e,1), CNTHFS3{3}(e,1)]; 
        [hHFS1,pHFS1(e)] = ttest2(cell2mat(HFTS1(e,:)),cell2mat(HFNTS1(e,:))); 
        [hHFS2,pHFS2(e)] = ttest2(cell2mat(HFTS2(e,:)),cell2mat(HFNTS2(e,:))); 
        [hHFS3,pHFS3(e)] = ttest2(cell2mat(HFTS3(e,:)),cell2mat(HFNTS3(e,:))); 
    end 
     for f=1:8 
        FLTS1(f,:) = [CTFLS1{1}(f,1), CTFLS1{2}(f,1), CTFLS1{3}(f,1)]; 
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        FLNTS1(f,:) =[CNTFLS1{1}(f,1), CNTFLS1{2}(f,1), CNTFLS1{3}(f,1)]; 
        FLTS2(f,:) = [CTFLS2{1}(f,1), CTFLS2{2}(f,1), CTFLS2{3}(f,1)]; 
        FLNTS2(f,:) =[CNTFLS2{1}(f,1), CNTFLS2{2}(f,1), CNTFLS2{3}(f,1)]; 
        FLTS3(f,:) = [CTFLS3{1}(f,1), CTFLS3{2}(f,1), CTFLS3{3}(f,1)]; 
        FLNTS3(f,:) =[CNTFLS3{1}(f,1), CNTFLS3{2}(f,1), CNTFLS3{3}(f,1)]; 
        [hFLS1,pFLS1(f)] = ttest2(cell2mat(FLTS1(f,:)),cell2mat(FLNTS1(f,:))); 
        [hFLS2,pFLS2(f)] = ttest2(cell2mat(FLTS2(f,:)),cell2mat(FLNTS2(f,:))); 
        [hFLS3,pFLS3(f)] = ttest2(cell2mat(FLTS3(f,:)),cell2mat(FLNTS3(f,:))); 
        %ANC 
        ANCTS1(f,:) = [CTANCS1{1}(f,1), CTANCS1{2}(f,1), CTANCS1{3}(f,1)]; 
        ANCNTS1(f,:) =[CNTANCS1{1}(f,1), CNTANCS1{2}(f,1), CNTANCS1{3}(f,1)]; 
        ANCTS2(f,:) = [CTANCS2{1}(f,1), CTANCS2{2}(f,1), CTANCS2{3}(f,1)]; 
        ANCNTS2(f,:) =[CNTANCS2{1}(f,1), CNTANCS2{2}(f,1), CNTANCS2{3}(f,1)]; 
        ANCTS3(f,:) = [CTANCS3{1}(f,1), CTANCS3{2}(f,1), CTANCS3{3}(f,1)]; 
        ANCNTS3(f,:) =[CNTANCS3{1}(f,1), CNTANCS3{2}(f,1), CNTANCS3{3}(f,1)]; 
        [hANCS1,pANCS1(f)] = ttest2(cell2mat(ANCTS1(f,:)),cell2mat(ANCNTS1(f,:))); 
        [hANCS2,pANCS2(f)] = ttest2(cell2mat(ANCTS2(f,:)),cell2mat(ANCNTS2(f,:))); 
        [hANCS3,pANCS3(f)] = ttest2(cell2mat(ANCTS3(f,:)),cell2mat(ANCNTS3(f,:))); 
     end 
    for g=1:13 
        BGTS1(g,:) = [CTBGS1{1}(g,1), CTBGS1{2}(g,1), CTBGS1{3}(g,1)]; 
        BGNTS1(g,:) =[CNTBGS1{1}(g,1), CNTBGS1{2}(g,1), CNTBGS1{3}(g,1)]; 
        BGTS2(g,:) = [CTBGS2{1}(g,1), CTBGS2{2}(g,1), CTBGS2{3}(g,1)]; 
        BGNTS2(g,:) =[CNTBGS2{1}(g,1), CNTBGS2{2}(g,1), CNTBGS2{3}(g,1)]; 
        BGTS3(g,:) = [CTBGS3{1}(g,1), CTBGS3{2}(g,1), CTBGS3{3}(g,1)]; 
        BGNTS3(g,:) =[CNTBGS3{1}(g,1), CNTBGS3{2}(g,1), CNTBGS3{3}(g,1)]; 
        [hBGS1,pBGS1(g)] = ttest2(cell2mat(BGTS1(g,:)),cell2mat(BGNTS1(g,:))); 
        [hBGS2,pBGS2(g)] = ttest2(cell2mat(BGTS2(g,:)),cell2mat(BGNTS2(g,:))); 
        [hBGS3,pBGS3(g)] = ttest2(cell2mat(BGTS3(g,:)),cell2mat(BGNTS3(g,:))); 
        %cerebellum 
         CPTS1(g,:) = [CTCPS1{1}(g,1), CTCPS1{2}(g,1), CTCPS1{3}(g,1)]; 
        CPNTS1(g,:) =[CNTCPS1{1}(g,1), CNTCPS1{2}(g,1), CNTCPS1{3}(g,1)]; 
        CPTS2(g,:) = [CTCPS2{1}(g,1), CTCPS2{2}(g,1), CTCPS2{3}(g,1)]; 
        CPNTS2(g,:) =[CNTCPS2{1}(g,1), CNTCPS2{2}(g,1), CNTCPS2{3}(g,1)]; 
        CPTS3(g,:) = [CTCPS3{1}(g,1), CTCPS3{2}(g,1), CTCPS3{3}(g,1)]; 
        CPNTS3(g,:) =[CNTCPS3{1}(g,1), CNTCPS3{2}(g,1), CNTCPS3{3}(g,1)]; 
        [hCPS1,pCPS1(g)] = ttest2(cell2mat(CPTS1(g,:)),cell2mat(CPNTS1(g,:))); 
        [hCPS2,pCPS2(g)] = ttest2(cell2mat(CPTS2(g,:)),cell2mat(CPNTS2(g,:))); 
        [hCPS3,pCPS3(g)] = ttest2(cell2mat(CPTS3(g,:)),cell2mat(CPNTS3(g,:))); 
    end 
    for h=1:16 
        HTS1(h,:) = [CTHS1{1}(h,1), CTHS1{2}(h,1), CTHS1{3}(h,1)]; 
        HNTS1(h,:) =[CNTHS1{1}(h,1), CNTHS1{2}(h,1), CNTHS1{3}(h,1)]; 
        HTS2(h,:) = [CTHS2{1}(h,1), CTHS2{2}(h,1), CTHS2{3}(h,1)]; 
        HNTS2(h,:) =[CNTHS2{1}(h,1), CNTHS2{2}(h,1), CNTHS2{3}(h,1)]; 
        HTS3(h,:) = [CTHS3{1}(h,1), CTHS3{2}(h,1), CTHS3{3}(h,1)]; 
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        HNTS3(h,:) =[CNTHS3{1}(h,1), CNTHS3{2}(h,1), CNTHS3{3}(h,1)]; 
        [hHS1,pHS1(h)] = ttest2(cell2mat(HTS1(h,:)),cell2mat(HNTS1(h,:))); 
        [hHS2,pHS2(h)] = ttest2(cell2mat(HTS2(h,:)),cell2mat(HNTS2(h,:))); 
        [hHS3,pHS3(h)] = ttest2(cell2mat(HTS3(h,:)),cell2mat(HNTS3(h,:))); 
    end 
    for i=1:17 
        THTS1(i,:) = [CTTHS1{1}(i,1), CTTHS1{2}(i,1), CTTHS1{3}(i,1)]; 
        THNTS1(i,:) =[CNTTHS1{1}(i,1), CNTTHS1{2}(i,1), CNTTHS1{3}(i,1)]; 
        THTS2(i,:) = [CTTHS2{1}(i,1), CTTHS2{2}(i,1), CTTHS2{3}(i,1)]; 
        THNTS2(i,:) =[CNTTHS2{1}(i,1), CNTTHS2{2}(i,1), CNTTHS2{3}(i,1)]; 
        THTS3(i,:) = [CTTHS3{1}(i,1), CTTHS3{2}(i,1), CTTHS3{3}(i,1)]; 
        THNTS3(i,:) =[CNTTHS3{1}(i,1), CNTTHS3{2}(i,1), CNTTHS3{3}(i,1)]; 
        [hTHS1,pTHS1(i)] = ttest2(cell2mat(THTS1(i,:)),cell2mat(THNTS1(i,:))); 
        [hTHS2,pTHS2(i)] = ttest2(cell2mat(THTS2(i,:)),cell2mat(THNTS2(i,:))); 
        [hTHS3,pTHS3(i)] = ttest2(cell2mat(THTS3(i,:)),cell2mat(THNTS3(i,:))); 
    end 
    for j=1:20 
        CTS1(j,:) = [CTCS1{1}(j,1), CTCS1{2}(j,1), CTCS1{3}(j,1)]; 
        CNTS1(j,:) =[CNTCS1{1}(j,1), CNTCS1{2}(j,1), CNTCS1{3}(j,1)]; 
        CTS2(j,:) = [CTCS2{1}(j,1), CTCS2{2}(j,1), CTCS2{3}(j,1)]; 
        CNTS2(j,:) =[CNTCS2{1}(j,1), CNTCS2{2}(j,1), CNTCS2{3}(j,1)]; 
        CTS3(j,:) = [CTCS3{1}(j,1), CTCS3{2}(j,1), CTCS3{3}(j,1)]; 
        CNTS3(j,:) =[CNTCS3{1}(j,1), CNTCS3{2}(j,1), CNTCS3{3}(j,1)]; 
        [hCS1,pCS1(j)] = ttest2(cell2mat(CTS1(j,:)),cell2mat(CNTS1(j,:))); 
        [hCS2,pCS2(j)] = ttest2(cell2mat(CTS2(j,:)),cell2mat(CNTS2(j,:))); 
        [hCS3,pCS3(j)] = ttest2(cell2mat(CTS3(j,:)),cell2mat(CNTS3(j,:))); 
    end 
    for k=1:18 
        PTS1(k,:) = [CTPS1{1}(k,1), CTPS1{2}(k,1), CTPS1{3}(k,1)]; 
        PNTS1(k,:) =[CNTPS1{1}(k,1), CNTPS1{2}(k,1), CNTPS1{3}(k,1)]; 
        PTS2(k,:) = [CTPS2{1}(k,1), CTPS2{2}(k,1), CTPS2{3}(k,1)]; 
        PNTS2(k,:) =[CNTPS2{1}(k,1), CNTPS2{2}(k,1), CNTPS2{3}(k,1)]; 
        PTS3(k,:) = [CTPS3{1}(k,1), CTPS3{2}(k,1), CTPS3{3}(k,1)]; 
        PNTS3(k,:) =[CNTPS3{1}(k,1), CNTPS3{2}(k,1), CNTPS3{3}(k,1)]; 
        [hPS1,pPS1(k)] = ttest2(cell2mat(PTS1(k,:)),cell2mat(PNTS1(k,:))); 
        [hPS2,pPS2(k)] = ttest2(cell2mat(PTS2(k,:)),cell2mat(PNTS2(k,:))); 
        [hPS3,pPS3(k)] = ttest2(cell2mat(PTS3(k,:)),cell2mat(PNTS3(k,:))); 
    end 
    for m=1:12 
        MOTS1(m,:) = [CTMOS1{1}(m,1), CTMOS1{2}(m,1), CTMOS1{3}(m,1)]; 
        MONTS1(m,:) =[CNTMOS1{1}(m,1), CNTMOS1{2}(m,1), CNTMOS1{3}(m,1)]; 
        MOTS2(m,:) = [CTMOS2{1}(m,1), CTMOS2{2}(m,1), CTMOS2{3}(m,1)]; 
        MONTS2(m,:) =[CNTMOS2{1}(m,1), CNTMOS2{2}(m,1), CNTMOS2{3}(m,1)]; 
        MOTS3(m,:) = [CTMOS3{1}(m,1), CTMOS3{2}(m,1), CTMOS3{3}(m,1)]; 
        MONTS3(m,:) =[CNTMOS3{1}(m,1), CNTMOS3{2}(m,1), CNTMOS3{3}(m,1)]; 
        [hMOS1,pMOS1(m)] = ttest2(cell2mat(MOTS1(m,:)),cell2mat(MONTS1(m,:))); 
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        [hMOS2,pMOS2(m)] = ttest2(cell2mat(MOTS2(m,:)),cell2mat(MONTS2(m,:))); 
        [hMOS3,pMOS3(m)] = ttest2(cell2mat(MOTS3(m,:)),cell2mat(MONTS3(m,:))); 
    end 
T Tests 
pvalues1=cell(1,174); 
pvalues1(1,1:3)=num2cell(pOBS1); 
pvalues1(1,4:7)=num2cell(pOAS1); 
pvalues1(1,8:10)=num2cell(pLS1); 
%pvalues1(1,11)=num2cell(pIS1); %need to fix insular cortext t test above! 
pvalues1(1,12:13)=num2cell(pOLS1); 
pvalues1(1,14:18)=num2cell(pTLS1); 
pvalues1(1,19:27)=num2cell(pPLS1); 
pvalues1(1,28:35)=num2cell(pFLS1); 
pvalues1(1,36:44)=num2cell(pHFS1); 
pvalues1(1,45:52)=num2cell(pANCS1); 
pvalues1(1,53:65)=num2cell(pBGS1); 
pvalues1(1,66:70)=num2cell(pBFS1); 
pvalues1(1,71:72)=num2cell(pSS1); 
pvalues1(1,73:88)=num2cell(pHS1); 
pvalues1(1,89:90)=num2cell(pPTS1); 
pvalues1(1,91:107)=num2cell(pTHS1); 
pvalues1(1,108:109)=num2cell(pES1); 
pvalues1(1,110:129)=num2cell(pCS1); 
pvalues1(1,130:147)=num2cell(pPS1); 
pvalues1(1,148:149)=num2cell(pTS1); 
pvalues1(1,150:162)=num2cell(pCPS1); 
pvalues1(1,163:174)=num2cell(pMOS1); 
PV1=transpose(pvalues1); 
pvalues2=cell(1,174); 
pvalues2(1,1:3)=num2cell(pOBS2); 
pvalues2(1,4:7)=num2cell(pOAS2); 
pvalues2(1,8:10)=num2cell(pLS2); 
%pvalues2(1,11)=num2cell(pIS2); 
pvalues2(1,12:13)=num2cell(pOLS2); 
pvalues2(1,14:18)=num2cell(pTLS2); 
pvalues2(1,19:27)=num2cell(pPLS2); 
pvalues2(1,28:35)=num2cell(pFLS2); 
pvalues2(1,36:44)=num2cell(pHFS2); 
pvalues2(1,45:52)=num2cell(pANCS2); 
pvalues2(1,53:65)=num2cell(pBGS2); 
pvalues2(1,66:70)=num2cell(pBFS2); 
pvalues2(1,71:72)=num2cell(pSS2); 
pvalues2(1,73:88)=num2cell(pHS2); 
pvalues2(1,89:90)=num2cell(pPTS2); 
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pvalues2(1,91:107)=num2cell(pTHS2); 
pvalues2(1,108:109)=num2cell(pES2); 
pvalues2(1,110:129)=num2cell(pCS2); 
pvalues2(1,130:147)=num2cell(pPS2); 
pvalues2(1,148:149)=num2cell(pTS2); 
pvalues2(1,150:162)=num2cell(pCPS2); 
pvalues2(1,163:174)=num2cell(pMOS2); 
PV2=transpose(pvalues2); 
pvalues3=cell(1,174); 
pvalues3(1,1:3)=num2cell(pOBS3); 
pvalues3(1,4:7)=num2cell(pOAS3); 
pvalues3(1,8:10)=num2cell(pLS3); 
%pvalues3(1,11)=num2cell(pIS3); 
pvalues3(1,12:13)=num2cell(pOLS3); 
pvalues3(1,14:18)=num2cell(pTLS3); 
pvalues3(1,19:27)=num2cell(pPLS3); 
pvalues3(1,28:35)=num2cell(pFLS3); 
pvalues3(1,36:44)=num2cell(pHFS3); 
pvalues3(1,45:52)=num2cell(pANCS3); 
pvalues3(1,53:65)=num2cell(pBGS3); 
pvalues3(1,66:70)=num2cell(pBFS3); 
pvalues3(1,71:72)=num2cell(pSS3); 
pvalues3(1,73:88)=num2cell(pHS3); 
pvalues3(1,89:90)=num2cell(pPTS3); 
pvalues3(1,91:107)=num2cell(pTHS3); 
pvalues3(1,108:109)=num2cell(pES3); 
pvalues3(1,110:129)=num2cell(pCS3); 
pvalues3(1,130:147)=num2cell(pPS3); 
pvalues3(1,148:149)=num2cell(pTS3); 
pvalues3(1,150:162)=num2cell(pCPS3); 
pvalues3(1,163:174)=num2cell(pMOS3); 
PV3=transpose(pvalues3); 
Pval=cell(174,5); 
Pval(1:174,1:2)=ROI; 
Pval(1:174,3)=(PV1); 
Pval(1:174,4)=(PV2); 
Pval(1:174,5)=(PV3); 
xlswrite('T Tests at 90% Confidence',Pval); 
Published with MATLAB® R2014a 
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Appendix 5: MatLab Script and Functions for Visualization of 3D Statistical 
Heatmap 
Creation Code 
Initial 
imgs = zeros(63,2604,2594,3,'uint8'); 
for l = 1:9 
    imgs(l,:,:,:) = imread(sprintf('png/Rat_Atlas_0%d.png', l)); 
end 
for l = 10:63 
    imgs(l,:,:,:) = imread(sprintf('png/Rat_Atlas_%d.png', l)); 
end 
 
counts = cell(63,1); 
 
% red min, red max, green min, green max, blue min, blue max 
colors = [180, 260,   0,  50,   0,  60; %red 
            0,  50, 145, 180,  50, 100; %green 
            0,  50,  80, 100, 100, 235; %blue 
          230, 265, 195, 235,   0,  70; %yellow 
          240, 256, 240, 256, 240, 256; %white 
          230, 260, 175, 210,  85, 110; %orange 
            0,  50,  0,   50,   0,  50; %black 
          100, 125, 195, 230, 235, 256; %cyan 
          120, 155,  40,  60, 135, 165; %purple 
          230, 250,  90, 110,  95, 110; %pink 
          210, 230,  50,  80,   0,  80; %dark orange 
          150, 170, 200, 220,  80, 100; %light green 
            0,  20, 120, 140,  60,  80; %dark green 
          0, 0, 0, 0, 0, 0]; 
cns = [1,0,0; 
       0,1,0; 
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       0,0,1; 
       1,1,0; 
       1,1,1; 
       1,0.5,0; 
       0,0,0; 
       0,0.5,1; 
       0.5,0,0.5; 
       1,0.3,0.3; 
       0.7,0.2,0]; 
Processing Portable Network Graphics 
function [ layer ] = ProcessPNG(l, imgs, colors ) 
%Coordinates the designated color ranges to search through the PNG's and 
%save coordinates in new array per color per picture 
 
layer = containers.Map(); 
 
for i = 5:2590 
    for j = 5:2600 
        c = match_pixel(imgs(l,j,i,:), colors); 
        if c < 14 
            coord = num2str([j i l*3]); 
            layer(coord) = c; 
        end 
    end 
end 
 
end 
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Match Pixel 
function [ c ] = match_pixel( px, colors ) 
%decides if pixel matches the color input ranges 
for c = 1:14 
    if (px(1)>=colors(c,1)) && (px(1)<=colors(c,2)) && (px(2)>=colors(c,3)) && 
(px(2)<=colors(c,4)) && (px(3)>=colors(c,5)) && (px(3)<=colors(c,6)) 
        break 
    end 
end 
end 
Storing New Array Data 
%stores and buffers for pixel storage and processing and plotting 
layers = cell(63,1); 
plotable = cell(63,2); 
 
for l = 1:63 
    layers{l} = ProcessPNG(l, imgs, colors); 
    plotable{l,1} = cell(1); 
    trace_count = 1; 
    while layers{l}.Count() > 0 
        plotable{l}{trace_count} = cell(2,1); 
 
        [buffer_x, buffer_y, buffer_z, buffer_count] = BFSMap(layers, l); 
        indexes = DouglasPeuker(buffer_x, buffer_y, 1, buffer_count-1, 8); 
 
        plot_buffer_x = zeros(1, length(indexes)+1); 
        plot_buffer_y = zeros(1, length(indexes)+1); 
        plot_buffer_z = zeros(1, length(indexes)+1); 
        plot_buffer_count = 1; 
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         for i = indexes 
            plot_buffer_x(plot_buffer_count) = buffer_x(i); 
            plot_buffer_y(plot_buffer_count) = buffer_y(i); 
            plot_buffer_z(plot_buffer_count) = buffer_z(i); 
            plot_buffer_count = plot_buffer_count + 1; 
        end 
        plot_buffer_x(plot_buffer_count) = buffer_x(buffer_count-1); 
        plot_buffer_y(plot_buffer_count) = buffer_y(buffer_count-1); 
        plot_buffer_z(plot_buffer_count) = buffer_z(buffer_count-1); 
 
        plotable{l}{trace_count}{1} = plot_buffer_x; 
        plotable{l}{trace_count}{2} = plot_buffer_y; 
        plotable{l}{trace_count}{3} = plot_buffer_z; 
        trace_count = trace_count + 1; 
    end 
    plotable{l,2} = trace_count-1; 
end 
 
hold all 
for l = 1:63 
    for t = 1:plotable{l,2} 
        plot3(plotable{l,1}{t}{1}, plotable{l,1}{t}{3}, 2000-plotable{l,1}{t}{2}, 'k-') 
    end 
end 
Ramer-Douglas-Peuker Algorithm 
-function [ indexes ] = DouglasPeuker( data_x, data_y, start, finish, epsilon ) 
%Runs algorith that connects point a and point b recursively to find line 
%of best fit. Will 'connect the dots' for processing data cloud. 
slope = (data_y(finish) - data_y(start)) / (data_x(finish) - data_x(start)); 
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offset = data_y(start) - slope * data_x(start); 
 
maxdistance = 0; 
maxindex = 1; 
 
for i = start:finish 
    distance = calcDistance(slope, offset, data_x(i), data_y(i)); 
    if distance > maxdistance 
        maxdistance = distance; 
        maxindex = i; 
    end 
end 
 
if maxdistance > epsilon 
    indexes1 = DouglasPeuker( data_x, data_y, start, maxindex, epsilon); 
    indexes2 = DouglasPeuker( data_x, data_y, maxindex, finish, epsilon); 
 
    indexes = [indexes1, indexes2]; 
 
else 
    indexes = start; 
end 
 
end 
Distance Offset for RDP Algorithm 
function [ distance ] = calcDistance( slope, offset, x, y ) 
%claculats the distance from point 1 to point2 of algorithm 
 
distance = abs((slope * x) + ((-1) * y) + offset) / sqrt((slope^2) + ((-1)^2)); 
end 
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Coordinate Storage 
function [ buffer_x, buffer_y, buffer_z, buffer_count ] = BFSMap( layers, l ) 
%creates storage an dprocessing optimization of PNG and point coordinates 
import java.util.LinkedList; 
 
buffer_x = zeros(1, 50000); 
buffer_y = zeros(1, 50000); 
buffer_z = zeros(1, 50000); 
buffer_count = 1; 
 
keys = layers{l}.keys(); 
current = keys{1}; 
 
color = layers{l}(current); 
 
queue = LinkedList(); 
queue.add(current); 
layers{l}.remove(current); 
 
while queue.size() > 0 
    current = queue.remove(); 
    if queue.size() > 6 
        queue.clear() 
    end 
    C = str2num(current); 
    buffer_x(buffer_count) = C(2); 
    buffer_y(buffer_count) = C(1); 
    buffer_z(buffer_count) = l*3; 
    buffer_count = buffer_count + 1; 
    for i = [-1, 0, 1] 
        for j = [-1, 0, 1] 
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            if i == 0 && j == 0 
                continue; 
            end 
            newcoord = num2str([C(1)+j C(2)+i l*3]); 
            if layers{l}.isKey(newcoord) 
                if layers{l}(newcoord) == color 
                    queue.add(newcoord); 
                    layers{l}.remove(newcoord); 
                end 
            end 
        end 
    end 
end 
 
end 
Optimized Code 
Load file plotable.mat. 
hold all 
for l = 1:63 
    for t = 1:plotable{l,2} 
        plot3(plotable{l,1}{t}{1}, plotable{l,1}{t}{3}, 2000-plotable{l,1}{t}{2}, 'k-') 
    end 
end 
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Appendix 6: Gantt Chart 
The Final design iterations and process are laid out in the following Gantt chart that goes over 
the major points of the project timeline.  
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